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Abstract 
Drug resistance is one of the major obstacles facing malaria control. 
Resistance to the combination sulfadoxine/pyrimethamine (SIP) (Fansidar) is now 
widespread, although the mechanism by which this arises is still not fully 
understood. Therefore, the molecular basis of SIP resistance was studied in the 
rodent malaria parasite, Plasmodium chabaudi. SIP resistant mutants were selected 
from a clone already resistant the pyrimethamine, AS (PYR), caused by the presence 
of an asparagine at position 106 in its dihydrofolate reductase (DHFR). Two SIP 
resistant clones, AS (50SIP) and AS (75S1P), were selected and chosen for further 
analysis. AS (PYR) parasites were eliminated by SIP treatment, whereas AS (505/P) 
and AS (75S1P) recrudesced following S/P pressure. However, each mutant 
possessed a different drug resistant phenotype. The AS (75SIP) clone always 
recrudesced before the AS (50SIP) clone following treatment with SIP, while AS 
(505/P) always appeared before AS (755/P) when treated with either sulfadoxine or 
pyrimethamine alone. 
Mutations in the genes encoding the targets of sulfadoxine and 
pyrimethamine, dihydropteroate synthase (DHPS) and DHFR, have been implicated 
in the mechanism of SIP resistance in P. falciparum. The P. chabaudi dhps gene was 
cloned by homology and sequenced. The sequence analysis of the both dhfr and 
dhps genes of AS (7551P) and AS(50SIP) did not reveal any polymorphisms when 
compared to the sequences of the AS (PYR) genes. The mechanism of resistance to 
SIP in these drug-selected lines is not therefore conferred by additional mutations in 
these genes. 
To determine the genetic basis of the S/P resistance, AS (50SP) was crossed 
with a drug sensitive clone, AJ. Sixteen independent recombinant progeny clones 
were phenotyped for their susceptibility to SIP and pyrimethamine and genotyped for 
the inheritance of 30 chromosome-specific markers. Linkage analysis shows that 
mutant dhfr is a major determinant of S/P resistance in P. chabaudi. Quantitative 
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trait analysis suggested that other loci, which may be involved in SIP resistance, are 
present on chromosomes 4, 5 and 9. In addition, the inheritance of loci on 
chromosomes 5 and 13 from the sensitive parent appear to contribute to the level of 
resistance observed. No association was found between SIP susceptibility and the 
inheritance of the dhps gene. 
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1. Introduction 
Malaria is endemic throughout most of Africa, South East Asia, the Indian 
sub-continent and the South Pacific region. Current estimates suggest that malaria is 
responsible for 1.5 to 2.7 million deaths a year (WHO 1999). Almost half the world's 
population is exposed to infection. 
Drug-resistance is well recognised as the single most important obstacle for 
malaria control (White et al. 1999). The genome project has lead to enormous 
advances in our knowledge of the basic biology of malaria parasites (Gardner 1999), 
but despite this, only a few genes determining resistance to the commonly used drugs 
have been identified. Identifying genes involved in drug-resistance is important for 
understanding and predicting how resistance to a given drug arises. It enables 
diagnostic molecular methods to be developed for identifying resistant parasites in 
clinical and field isolates, allows strategies to slow development of resistance to be 
implemented and paves the way for the pharmaceutical companies to redesign the 
inhibitors through rational drug design. 
Resistance to the combination sulfadoxine/pyrimethamine (SIP) (Fansidar) is 
now widespread in the most pathogenic malaria species, Plasmodium falciparum, 
although the mechanism by which this arises is still not fully understood. The aim of 
this work is to identify genes conferring resistance to this drug combination, making 
use of the rodent model, P. chabaudi. 
1.1 Malaria 
Malaria is caused by the protozoan parasite, Plasmodium. There are four 
species which infect humans; P. vivax, P. falciparum, P. malariae and P. ovale, the 
most virulent of these being P. falciparum. There are many other malaria species 
which infect a variety of vertebrates including primates, rodents, birds and lizards 
(Garnham 1966). The rodent malaria parasites are widely used as models for human 
malaria. Four species, P. berghei, P. chabaudi, P. vinckei and P. yoelii, have been 
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isolated from thicket-rats in five countries in Africa (Killick-Kendrick and Peters 
1978), all of which have been adapted to grow in laboratory rodents. 
The incidence of malaria was greatly reduced in the 1960's by the use of 
insecticides to eliminate the mosquito from areas of human habitat, most notably 
dichloro-diphenyl-trichloro-ethane (DDT) (reviewed by Bruce-Chwatt 1985). 
However, the incidence of the disease is now increasing due to the failure of many 
control programmes. Attempts to control malaria include draining or treating 
breeding areas to reduce mosquito populations, together with the use of residual 
insecticides, bed nets and antimalarial drugs. However, changes in vector behaviour, 
mosquito resistance to insecticides, the development of drug resistance by the 
parasite, increased travel, lack of financial support and political unrest, especially in 
Africa, have resulted in the breakdown and failure of many programmes. Attempts to 
develop a vaccine have so far been unsuccessful and it looks increasingly unlikely 
that a vaccine conferring sterilising immunity will ever be feasible (Holder 1999). 
Until a protective vaccine or new effective chemotherapeutic drugs are developed, 
present malaria control measures must be relied on to control the disease. 
1.2 Life-cycle of malaria parasites 
Malaria parasites belong to the Apicomplexa, a phylum consisting entirely of 
parasitic protozoa. They are classified by the presence of an apical complex which is 
used by the invasive stages of these organisms to invade host cells. In all malaria 
species, the parasite is transmitted by the mosquito and has a complex life cycle, 
summarised in Figure 1 (reviewed by Garnham, 1988). Malaria parasites are 
ingested by the female mosquito during feeding on a vertebrate host with parasites in 
the circulation. In the mosquito midgut, the male gametocyte undergoes 
exflagellation, releasing around 8 motile gametes which fertilise the female 
macrogametes (Sinden 1982). Fertilisation results in the development of the motile 
ookinete which passes through the midgut wall (Sinden 1984). It then encysts on the 
outer wall of the midgut, and develops over the next 7 to 14 days as an oocyst. 
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Figure 1. The life-cycle of malaria parasites. Adapted from Taylor (1997). 
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Sporogonic development occurs within the oocyst, and sporozoite formation begins 
about 6 to 9 days after the infective blood meal, depending on the species 
(Vanderberg et al. 1967, Sinden and Strong 1978). After 8 to 15 days, the oocyst 
ruptures releasing 1000 to 10000 sporozoites which migrate to the salivary glands 
(Pringle 1965, Garnham 1966, Rosenberg and Rungsiwongse 1991). A new host 
becomes infected when the sporozoites are injected with saliva when the mosquito 
takes its next bloodmeal. The sporozoites rapidly infect hepatocytes in the liver, 
maturing into liver schizonts. Two to five days after infection, 5000 - 30 000 
merozoites are released from the liver cells into the circulation, where they invade the 
red blood cells almost immediately (Shortt et al. 1951, Bray 1957a, Bray 1957b). 
The merozoites develop into trophozoites and then mature schizonts. One invading 
merozoite produces 4 to 40 daughter parasites asexually within 24 to 48 hours, 
depending on the parasite species (Garnham 1966). Infections are synchronous, 
therefore when the schizonts rupture, thousands of merozoites and their waste 
products are released into the bloodstream producing the fever characteristic of 
malaria. This asexual erythrocytic cycle is repeated many times in an infection, 
resulting in an increase in parasitaemia until the process is either controlled by the 
immune system of the host or the host dies. The intracellular environment of the red 
blood cell results in the parasite being relatively inaccessible to the host immune 
system, thus avoiding immune destruction. Furthermore, the erythrocyte provides a 
supply of protein in the form of haemoglobin that is utilised as a source of amino 
acids, nitrogen and, possibly, energy. During the course of an infection and 
depending on the species, a certain number of merozoites develop into the sexual 
stages, gametocytes, to be taken up by a mosquito for transmission to another host. 
1.3 Genetics of malaria parasites 
Malaria parasites are haploid for most of their life cycle. The only diploid 
stage is the zygote, produced by fertilisation of the gametes in the mosquito gut. 
Meiosis occurs within three hours of fertilisation followed by mitosis to produce the 
oocyst and subsequently haploid sporozoites (Sinden and Hartley 1985). All 
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Plasmodium spp so far examined have 14 chromosomes that range in size between 
0.6 kilobases (kb) for chromosome 1 and 3400 kb for chromosome 14 and the 
genome is thought to encode up to 7500 genes (Kemp et al. 1987, Triglia et al. 1992, 
Canton et al. 1999). Chromosomes are polymorphic both between species of malaria 
parasites and between isolates of the same species, while the chromosome location of 
different genes among the four species of human malaria is highly conserved 
(synteny) (Canton et al. 1999). In addition, gene synteny is conserved between the 
rodent malaria parasites (Janse et al. 1994) and between P. chabaudi and P. 
falciparum (Carlton et al. 1998b). In addition to the nuclear genome, malaria 
parasites possess two extra-chromosomal DNA elements. A 35 kb genome in the 
apicoplast contains genes for several rRNAs, tRNA and RNA polymerase genes 
(Wilson et al. 1996) while a linear 6 kb element contains certain mitochondrial 
genes, thought to be necessary for an electron transport system. Only female 
gametocytes were found to have mitochondria, and thus inheritance of the 6 kb 
mitochondrial element is uniparental through the female gamete (Creasey et al. 
1993). The presence of the apicoplast genome is unusual and it has been speculated 
that this is indicative of an early evolutionary origin some 800 million to 1 billion 
years ago at the time plants and animals diverged (Kohler et al. 1997, Denny et al. 
1998). 
Most P. falciparum infections consist of more than one genetically distinct 
genotype of the parasite. Genetic analysis using polymerase chain reaction (PCR) in 
Tanzania, Senegal and Papua New Guinea have shown that between 70 and 85% of 
infected individuals have more than one parasite genotype present (Babiker et al. 
1994, Ntoumi et al. 1995, Paul et al. 1995). This has important implications for 
population structure, as cross-fertilisation between genetically distinct gametes can 
lead to the generation of parasites with novel genotypes through the processes of 
recombination. This has been demonstrated in P. yoelii (Walliker et al. 1971, 
Walliker et al. 1973), P. chabaudi (Walliker et al. 1975, Carlton et al. 1998a) and P. 
falciparum (Walliker et al. 1987, Wellems et al. 1990, Ranford-Cartwright et al. 
1993). 
5 
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Genetic recombination is important in understanding how parasites resistant 
to more than one drug can arise. If resistance to each drug is due to mutations in 
separate, unlinked genes, then a parasite must gain mutations in both genes to 
become double-resistant. It is unlikely that two mutations will arise simultaneously 
in one parasite. However, recombination can bring together genes conferring 
resistance to more than one drug in a single parasite, but could also dissociate such 
combinations during any subsequent transmissions. Therefore, predictions on how 
drug resistance will spread and persist in parasite populations will depend on the 
number of genes determining resistance, the selection pressure applied (drug use), the 
frequency with which recombination between the genes occurs in nature and the 
relative fitness of the drug resistant forms in competition with sensitive forms in the 
absence of drug pressure (Babiker and Walliker 1997). Mathematical modelling has 
shown that even when resistance is encoded by two mutant alleles at unlinked loci, as 
is likely for S/P resistance, the frequent breakdown of the double mutant under high 
transmission may not be sufficient to prevent the double mutant surviving, as 
selection for resistance by the presence of drug pressure may outcompete 
recombination to keep the mutants in the population (Mackinnon 1997). 
1.4 Linkage analysis and positional cloning in malaria parasites 
The identification of restriction fragment length polymorphisms (RFLPs) 
(Botstein et al. 1980), abundant, highly polymorphic microsatellite (short tandemly 
repetitive DNA) loci (Jeffreys et al. 1985) and more recently, single nucleotide 
polymorphisms (SNPs) (Zhao et al. 1998), has lead to chromosomal mapping of 
many loci through linkage analysis. The technique relies on the ability to detect a 
marker such as an RFLP or microsatellite, that is linked to the locus of interest. Loci 
are linked if they are close together on the same chromosome. Recombination is 
likely to separate them only rarely and they will therefore normally be inherited 
together. Linkage analysis involves the collection of genetic cross data or family 
pedigrees in which the trait of interest is co-segregating with known marker genes. 
The parents and progeny are phenotyped for the inheritance of the trait and genotyped 
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for the inheritance of multiple polymorphic markers. Markers closest to the gene will 
show the strongest correlation with the trait and tracking recombination events can 
narrow the region harbouring the gene to between 100 and several thousand kilobases 
(kb). Fine mapping of the gene is therefore limited by the number of informative 
meioses available. Final identification of the gene requires physical mapping, which 
has been made much easier in recent years by the development of high-throughput 
DNA sequencing. 
As the complete sexual life-cycle of P. falciparum can only be studied by 
transmission through a primate host, classical genetics in this species can be 
performed only with great difficulty (Walliker et al. 1987). Therefore, only two 
genetic crosses have been made and only a few traits mapped. Detection of genetic 
determinants is now feasible because of the large number of genetic markers 
covering the genome (Su et al. 1999). Linkage studies of P. falciparum crosses have 
mapped genetic determinants contributing to drug resistance (Peterson et al. 1988, Su 
et al. 1997, Wang et al. 1997a) and mosquito infectivity (Vaidya et al. 1995). 
Linkage analysis in P. chabaudi became possible with the development of RFLPs as 
genetic markers and a genetic map (Carlton 1995, Carlton et al. 1998a). 
1.5 Quantitative trait analysis 
The advent of genetic maps has permitted genetic dissection of individual 
quantitative traits. Mendel developed the theory of inheritance based on experiments 
with garden peas, studying traits that could be classified on an either-or basis, i.e. all 
the variation was due to a simple difference at a single locus. However, there are 
many traits for which this classification is impossible because the characters vary in 
the population along a continuum. These are quantitative characters where the 
individual phenotype results from the sum total of the effects of all of the 
contributing loci. Therefore, quantitative variation usually indicates polygenic 
inheritance, i.e. that there is an additive effect of two or more genes on a single 
phenotypic character. 
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Mapping quantitative trait loci (QTL) is similar to linkage analysis and 
involves performing a cross between two clones that differ substantially in the 
quantitative trait. The progeny are then scored for the trait and the inheritance of a 
number of genetic markers (Paterson et al. 1988). Single genetic markers are studied 
one at a time. The phenotypic means of the character under investigation (e.g. drug-
resistance) are calculated for the two groups of progeny genotypes and compared: 
those inheriting the allele from parent A are compared with those inheriting the 
marker allele from parent B. The difference between the means provides an estimate 
of the phenotypic effect of inheriting either allele. A statistical test is then applied to 
test whether the inferred phenotypic effect is significantly different from zero; the 
difference in the means will be zero if inheritance of either allele has the same effect 
on the phenotype. If the difference is statistically significant, this implies that the 
marker is close to a gene or QTL that contributes to the quantitative trait of interest. 
Fine mapping of the region will eventually lead to the cloning of the gene underlying 
the trait. 
The only QTL analysis study in species of Plasmodium reported to date, is 
that of Carlton et al. (1998a), on chloroquine resistance in P. chabaudi, although the 
construction of a detailed genetic map of P. falciparum (Su et al. 1999) now permits 
detailed analysis of accessible quantitative traits in the human malaria parasite 
(Ferdig and Su 2000). 
1.6 Chemotherapy and drug-resistance 
1.6.1 Drug-resistance 
The failure of a drug to clear an infection can be due to either inadequate 
levels of drug in the patient (inappropriate dose taken, failure to complete the course, 
poor absorption, unusual metabolism) or to drug resistance. Resistance is selected by 
exposure of the organisms to the drug and can be expected to be due to a variety of 
mechanisms. Stable gene mutations are of most concern since they may persist in the 
parasite population once they have arisen. 
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1.6.2 Identifying genes involved in drug-resistance 
The most useful starting material for identifying genes determining resistance 
is resistant mutants selected from sensitive clones. The sensitive and resistant forms 
are therefore genetically identical, except for the gene(s) determining the resistance. 
Direct examination of the sensitive and resistant forms can then be made to search 
for mutations in candidate genes which cause the resistance. 
In practice, it is very difficult to select resistant P. falciparum lines which 
exhibit stable resistance in the absence of drug pressure. Only a few successes have 
been reported following many months of prolonged culture in the presence of 
gradually increasing doses of drug (Oduola 1988, Lim and Cowman 1996). In 
contrast, it is usually easy to obtain stable drug-resistant mutants of rodent parasites 
by exposing infected mice to various drug regimes. In P. chabaudi, stable mutants 
have been produced in this way that are resistant to pyrimethamine (Walliker et al. 
1975), chloroquine (Rosario 1976b, Padua 1981) and mefloquine (Padua and 
Walliker 1978). If the target(s) of the drug are known, their gene sequences are 
analysed from resistant and sensitive forms to search for mutations that may be 
associated with resistance. In the absence of a candidate gene, or to confirm the role 
of mutations in resistance, crosses need to be made between resistant mutants and 
unrelated sensitive clones and the genetic determinant mapped by linkage analysis. 
Transfection of candidate genes into drug-sensitive clones can then be carried out to 
confirm a causal relationship with resistance (van Dijk et al. 1995, Wu et al. 1996). 
1.6.3 Quinine 
The bark of the cinchona tree has been used to treat malaria fevers for 
centuries (Meshnick 1997). Extracts of this bark contain quinine, a 
quinolinemethanol, which is now produced synthetically. It is a low cost drug, now 
considered too toxic for prophylaxis or routine treatment of the disease, but it is still 
used under hospital supervision to treat cerebral malaria (Foley and Tilley 1997). 
While a few cases of quinine-resistant malaria have been reported, these have not 
been confirmed by in vitro tests and quinine still remains effective (see Peters, 1987). 
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The reasons for this are unclear, since quinine has been used for centuries, but the 
short half-life is thought to minimise selection pressure on the parasite. Furthermore, 
as quinine is mainly administered in hospitals, patients are more likely to receive a 
course of quinine therapy (Meshnick 1998). Today, quinine is the last line treatment 
for patients infected with multi-drug resistant P. falciparum. Attempts to select for 
quinine resistance have met with little success. Therefore, it has not been possible to 
determine any potential mechanisms of resistance. 
1.6.4 Chloroquine 
Modern quinine derivatives, which are less toxic than quinine itself, include 
chloroquine, amodiaquine and more recently, mefloquine (Lariam®)  and halofantrine. 
However, P. falciparum isolates resistant to almost every antimalarial drug and the 
various drug combinations have now been reported (see Peters, 1987). Chloroquine 
is one of the cheapest and most widely available antimalarials. The development of 
resistance to chioroquine in P. falciparum was thus one of the most important 
setbacks to malaria control. Parasites resistant to chioroquine were first reported in 
the early 1960's, almost simultaneously in Thailand (Harinasuta et al. 1962) and 
South America (Moore and Lanier 1961, Young and Moore 1961). Today, 
chioroquine is only effective in Central America and some areas in West Africa 
(Wernsdorfer 1991, Bloland et al. 1993). 
The mechanism of action of chloroquine is not fully understood. The 
metabolism of haemoglobin by the parasite results in the production of potentially 
toxic, free haem. This is sequestered into the food vacuole as non-toxic crystals of 
haemazoin (malaria pigment). Chloroquine is proposed to inhibit the polymerisation 
and detoxification of haem in the vacuole, resulting in swelling of the vacuole and 
ultimately cell lysis (Jacobs et al. 1988, Goldberg et al. 1990, Egan et al. 1994). 
The mechanism of resistance to chloroquine is a highly debated topic. 
Resistance appears to be associated with either a decreased uptake or increased 
expulsion of the drug. Resistant parasites have been reported to expel chioroquine 
40-50 times more rapidly than sensitive parasites (Krogstad et al. 1987). This 
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resistance phenotype was found to be reversed by the calcium channel blocker 
verapamil, leading to the hypothesis that chioroquine resistance is similar to the 
multi-drug resistant (MDR) phenotype in mammalian tumour cells (Martin et al. 
1987). MDR tumour cells overexpress an ATP-dependent transporter, the P-
glycoprotein which can pump out a wide range of chemically dissimilar compounds 
(Riordan et al. 1985). Two P-glycoproteins have been identified in P. falciparum 
which are encoded by the pfindrl and pfindr2 genes (Foote et al. 1989, Wilson et al. 
1989, Cowman et al. 1991). Amplification of the pfindrl gene has been observed in 
some chloroquine resistant isolates suggesting that increased expulsion was the 
mechanism of resistance (Foote et al. 1989). Further studies have cast doubts on the 
role of amplification as the level of chloroquine resistance in a number of strains did 
not correlate with the level of pfmdrl expression (Wilson et al. 1993, Cowman et al. 
1994). Alleles of the pfindrl gene identified in field isolates of P. falciparum have 
also been linked with chloroquine resistance, although there are numerous exceptions 
(Foote et al. 1990). Furthermore, analysis of a genetic cross between parasite clones 
HB3 (chloroquine-sensitive) and Dd2 (chloroquine-resistant) revealed no linkage 
between either of the pfi'ndr genes and chloroquine resistance (Wellems et al. 1990). 
Instead, a gene on chromosome 7 showed linkage with the chloroquine-resistant 
phenotype (Wellems et al. 1991). Further mapping identified a gene denoted cg2 on 
this chromosome that segregated with resistance (Su et al. 1997). More recently, 
transfection of resistant parasites with the 'chloroquine-sensitive' allele of cg2 was 
shown not to alter the chloroquine response of the recipient parasite (Fidock et al. 
2000a). Instead, a gene denoted crt, which is closely linked to cg2, has been 
demonstrated to be a stronger candidate (Fidock et al. 2000b). 
Other candidate genes include a chloroquine importer that has been identified 
in P. falciparum and differences in chloroquine uptake have been shown to be 
genetically linked to the chloroquine resistance phenotype (Sanchez et al. 1997). 
Recent data suggests that decreased vacuolar pH is the determinant of chloroquine 
resistance, which lowers the availability of free haem for chloroquine binding, 
resulting in decreased chloroquine uptake (Dzekunov et al. 2000, Ursos et al. 2000). 
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Clearly, it will be of interest to see if the locus on chromosome 7 is able to regulate 
vacuole pH in a verapamil reversal manner. 
It is likely that there are two or more different mechanisms of chloroquine 
resistance, which confer different levels of resistance (Cowman and Foote 1990). 
Resistance to chioroquine was slow to emerge in P. falciparum, and may have arisen 
only twice, once in South East Asia and once in South America (Payne 1987). This 
is indicative of a multigenic trait, i.e. resulting from an additive effect of mutations in 
many genes. Recent transfection experiments have shown that one allele of pfindrl 
modulates resistance to chloroquine, as well as to mefloquine and quinine (Reed et 
al. 2000), suggesting that Foote's hypothesis that the chromosome 7 locus is epistatic 
to pfmdrl , may indeed be correct (Foote et al. 1990). 
In P. chabaudi, linkage analysis of progeny from crosses between 
chloroquine-sensitive and -resistant clones has been reported (Carlton et al. 1998a). 
Twenty independent recombinant progeny were typed for their response to 
chloroquine and their inheritance of 46 chromosome-specific markers. A region of 
chromosome 11 was linked to resistance, while no linkage was observed with the 
pcmdrl gene, the P. chabaudi homologue of pfmdrl. Quantitative trait mapping 
produced strong evidence for a gene determining resistance on chromosome 11, with 
other possible genes on chromosomes 3, 5 and 9. These genes have yet to be 
characterised. 
1.6.5 Mefloquine 
Pfindrl has also been implicated in determining mefloquine-resistance in P. 
falciparum. Mefloquine-resistant mutants have been selected in the laboratory in 
which over-expression and duplication of pfindrl have been observed (Cowman et al. 
1994, Peel et al. 1994). Duplication and overexpression of mdr have also been 
associated with mefloquine-resistant P. chabaudi (Phillips 1997) and P. berghei 
(Gervais et al. 1999). Reed et al. (2000) have also shown that different allelic forms 
of pfindrl conferred different levels of susceptibility to mefloquine. 
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1.6.6 Inhibitors of the folate pathway 
Compounds that inhibit enzymes in the folate pathway have been used to treat 
many pathogens and have been widely exploited as antimalarials. Tetrahydrofolate is 
a cofactor essential for the transfer of one-carbon groups in various biosynthetic 
pathways. Folate derivatives are essential co-factors in the synthesis of DNA and 
certain amino acids. Plasmodium, like many plants and bacteria, synthesises 
tetrahydrofolate de novo from guanosine triphosphate (GTP) via the folate pathway 
(Figure 2). This pathway is absent from mammalian cells as dihydrofolate is derived 
from dietary folic acid. However, in all organisms, dihydrofolate must be reduced to 
tetrahydrofolate by the enzyme, dihydrofolate reductase (DHFR). Fortunately for 
antimalarial chemotherapy, the mammalian DHFR has a much higher substrate 
specificity than the Plasmodium enzyme and is less susceptible to inhibition by 
antifolates. The mode of action of the antifolates was elucidated in bacteria, where 
de novo synthesis of folate is obligatory. However, the situation is complicated in 
Plasmodium by the presence of salvage mechanisms, permitting the parasites to use 
exogenous folate (Chulay et al. 1984, Milhous et al. 1985, Watkins et al. 1985, 
Krungkrai et al. 1989, Wang et al. 1997c). This may even be the primary source of 
their folate requirements in the mammalian host. Therefore, the fact that antifolates 
and sulfonamides have antimalarial activity at all is somewhat surprising. 
1.6.7 Antifolate resistance 
The mechanism of resistance to the antifolate drugs is the only mechanism of 
drug-resistance in malaria parasites that is well understood. Antifolates are DHFR 
inhibitors and pyrimethamine is one of the most widely used inhibitors (Figure 3). 
Pyrimethamine was first introduced into the field in 1952, but reports of resistance in 
P. falciparum followed shortly afterwards (Peters 1987). 
Pyrimethamine resistant parasites have been selected from all the rodent 
malaria species; from P. berghei (Rollo 1952, Diggens 1970, van Dijk et al. 1994), 
P. yoelii (Walliker etal. 1973), P. chabaudi (Walliker et al. 1975) and P. vinckei 
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Figure 2. The pathway for dihydrofolate and DNA synthesis from 
guanosine triphosphate (GTP) in Plasmodia. Adapted from Warhurst 
(1986). Enzymes are shown in bold, substrates in italics. 
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Figure 3. The structures of folic acid and pyrimethamine. 
(Yoeli et al. 1969). Pyrimethamine resistance became the first selectable marker 
available and this led to the first classical genetic studies being carried out in species 
of Plasmodium. Analysis of the cloned progeny of these crosses, between 
pyrimethamine-sensitive and resistant lines of P. yoelii and P. chabaudi respectively, 
demonstrated that the resistant phenotype appeared to segregate as a single locus, 
since progeny clones exhibited phenotypes similar to each parent with no 
intermediate levels (Walliker et al. 1973, Walliker et al. 1975). Subsequently, a 
mutation in the dhfr gene was identified as a probable cause of pyrimethamine 
resistance in P. falciparum. In the first genetic cross carried out in this species, all 
resistant progeny were shown to inherit an RFLP associated with the dhfr of the 
resistant parent (HB3), while all sensitive progeny inherited the 3D7 allele (Peterson 
et al. 1988). The only difference in the DHFR of each parent was residue 108, which 
is serine (S) in 3137 and asparagine (N) in HB3. This result has been supported by 
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numerous field surveys of P. falciparum, in which S 108N is found in almost all 
confirmed pyrimethamine-resistant isolates (Siriwaraporn 1998). Convincing proof 
of the key role of this allele of dhfr has also been obtained in transfection 
experiments using mutant dhfr as a selectable marker in P. berghei (van Dijk et al. 
1995) and P.falciparum (Wu et al. 1996). 
Mutations at other sites in the dhfr gene have been associated with increased 
resistance to pyrimethamine, as well as resistance to a second antifolate drug, 
cycloguanil (Siriwaraporn 1998), but crossing and/or transfection experiments to 
confirm the role of these mutations have not been done in either P. falciparum or in 
rodent malaria species. 
Molecular analysis of several pyrimethamine-resistant rodent clones has 
shown that the mechanisms of pyrimethamine resistance are remarkably similar to 
those seen in P. falciparum, and may provide additional insights into the means by 
which resistance occurs and spreads in the field. In P. chabaudi and P. yoelii, 
resistance is associated with a point mutation in their dhfr genes which causes an 
amino acid change at position S 106N, thought to be equivalent to the S 108N change 
in P. falciparum (Cowman and Lew 1990, Cheng and Saul 1994). In addition, a low 
level resistant line of a subspecies of P. chabaudi, P. c. adami (DS) was selected 
using a continuous low-pressure method and found to have an extra copy of the dhfr 
gene as a result of a partial gene duplication event (Cowman and Lew 1989) and a 
similar result was reported for a low-level resistant line selected from the P. berghei 
ANKA clone (van Dijk et al. 1994). Further selection to give a higher level of 
resistance in the P. c. adami mutant resulted in the loss of the duplicated gene and a 
point mutation at Si 06N in the remaining copy (Cowman and Lew 1990). The 
increase in resistance as a result of the point mutation was several orders of 
magnitude greater than the resistance conferred by the duplication, which may 
explain why amplification of P. falciparum dhfr has not been observed in the field. 
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1.6.8 The sulfa drugs 
A variety of sulfa drugs (sulfonamides) have been developed to combat 
human pathogens. Sulfachryscidine and sulfanilamide were first used to treat malaria 
in the 1930's and many derivatives have since been used as antimalarials with varying 
success (for review, see Peters, 1987). These drugs had a slow and relatively short-
lived action resulting in the need for high, potentially toxic doses and so their use 
was discontinued. Once chloroquine resistance became established and there was a 
need to find alternatives, the long acting sulfonamide compounds, sulfadiazine and 
sulfadoxine were developed. These compounds bind strongly to plasma proteins and 
have long half-lives. The sulfonamides act on trophozoites and schizonts, the DNA 
replicating stages of the asexual cycle. They are analogues of para-aminobenzoic 
acid (PABA) (Figure 4) and competitively inhibit the dihydropteroate synthase 
(DHPS) enzyme, required for folate biosynthesis. DHPS catalyses the condensation 
of PABA with phosphorylated pteridine to form dihydropteroate (Figure 2). This is 
then converted to dihydrofolate. This pathway is absent in the mammalian host 
where dihydrofolate is obtained from dietary folic acid, making the malaria enzymes 
ideal targets for rational drug design. 
PABA 




Figure 4. Structures of para-aminobenzoic acid (PABA) and the 
analogue, sulfadoxine. 
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1.6.9 Sulfonamides: mechanism of action 
Sulfonamides compete with PABA for DHPS. They deplete the 7,8-
dihydropterin pool by reacting as a PABA-substrate analogue to form a 7,8-
dihydropterin-sulfonamide adduct (Roland et al. 1979). Inhibition of the next 
enzyme in the pathway, dihydrofolate synthase, or other folate enzymes, was found to 
be irrelevant at physiological concentrations and it was concluded that competition 
with PABA is the primary mode of action (Roland et al. 1979). The subsequent 
reduction in the rate of 7,8-dihydropteroate synthesis decreases the concentration of 
tetrahydrofolate cofactors, reducing the rate of synthesis of the products of the 
pathway, thus inhibiting cell growth. 
The extent to which Plasmodium can synthesise PABA de novo is a much-
debated topic. Milk diets, which are deficient in PABA, were shown in early work to 
inhibit the development of the respective malaria infections in rats, mice, chicks and 
monkeys (Maegraith et al. 1952, Bray and Gamham 1953, Hawking 1953, Greenberg 
et al. 1954). Furthermore, the addition of PABA to the diet restored growth, 
indicating that Plasmodium have a requirement for exogenous PABA. These studies 
have been disputed in more recent work. The majority of P. falciparum parasites 
grow in vitro in PABA- and folate-free medium at normal rates, suggesting that the 
parasites are able to synthesise the PABA they require (Milhous et al. 1985, Watkins 
et al. 1985, McConkey et al. 1994, Wang et al. 1997c). Dieckmann and Jung (1986) 
detected activities of four of the shikimate pathway enzymes, required for PABA 
synthesis, in P. falciparum. McConkey et al. (1994) were able to select for 
auxotrophs of P. falciparum that were dependent on exogenous PABA for growth, 
unlike the clone from which they were derived. Conclusive proof of the presence of 
the pathway necessary for PABA biosynthesis, the shikimate pathway, in malaria 
parasites was obtained when the gene encoding chorismate synthase, the final 
enzyme in the pathway, was identified in the genome project (Roberts et al. 1998). 
The precise role of the shikimate pathway in Plasmodium is still unclear. 
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1.6.10 Sulfonamides: mechanism of resistance 
In bacteria, sulfonamide resistance is well characterised. Resistance in 
Escherichia coli is caused by a point mutation in a highly conserved region of the 
dhps gene (Dallas et al. 1992), while a two amino acid insertion in the DHPS of both 
Streptococcus pneumoniae and Neisseria meningitidis have also been shown to 
confer sulfonamide resistance (Lopez et al. 1987, Fermér et al. 1995). Mutations in 
the genes that encode DHPS have also been found to confer resistance to 
sulfonamides in Mycobacterium leprae (Kai et al. 1999) and Streptococcus 
pyrogenes (Swedberg et al. 1998) and have been associated with sulfonamide failure 
in Pneumocystis carinii (Heiweg-Larsen et al. 1999). 
Therefore, it was assumed that resistance to sulfadoxine in P. falciparum 
would also be conferred by mutations in dhps. The dhps gene has been cloned from 
P. falciparum and the gene found to encode both DHPS and 7, 8-dihydro-6-
hydroxymethyipterin pyrophosphokinase (PPPK), the enzyme prior to DHPS in the 
folate pathway (Figure 2) (Brooks et al. 1994, Triglia and Cowman 1994). All the 
protozoan DHPS enzymes characterised to date have been either bifunctional, with 
both PPPK and DHPS domains, as in P. falciparum and T. gondii (Pashley et al. 
1997), or trifunctional as in Pn. carinii, with the domain of another enzyme from the 
folate pathway, dihydroneopterin aldolase (Volpe et al. 1992). 
The identification of amino acid differences among alleles of dhps of P. 
falciparum isolates, suggested that as in other organisms, the mechanism of 
sulfonamide resistance involved mutations in the dhps gene. The relevance of these 
mutations is discussed in section 1.6.12. 
1.6.11 Antifolate/sulfonamide combinations 
It was observed that if pyrimethamine and sulfadoxine were administered 
together, a high level of synergism was displayed (Richards 1966, Chulay et al. 
1984), and the rates at which resistance to these compounds developed was reduced 
(Peters 1974). This led to the introduction of the drug Fansidar ® (SIP, Roche 
Pharmaceuticals, 25 mg pyrimethamine and 500 mg sulfadoxine). SIP is used both 
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prophylactically and therapeutically and, given the spread of chioroquine resistance, 
represents the only effective antimalarial affordable in Africa on a mass-scale (Foster 
1991, Bloland et al. 1993, White etal. 1999). 
The antimalarial activity of SIP is far greater than can be explained by simple 
additive effects of the two individual drugs. Wang et a! (1999) explain the synergy 
between sulfa drugs and pyrimethamine by showing that pyrimethamine has a second 
site of action, in addition to inhibiting DHFR. It appears that pyrimethamine also 
blocks the utilisation of exogenous folate, which forces the parasite to use the 
endogenous folate pathway, rendering it extremely susceptible to sulfa inhibition. 
The mechanism by which this occurs is unknown, but it is likely that since 
pyrimethamine is a structural analogue of folic acid, it inhibits either the uptake or 
processing of exogenous folate (Wang et al. 1999). 
1.6.12 Resistance to sulfadoxine/pyrimethamine 
Despite evidence that resistance to antimalarial combinations is slow to arise 
(Peters 1974, White 1998), resistance to SIP has been quick to appear in P. 
falciparum. Reports of resistance to SIP treatment appeared in Thailand soon after it 
was introduced (Chongsuphajaisiddhi et al. 1979, Reacher et al. 1980). It is thought 
that the long half-life of SIP results in a strong selection pressure (Watkins and 
Mosobo 1993, Nzila etal. 2000a). By the mid-1980's, S/P was no longer effective in 
many areas of South America and South East Asia. Today, it is only in Africa, where 
extensive use of S/P is recent, that it is still effective. S/P is now the first-line 
antimalarial of four African countries; Botswana, Kenya, Malawi and South Africa, 
so the widespread development of S/P resistance in Africa would be disastrous 
(White et al. 1999). 
While some studies suggest that S/P failure may be determined simply by 
high level resistance to pyrimethamine conferred by multiple mutations in dhfr 
(Watkins et al. 1997), it is also possible that it could be due to an additive effect of 
mutations conferring resistance to each drug separately. An association of mutations 
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in dhfr with those in dhps has thus been sought to explain SIP resistance (Wang et al. 
1997b, Plowe et al. 1998). 
A major problem in studying this subject in P. falciparum is the lack of a 
reliable in vitro test for S/P resistance. A good test is available for measuring 
pyrimethamine response (Nguyen-Dinh and Payne 1980), but phenotyping 
sulfadoxine responses is difficult due to variations in quantities of PABA and folate 
in the culture constituents, especially serum and erythrocytes (Tan-Ariya and 
Brockelman 1983, Chulay et al. 1984, Spencer et al. 1984, Milhous et al. 1985, 
Watkins et al. 1985, Schapira et al. 1986, Wang et al. 1997c). For this reason, 
attempts to identify mutations which confer resistance to SIP have relied largely on 
molecular typing of dhfr and dhps genes from patients in whom therapeutic failure 
has occurred (Reeder et al. 1996, Plowe et al. 1997, Wang et al. 1997b, Basco et al. 
1998a, Basco et al. 1998b, Curtis et al. 1998, Duraisingh et al. 1998, Jelinek et al. 
1998, Plowe et al. 1998, Diourté et al. 1999). The absence of in vitro tests, and 
sometimes sensitive controls, has made these field studies difficult to interpret, but it 
appears that SIP selects for mutations in dhfr and that selection on dhps only occurs 
in parasites already harbouring multiple mutations in dhfr (Nzila et al. 2000a, Nzila 
et al. 2000b). It has been suggested therefore, that triple mutant dhfr can be used as a 
marker for SIP resistance (Basco et al. 1998b, Plowe et al. 1998, Nzila et al. 2000b). 
However, Plowe et al. (1998) and Nzila et al. (2000b) note that there are numerous 
exceptions and that dhps and dhfr genotyping is not a perfect predictor of clinical 
outcome in SIP treated patients. 
More recently, transfection work has suggested that in P. falciparum, DHPS 
amino acids serine-436, glycine-437, lysine-530, alanine-58 1 and alanine-613 
specifically confer sulfadoxine resistance, with glycine-437 being the key residue 
(Triglia et al. 1998). However, the transfection studies were complicated by the fact 
that an additional copy, or copies, of the dhfr gene were transfected into the recipient 
sensitive parasites, the activity of which could affect their response to sulfonamide 
drugs. Furthermore, the characterisation of the transfected parasites was carried out 
with sulfadoxine only in PABA- and folate-deficient medium, so the relevance of 
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these amino acid changes to S/P at physiological concentrations was unclear. 
Genetic crossing work has produced evidence that a dhps allele containing 
phenylalanine-436, glycine-437 and serine-613 is linked to sulfadoxine resistance, 
although another locus linked to dhfr on chromosome 4, which influences the use of 
exogenous folate by the parasite, has also been implicated (Wang et al. 1997a). 
Again, these in vitro assays were only carried out with sulfadoxine and in PABA- and 
folate-free medium. 
The rodent malarias are more satisfactory to study resistance to these drugs 
because they allow levels of PABA and folate to be controlled in the animal diet. 
Parasites resistant to sulfonamide drugs, such as sulfadiazine, have been selected in 
P. berghei (Peters 1974) and P. chabaudi (MacLeod 1977). In general, sulfadiazine-
resistant parasites have a reduced requirement for PABA, suggesting that they may 
have acquired the ability to synthesise PABA de novo (Jaswant-Singh et al. 1954, 
Ramakrishnan et al. 1956). Pyrimethamine-resistant parasites, however, have an 
increased requirement for PABA (Jacobs 1964). There are few data on the PABA 
requirements of SIP resistant parasites, although Merkli and Richie (1983) reported 
that the development of resistance to the SIP combination in P. berghei was 
accelerated by a diet containing a high level of PABA. A cross between a sensitive 
line of P. chabaudi and one resistant to both pyrimethamine and sulfadiazine 
suggested that resistance to these two compounds was determined by genes at two 
loci (MacLeod 1977). Unfortunately, there are no sequence data on the dhfr or dhps 
genes of any of these parasites. 
1.7 Outline of present study 
The object of this study was to investigate the genetic basis of SIP resistance 
in the rodent malaria parasite, P. chabaudi. Of the four rodent malaria models, P. 
chabaudi is the most similar to P. falciparum; both have a preference for mature 
erythrocytes, infections are highly synchronous and mature parasites are sequestered 
from the peripheral circulation (Killick-Kendrick and Peters 1978). Furthermore, the 
mechanisms of pyrimethamine resistance in both species have been shown to be 
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identical (Peterson et al. 1988, Cheng and Saul 1994) and chromosome location of 
groups of genes between the two species is highly conserved (Canton et al. 1998b). 
Therefore, once the gene(s) conferring resistance to SIP are identified in P. chabaudi, 
examination of the two genomes will identify the corresponding P. falciparum 
gene(s). 
The first section describes selection for S/P resistant mutants. Several 
mutants were obtained following single-step selection by the drug combination on a 
clone already resistant to pyrimethamine, AS (PYR). Pyrimethamine resistance in 
AS (PYR) is conferred by the presence of asparagine at position 106 in DHFR, 
equivalent to the serine to asparagine change at position 108 conferring resistance to 
pyrimethamine in P. falciparum (Peterson et al. 1988, Cowman and Lew 1990, 
Cheng and Saul 1994). A clone already resistant to pyrimethamine was chosen as the 
starting material for selection because in P. falciparum, pyrimethamine resistance 
and hence mutations in dhfr, were already widespread when S/P was introduced in 
the field (Peters 1987). 
Mutations in the gene encoding DHPS have been implicated in the 
mechanism of SIP resistance in P. falciparum (Triglia et al. 1998). Therefore, to 
identify any possible sequence variations associated with resistance to SIP, the P. 
chabaudi pppk-dhps homologue was isolated. Analysis of this gene and the dhfr-ts of 
the resistant mutants did not reveal any sequence changes when compared to the 
respective sequences of the AS (PYR) genes. This is presented in the second part of 
the study. 
In the third section, crosses were made between an S/P resistant clone, AS 
(5051P) and a sensitive clone, AJ. Sixteen independent recombinant progeny clones 
were phenotyped for their susceptibility to SIP and pyrimethamine and genotyped for 
the inheritance of 30 chromosome-specific markers. Linkage analysis showed that 
mutant dhfr is a major determinant of SIP resistance in P. chabaudi. However at 
least one other gene is involved. Quantitative trait analysis suggested that other loci 
for S/P resistance could be present on chromosomes 4, 5 and 9. In addition, loci on 




association was found between S/P susceptibility and the inheritance of the dhps 
gene 
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2. Materials and Methods 
The composition of buffers and solutions are given in Appendix I. 
2.1 Definition of terms 
The terms describing the parasites used throughout this work are as follows 
(after Walliker 1983): 
Isolate - 	 A sample of parasites collected on a single occasion from a 
natural host. An isolate may contain parasites of more than 
one species. 
Line 	- 	 A collection of parasites that have undergone a particular 
laboratory passage or treatment. 
Clone - 	 A group of genetically identical organisms derived from a 
single cell by asexual multiplication. 
2.2 Laboratory maintenance of P. chabaudi 
2.2.1 Parasite clones 
The P. chabaudi clones used in this work, AS and AJ, were cloned from 
isolates taken from wild thicket rats, Thamnomys rutilans in the Central African 
Republic (Carter and Walliker 1975). Both AS (SENS) and AJ are pyrimethamine 
and sulfadoxine/pyrimethamine (SIP) sensitive and known to be genetically distinct 
clones (Carter 1978, Sanderson et al. 1981, Carlton et al. 1998a). Clone AS (PYR) 
was derived from the AS (SENS) clone, by selection for in vivo resistance to 
pyrimethamine (Walliker et al. 1975). The resistance was produced by single step 
treatment of AS (SENS) parasites in vivo with 50 mg/kg pyrimethamine. AS (PYR) 
parasites are able to grow in the presence of 25 mg/kg pyrimethamine administered 
for 4 days, which normally eradicates all sensitive forms. The S/P resistant clones, 
AS (50S/P) and AS (75S1P), were derived from AS (PYR) for the work presented; 
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their derivation and characterisation will be described later in the chapter (section 
2.3.3). 
Table 1. Clones of P. chabaudiused in this work 
Drug Sensitivitya 
Clone 	 PYR 	 S/P 
AJ 	 S 	 S 
AS (SENS) 	S 	 S 
AS (PYR) 	R 	 LR 
AS (50S/P) 	R 	 R 
AS (75S/P) 	R 	 HR 
apy pyrimethamine; SIP, sulfadoxine/pyrimethamine; 5, sensitive; 
LR, low-level resistance; R, resistant; HR, high-level resistance. 
2.2.2 Rodent hosts 
Laboratory mice (Mus musculus) were used as mammalian hosts. Clones 
were routinely passaged in outbred (TO) laboratory mice (Bantim and Kingman, 
Hull, UK). Inbred CBA/Ca male mice, 6-9 weeks old (Edinburgh University or 
Bantim and Kingman, Hull, UK), were used for drug susceptibility tests. Mice were 
routinely fed SDS Formula Number 1 (Special Diets Services Ltd, Essex, UK) 
supplemented with 0.05% PABA in their drinking water to promote high 
parasitaemia (Hawking 1953). Mice used for sulfadoxine tests were fed a folic acid-
deficient diet (ICN) supplemented with water alone or with 0.005% PABA in the 
drinking water to assist parasite growth. Newly-weaned female Wistar rats (Bantim 
and Kingman, Hull, UK) were used for crossing studies. All animals were kept at 
22-25°C with alternating 12 hour cycles of light and darkness, in polypropylene 
cages with wood shavings. 
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2.2.3. Mosquito hosts 
Parasites were transmitted through Anopheles stephensi mosquitoes for 
crossing studies. Mosquitoes were maintained as described (Walliker et al. 1973) at 
24-26°C and 70-90% humidity with alternating 12 hour cycles of light and darkness. 
2.2.4 Syringe passage 
P. chabaudi infections were maintained by direct blood passage from infected 
mice with high parasitaemias to uninfected mice. One to five drops of blood were 
collected from mouse tail snips into either 0.2 ml citrate saline (Appendix I) or 
heparinised calf serum/Ringer solution (Appendix I), and 0.1 ml injected 
intraperitoneally (ip). The day of inoculation was referred to as day 0. Infections 
were monitored by making thin blood films from tail snips. The blood films were 
fixed in methanol, stained with Giemsa's stain (Gibco BRL) at pH 7.2, and examined 
microscopically. The smears were either scored using a simple system based on that 
of Padua (1981) or the parasitaemia was calculated by counting the total number of 
red blood cells and then the number of parasitised cells. Parasitaemias were then 
expressed as the percent of cells infected. At least 1000 cells were examined for each 
count. The number of erythrocytes per ml was calculated by using a haemocytometer 
or a Coulter Counter (Coulter Electronics), which together with the parasitaemia, was 
used to calculate the number of infected cells per ml of blood. 
2.2.5 Cryo-preservation of parasites 
Parasites were preserved in liquid nitrogen as follows (Rowe et al. 1968). 
Mice with pre-peak parasitaemias were anaesthetised with 2-4 % volatile halothane 
(Rhodia Ltd, Bristol, UK), and blood was collected into citrate saline by cardiac 
dissection. The blood was centrifuged at 1500 x g for 10 minutes. The supernatant 
was removed and a volume of deep freeze solution (Appendix I) equal to that of the 
pelleted cells added and gently mixed. Aliquots (20-100 .tl) were either pipetted into 
cryo-preservation ampoules (Nunc) and immediately immersed in liquid nitrogen, or 
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dispensed into glass capillaries which were sealed with a Bunsen flame and 
immersed in liquid nitrogen. 
Parasites were taken from storage by thawing frozen capillaries or ampoules, 
diluted into 0.2 ml citrate saline and inoculated into mice (ip). Infections became 
patent 5-10 days after inoculation and were passaged at least once before being used 
in an experiment. 
2.2.6 Cloning 
Clonal infections were established by injecting mice (ip) with inocula 
containing 1.0 parasite per mouse (Walliker et al. 1975). A donor mouse with a low 
parasitaemia was used in order to minimise the number of cells with multiple 
infections. The donor was bled from the tail into fixed-volume glass micropipettes 
(Camlab) and serial dilutions made into citrate saline. The final dilution was made 
into calf serumlRinger such that it contained 10 parasites/mi. Groups of 15-30 mice 
were inoculated with 0.1 ml aliquots. Blood smears were taken after 10-14 days and 
examined for the presence of parasites. Clonal infections were confirmed by 
examing a number of genetic markers (see section 2.10). 
2.3 Drug-resistance studies 
2.3.1 Drugs and chemicals 
Pyrimethamine was originally obtained from Wellcome Research 
Laboratories (Kent, UK), sulfadoxine and Fansidar® were kind gifts from Roche 
Pharmaceuticals. Dilutions of drugs were made in dimethyl sulfoxide (DMSO) 
(Sigma, UK). 
2.3.2 In vivo drug susceptibility tests 
Parasites were tested for their susceptibility to pyrimethamine, sulfadoxine 
and SIP, by inoculating (ip) 106  parasitised red blood cells into groups of five 6-9 
week old CBA/Ca male mice. Dilutions of pyrimethamine, sulfadoxine or SIP were 
administered orally to three of the mice three hours after inoculation, and at the same 
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time of day, for the next 3 days. Drug doses were expressed as mg per kg of mouse 
body weight (mg/kg). Each mouse was weighed daily before administering the drug. 
Blood smears were taken from day 4 onwards and parasitaemias counted 
microscopically. Each clone was tested for the individual drug responses in at least 2 
experimental trials. Further details of drug doses and dietary regimes are described 
in Chapter 3. 
2.3.3 Selecting for sulfadoxine/pyrimethamine resistance 
TO mice were each infected (ip) with 10 6 parasites on day 0. A high, curative 
dose of drug was administered orally to each mouse once daily, from day 3, for a 
total of 4 days. Blood smears were examined for parasites every 2 days from day 14. 
Any mice developing parasitaemias were sacrificed and their blood was stored in 
ampoules under liquid nitrogen. For subsequent work, ampoules were thawed, the 
contents injected (ip) into mice and the parasites' susceptibility to SIP, 
pyrimethamine and sulfadoxine assessed. Lines chosen for further studies were 
cloned as described previously. 
2.3.4 Stability of resistance 
To investigate the stability of resistance in the absence of drug, the resistant 
parasites were passaged weekly without drug pressure. Each week, the parasites were 
also sub-inoculated into groups of CBAICa mice and analysed for their responses to 
S/P as described in section 2.3.2. To test the stability of resistance during 
transmission, the drug resistant clones were transmitted through mosquitoes as 
described in section 2.9.1 and the resulting parasites tested for their response to SIP. 
2.4 Extraction of genomic DNA 
2.4.1 Phenol/chloroform extraction 
Mice with high parasitaemias were anaesthetised with halothane and blood 
was collected into citrate saline by cardiac dissection. The blood was passed through 
a CF1 1 cellulose (Whatman) column equilibrated with 1 x PBS (Appendix I), to 
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remove murine leucocytes (Fulton and Grant 1956). P. chabaudi parasites were 
purified following saponin (Appendix I) lysis of erythrocytes (Kreier 1977). After 
washing twice with 1 x PBS, the parasite pellet was stored at -20°C. Prior to DNA 
extraction, the parasite pellet was incubated overnight at 42°C in an equal volume of 
lysis solution (Appendix 1) containing 0.2 mg/ml proteinase K (Roche Diagnostics). 
DNA was extracted by mixing once with TE buffer (Appendix 1)-equilibrated phenol 
(Sigma) containing 0.1% (w/v) 8-hydroxyquinoline, twice with 1:1 (vlv) 
phenol/chloroform (Sigma) and finally with 24:1 (vlv) chloroform/isoamylalcohol 
(Sigma). The DNA was precipitated in 0.3 M ammonium acetate and one volume of 
isopropanol by gentle mixing. The precipitate was removed with the tip of a syringe 
needle and resuspended in TE pH 8.0. The DNA was stored at -20°C. 
2.4.2 DNA for PCR template 
A few drops of infected blood were collected from tail snips into citrate saline 
in an Eppendorf tube and centrifuged briefly at 12 000 x g. The supernatant was 
removed and the red blood cell pellet stored at -20°C. To extract DNA, 6 tl of the 
pellet was added to 1.5 ml of sterile H20, mixed by inversion and incubated at room 
temperature for 30 minutes. The tubes were spun at 12 000 x g for 2 minutes and all 
but 20-30 tl of supernatant removed and discarded. 200 ill  of Instagene matrix 
(BioRad) was added to the pellet and incubated at 56°C for 30 minutes. The samples 
were then vortexed and placed in a heating block at 100°C for 8 minutes. After 
vortexing, the tubes were spun at 12 000 x g for 2-3 minutes and stored at -20°C. 
1 p1 of the resulting supernatant was used per PCR reaction. 
2.5 Polymerase chain reaction (PCR) 
2.5.1 PCR reagents and electrophoresis 
Amplification reactions (Saiki et al. 1988) were performed on a TRIO-
thermoblock PCR machine (Biometra). Reactions were carried out in 50 p1 volumes 
containing 62.5 pM of each deoxynucleotide (Roche Diagnostics), 50 ng of each 
primer, 1.5 mIVI MgCl, 1 unit Taq polymerase (Roche Diagnostics or Promega Corp), 
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100-500 ng of genomic DNA in 1 x PCR buffer (Roche Diagnostics or Promega). 
The primers used in this work are listed in Table 2. Negative controls for each 
primer pair omitted the addition of DNA. Reactions were overlaid with 2 drops of 
light mineral oil (Sigma) and PCR performed using appropriate conditions. After 
cycling, 15 p1 of PCR product was mixed with 5 x gel loading buffer (Appendix 1) 
and electrophoresed on 1.5 % w/v agarose gels in 1 x TBE (Appendix I) in the 
presence of 0.5 j.tg/ml ethidium bromide (Sambrook et al. 1989). DNA size markers 
(Roche Diagnostics) were run alongside samples. Bands on the gel were viewed 
under ultra-violet light after an appropriate running time. 
Table 2. Oligonucleotide primers used for polymerase chain reaction. 
Primer a Sequence (5'-43') Template 
DHPS 1 TGATFG(G/T)TF(A/T)(C/T)AGATGG pppk-dhps 
DHPS2 G(A/T)GG(A/C)TTC(A/T)CC(A/T)CC(AJT)ATATC pppk-dhps 
DHPS3 GAAAAAACAAATATAGTTGGC pppk-dhps 
DHPS4 AATTCTATACCTAGGTATGCC pppk-dhps 
DHPS5 TTFCTTCGACAATTGCATG pppk-dhps 
DHPS6 TATGAGGATGTTGTATATG pppk-dhps 
PPPK1 GAAAAGCATAAAAATAAATACTACAC pppk-dhps 
PPPK2 GAAACTTTTAAAAACTACGGC pppk-dhps 
PPPK3 CTCAGATAGTCTATTAAATGTAAG pppk-dhps 
DHFR 1 GAAGATATCTCTGAAATATTCGATATATATG dhfr-ts 
DHFR2 YTCATTGATATCTGGAAATAAAACATCAC dhfr-ts 
DHFR4 CAAGTATAAGCATFAmATI'CTTG dhfr-ts 
DHFR5 GATTYFGTAATGGCTFAAAYITFGAG dhfr-ts 
TS 1 AGAGAAGTTAATGACTFAGGTCC dhfr-ts 
TS2 TAAGCTGCCATATCCATACTG dhfr-ts 
SER AGGGGATGCTITFCCCAtCb dhfr-ts 
ASN TGTAGTAATGGGAAAAGCAtAb dhfr-ts 
MSP1#3 GTFACAACAAATCGAAGCT mspl 
31 
Materials & Methods 	 Chapter II 
MSP1#4 TTGAGCATAAAGTFCAGC mspl 
AJMDR CAATFATGCATFrATFGATGCGATITItcb mdrl 
ASMDR CAATFATGCAmATFGATGCGA'YITItI" mdrl 
MDR1 CAGCTCTATCTI'TAATATCAACAATAG mdrl 
PccglO/19 CTCTGGTCATATVFGAAAAGC 	 cglO 
Pccgl 0/20 GCAAACTAATFGGAAATGAAATG 	 cgIO 
vecDHPS 1 GGTCTI'TAATFTCTFGCACTAAACC 	 Vectorette (outer) 
vecDHPS2 GGACATAATCTTAATAAACTLTGTCCTC 	Vectorette (nested) 
vecDHPS3 GGAGCAGAGGACTCACCACC Vectorette (outer) 
vecDHPS4 ATFCTGCGTACAGCAATATCCGG Vectorette (nested) 
vecDHPS5 CCTCGTCTCCTGAGTGGTGG Vectorette (outer) 
vecDHPS6 AAGACGCATGTCGTTATAGGCC Vectorette (nested) 
vecDHPS7 ATTAGCTCATTCTTGTGCTATAATAGC Vectorette (outer) 
vecDHPS8 CACAGGTGGATTAGCCATTGCG Vectorette (nested) 
vecPPPK 1 CAATTATFGTCACATTCTATATTG Vectorette (outer) 
vecPPPK2 ACACATAATTGCATATAAAC Vectorette (nested) 
vecPPPK3 CATATATGAGGTTCCTCATAGG Vectorette (outer) 
vecPPPK4 CCAATAAGTFTATGTACATATACGC Vectorette (nested) 
a  Oligonucleotides were supplied by Oswel DNA Service (Southampton, UK) or PE 
Applied Biosystems (Warrington, UK). 
Mutation-specific primers; specific-mismatches to either wild-type (ASN) or to 
mutant (SER) dhfr alleles, or AS-type and AJ-type mdr alleles are underlined. 
Lower-case letters indicate nucleotides mismatched to both alleles introduced to 
destabilise further the annealing of primer to the non-target sequence. 
2.5.2 Mutation-specific dhfrPCR 
In AS (PYR), resistance to pyrimethamine is conferred by an asparagine at 
position 106 in its DHFR. The wild-type allele codes for a protein with serine at 
position 106. Therefore, two allele-specific amplification assays were designed that 
were able to detect either the wild-type P. chabaudi dhfr allele, or the presence of the 
mutation at nucleotide 319. The oligonucleotides for the serine-specific 
amplification (SER and DHFR1) and the asparagine-specific amplification (ASN and 
DHFR4) are described in Table 2. Cycling conditions; serine-specific, 94°C for 30 s, 
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46°C for 30 s, 65°C for 30 s for 35 cycles; asparagine-specific, 94°C for 30s, 43°C 
for 30s, 65°C for 30s for 35 cycles. 
2.5.3 Mutation-specific mdrl PCR 
Sequencing studies of the P. chabaudi mdrl gene by P. Cravo (University of 
Edinburgh) revealed a polymorphism between the AS and AJ allele at a nucleotide 
denoted position 183. The AJ allele has a C at this position, while a T is present in 
the AS allele. Therefore, two allele-specific amplification assays were designed that 
were able to detect either the AJ or AS (50SIP) mdrl allele. The oligonucleotides for 
the AJ-specific amplification (AJMDR and MDR1) and the AS-specific 
amplification (ASMDR and MDR1) are described in Table 2. Cycling conditions; 
AJ-specific, 94°C for 30 s, 50°C for 30 s, 65°C for 30 s for 35 cycles; AS-specific, 
94°C for 30s, 48°C for 30s, 65°C for 30s for 35 cycles. 
2.5.4 Allele-specific mspl PCR 
The allele-specific mspl PCR was adapted from Taylor (1997). The primers 
MSP1#3 and MSP1#4 (Table 2) were used to amplify the polymorphic region of the 
P. chabaudi mspl gene using cycling parameters of 94°C for 30s, 56°C for 30s and 
65°C for 60s for 35 cycles. Size polymorphisms in the resulting PCR products were 
analysed on a 1.5% agarose gel as described. 
2.6 Isolation of the P. chabaudiAS dhps gene 
2.6.1 PcdhpsPCR using degenerate primers 
Mutations in the gene encoding DHPS have been implicated in the 
mechanism of S/P resistance in P. falciparum (Triglia et al. 1998). Therefore, the P. 
chabaudi dhps-pppk was cloned and sequenced. Subsequently, the dhps gene was 
sequenced from all the S/P selected lines to identify any possible mutations 
associated with resistance to S/P. 
Sequences of dhps genes from P. falciparum (Brooks et al. 1994, Triglia and 
Cowman 1994), Toxoplasma gondii (Pashley et al. 1997), Pneumocystis carinii 
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(Volpe et al. 1992), Escherichia coli (Dallas et al. 1992), Bacillus subtilis (Slock et 
al. 1990), and Streptococcus pneumoniae (Lopez et al. 1987) were aligned using the 
University of Wisconsin Genetics Computer Group DNA analysis software 
(UWGCG) to identify regions of sequence conservation. Two highly conserved 
regions were identified and degenerate oligonucleotides were designed for use in 
PCR. The primers DHPS 1 and DHPS2 (Table 2) were used to amplify the 
homologous gene from genomic DNA of the AS clone of P. chabaudi using cycling 
parameters of 94°C for 30s, 45°C for 120s and 65°C for 120s for 35 cycles. The 
resulting PCR products were analysed on a 1.5% agarose (Roche Diagnostics) gel. A 
band of approximately 100 bp was observed and was sequenced as described in 
section 2.6.2. 
2.6.2 ABI Prism® BigDyeTM terminator cycle sequencing 
PCR products were purified using a Concert kit (Gibco GBL) according the 
manufacturer's instructions, and sequenced directly using BigDyeTM (Perkin Elmer) 
chemistry on an ABI 377 Prism  Sequencer. 30-90 ng of template DNA was mixed 
with 4 jil of BigDyeTM terminator ready reaction mix (Perkin Elmer) and 1.6 pmol of 
appropriate primer. Reactions were overlaid with one drop of light mineral oil and 
subjected to 25 cycles of 96°C for 30 seconds, 50°C for 15 seconds and 60°C for 4 
minutes. The annealing temperature occasionally needed to be reduced for primers 
with a low melting temperature. After cycle sequencing, unincorporated terminators 
were removed by adding 25 p1 of 95% ethanol and 1 .tl of 3M sodium acetate pH 4.8 
to the reaction mixture. Tubes were incubated at room temperature for 15 minutes 
and centrifuged at 12 000 x g for 30 minutes. The supernatant was removed and 
discarded and the pellet carefully rinsed with 125 p1 of 70% ethanol and dried by 
incubating at 90°C for 2 minutes. Pellets were stored at -20°C. Immediately before 
loading, pellets were resuspended in 3 p1 of sequencing gel loading buffer (Appendix 
1) and denatured by heating at 95°C for 2 minutes. 2 p1 of each sample were loaded 
into a separate lane of the gel and the ABI 377 Prism®  Sequencer was run according 
to the manufacturer's instructions. Sequencing was repeated at least three times on 
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different templates to minimise artefacts due to Taq polymerase errors. DNA 
sequences were entered into UWGCG and submitted to BLAST (Altschul et al. 
1997) to search for homology to known sequences in the EMBLTm and GenbankTm  
databases. 
2.6.3 Construction of P. chabaudi Vectorette libraries 
The P. chabaudi dhps sequence was extended by PCR-walking using P. 
chabaudi Vectorette II (Genosys) libraries generated from genomic AS (SENS) 
DNA, digested with either AluI, ClaI, EcoRI, Hindffl, MfeI, or TaqI (Roche 
Diagnostics) restriction enzyme (Figure 5) (Arnold and Hodgson 1991). 100 ng of 
AS DNA were added to 20 units of restriction enzyme in 50 j.tl reactions containing 
the appropriate buffer. To ligate the Vectorette adapters, 5 p1 of the restriction 
enzyme-specific adapter were added to the digest with 1 p.1100 mM ATP (Sigma), 
1p.1 100 mM dithiothreitol (DDT) (Sigma) and 1 unit of T4 DNA ligase (Roche 
Diagnostics). Ligations were subjected to three cycles of 20°C for 60 minutes, 
followed by 37°C (60°C for TaqI) for 30 minutes. The original restriction site is not 
reformed by the target-Vectorettte construct. During cycling any ligated target-target 
molecules will therefore be cut by the restriction enzyme, increasing the overall yield 
of Vectorette constructs. After ligation, 200 p.1 of sterile H 20 were added to the 
ligation reaction and stored at -20°C in 20 p.1 aliquots. 
2.6.4 Extending the P. chabaudi dhps sequence 
Gene-specific primers (Table 2) were designed from sequences obtained from 
the initial dhps PCR product, and these were used with the Vectorette outer and 
nested adapter primers (Genosys) to generate additional PCR fragments from the 
libraries (Figure 3). Separate outer and nested primers were designed for each round 
of Vectorette amplification, such that the nested primer was internal to the outer 
primer. 
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round of amplification. 
3b) In the second and all subsequent rounds 
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specific primer and Vectorette primer. 
4) Step 3 is repeated in a second (nested) 
round of PCR to eliminate non-specific 
amplification products. 
5). The purified amplification product is 
sequenced using the Vectorette sequencing 
primer. The novel sequence is used to 
synthesise new DHPS-specific primers for use 









Figure 5. The Vectorette system. Diagram to illustrate the construction of a 
Vectorette DNA library (1 & 2) and one-sided PCR amplification (3 & 4) in order to 
generate new sequence by chromosome walking (5). 
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Outer reactions were carried out in 100 tl volumes containing 50 tM of each 
dNTP, 250 nM of gene-specific primer, 250 nM of Vectorette outer primer 
(Genosys), 1.5 MM  MgC12  and 1 pi of Vectorette library in 1 x PCR buffer. 
Reactions were incubated at 94°C for 3 minutes before the addition of 2.5 units of 
Taq polymerase and were subjected to 40 cycles of 94°C for 60s, 40-60°C 
(depending on the annealing temperature of the gene-specific primer) for 120s and 
65°C for 240s. Nested reactions were set up with 1 .tl of a 1 in 10 000 dilution of the 
product from the outer reaction and cycling conditions were identical to the outer 
reaction, except they contained 1 jilVi of gene-specific primer and 1 PM of Vectorette 
nested primer (Genosys). 
2.7 Manipulation of recombinant DNA 
2.7.1 Cloning PCR products 
Some PCR products, such as the initial dhps fragment and occasions when 
the sequences in the immediate proximity of the primer were desired, were cloned 
into the pCRTMII  vector using the TA CloningTM System (Invitrogen) according to the 
manufacturers instructions. 
2.7.2 Transformations 
Competent E. coli strain INVaF (Invitrogen) were transformed with vector 
DNA following the manufacturers protocol and plated onto LB (Appendix I) agar 
containing 50 pg/ml kanamycin (Sigma) and 50 jig/ml 5-bromo-4-chloro-3-indolyl-
a-D-galactosidase (X-Gal) (Sigma). Recombinant colonies were identified by 
blue/white colour screening (Sambrook et al. 1989). 
2.7.3 Long-term storage of transformed cells 
E. coli transformed with recombinant vector DNA were preserved as glycerol 
stocks at -70°C (Sambrook et al. 1989). 0.15 ml of sterile glycerol were added to 
0.85 ml of bacteria culture, briefly vortexed and flash-frozen in liquid nitrogen. 
Tubes were then transferred to -70°C for long term storage. Viable bacteria were 
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later recovered by scratching the surface of the frozen cells and streaking onto LB 
agar plates containing the appropriate antibiotic. 
2.8 Sequencing the pppk-dhps and dhfr-ts alleles 
2.8.1 Sequencing the pppk-dhps alleles 
Fragments of pppk-dhps gene were amplified using oligonucleotides designed 
from the deduced sequence. The primers PPPK1, PPPK3, DHPS3, DHPS5 and 
vecDHPS4 were used to amplify the pppk-dhps gene from genomic DNA from AS 
(PYR) and all the parasites that survived SIP selection, including AS (5051P) and AS 
(75S1P). The cycling parameters were as follows; DHPS3 and DHPS5, 94°C for 30s, 
40°C for 60s, 65°C for 120s for 35 cycles; DHPS4 and PPPK1, 94°C for 30s, 40°C 
for 60s, 65°C for 120s for 35 cycles; PPPK3 and vecDHPS4, 94°C for 30s, 45°C for 
60s, 65°C for 120s for 35 cycles. Amplification products were purified and both 
strands sequenced as described previously. 
2.8.2 Sequencing the dhfr-ts alleles 
Fragments of the dhfr-ts gene were amplified from parasite DNA using 
primers designed from available sequences of the genes from P. chabaudi AS (Cheng 
and Saul 1994) and P. chabaudi adami clone DS (Cowman and Lew 1990). The 
primers DHFR1 and DHFR2, TS 1 and TS2, and TS3 and DHFR5 (Table 2) were 
used to amplify dhfr-ts from genomic DNA of AS (PYR), AS (50S/P) and AS 
(75SIP). The cycling conditions were as follows ; DHFR1 and DHFR2, 94°C for 
30s, 45°C for 60s, 65°C for 120s for 35 cycles; TS  and TS2, 94°C for 30s, 45°C for 
60s, 65°C for 120s for 35 cycles; TS3 and DHFR5, 94°C for 30s, 45°C for 60s, 65°C 
for 120s for 35 cycles. Amplification products were purified and both strands 
sequenced as described previously. 
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2. 9 Crossing technique and analysis of the uncloned progeny 
2.9.1 Conducting the crosses and recovering the progeny 
In order to determine the genetic basis of resistance to SIP, the AS (50S/P) 
was crossed with a drug sensitive clone, AJ. Clones AJ and AS (5051P) and AJ and 
AS (7551P) were crossed by transmission through Anopheles stephensi mosquitoes 
following the basic procedure of Walliker et al. (1975) with modifications as 
described below (Figure 6). AJ and the relevant AS parasite were inoculated into 
separate groups of 4 CBA/Ca mice. On day 4-6, when parasitaemias were between 
20-40%, mice were sacrificed and blood collected by cardiac dissection, using 
heparin as an anticoagulant. 0.5 ml of blood from mice infected with each clone 
were mixed and injected (ip) into a newly weaned, splenectomised rat; a higher 
number of gametocytes is produced in this host than in mice (MacLeod and Brown 
1976, Cornelissen and Walliker 1985). 1.0 ml of infected blood from each clone 
were also injected into separate splenectomised rats as controls. When a large 
number of mature gametocytes were present in the blood (day 3-4), approximately 
500 4-6 day old A. stephensi which had been starved of glucose for 24 hours, were 
allowed to feed on the rats, which were anaesthetised (ip) with a combination of 2.5 
mg/kg Hypnovel (Roche Pharmaceuticals) and 1.25 mg/kg Hypnorm (Janssen 
Pharmaceuticals, Bristol, UK). 
Samples of mosquito midguts were examined for mature oocysts from day 7 
onwards. Sporozoite induced infections were established in CBAICa mice once 
sporozoites were present in salivary gland dissections, usually from day 16 onwards. 
Mice were infected either by feeding mosquitoes on mice (crosses 1 and 3), or by 
removing salivary glands from mosquitoes by dissection into Grace's insect medium 
(Gibco GBL), releasing the sporozoites by use of a teflon pestle and injecting them 
into mice (ip) (crosses 2 and 4). Approximately 100 mosquitoes were used for each 
feed or injection. 
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Figure 6. Crossing methodology. Rats were infected with AJ mixed with 
either AS (50S/P) or AS (75/SP). Mosquitoes were permitted to feed on rats on day 
3 or 4 and mice were inoculated with the resulting sporozoites approximately 16 days 
later. 
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2.9.2 Testing for recombination 
To test whether transmission of both parents had been successful, mutation-
specific PCR of dhfr was performed on DNA from the uncloned progeny to 
determine whether both parent clone alleles were present. To test whether crossing 
had occurred, the uncloned progeny were treated with pyrimethamine in a standard 
drug test and then examined for the presence of parental mspl types using allele-
specific PCR of this gene (Taylor 1997). The presence of the AJ mspl allele among 
drug-treated uncloned progeny would indicate recombination between the dhfr and 
mspl and that crossing between AJ and AS gametes had occurred. 
2.9.3 Cloning of progeny 
In order to perform further genetic analysis, clones were made from the 
uncloned progeny of both AJ x AS (50SIP) crosses by limiting dilution, as described 
in section 2.2.6. 
2.10 Chromosome-specific markers 
2.10.1 Types of markers used in this study 
Five types of probe were used as chromosome markers for the P. chabaudi 
genome; i) genes which had been cloned by other laboratories and developed as 
chromosome markers by Carlton (1995), and Canton et al. (1998a); ii) anonymous 
markers from a P. chabaudi genomic DNA library (Canton 1995, Carlton et al. 
1998a), iii) mutation-specific PCR; iv) allele-specific PCR (Taylor 1997) and v) 
detection of polymorphisms by PCR and restriction digestion. The original source, 
chromosome location and probing conditions of the markers used in this study are 
listed in Table 3. The majority of the markers were either known genes or 
anonymous DNA. Polymorphisms between AS (50S/P) and AJ were detected by 
RFLPs on Southern blots. 
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Table 3. Source of the markers used in this study, chromosome location and probing conditions 
Probe Marker P. chabaudi Reference! Type RFLP Washing stringency 
No. Chromosome Source Analysed for Southern blots or Information 
Location  PCR conditions 
1 Ag3020 1 (Favaloro 1993, RFLP Hindll 0.5 x SSC, 0.1 % Uncharacterised P. chabaudi 
Favaloro et al. SDS, 65°C cDNA clone (1.3 kb in EcoRI 
1993) site of pGEX-2T). 
2 Ca 2+ b (Murakami et al. RFLP AsnI 1 x SSC, 0.1 % SDS, Contains 70% of the P. yoelii 
ATPase 1990) 60°C Ca2 -ATPase gene (3.3 kb in 
HindIll site of pUC19; clone 
yH4) 
3 pBSJJO 3 W. Deleersnijder RFLP AluI 0.5 x SSC, 0.1 % P.chabaudi schizont-specific 
Institute for SDS, 65°C gene (1.2 kb cDNA in EcoRI 
Molecular Biology, site of pBluescript) 
Brussels, 
Belgium 
4 Ag3003 3 (Favaloro 1993, RFLP AluI 0.5 x SSC, 0.1 % P. chabaudi cDNA(1.5 kb in 
A Favaloro et at. SDS, 65°C EcoRI site of pGEX-2T) that 
1993) expresses a protein that reacts 
with hyperimmune serum 
5 P.1 4 (Canton et al. RFLP SspI 0.5 x SSC, 0.1 % Anonymous marker isolated 
1998a) SDS, 65°C from a P. chabaudi Sau3A 
genomic library 
6 P.9 4 (Carlton et al. RFLP HindH 0.5 x SSC, 0.1 % Anonymous marker isolated 
1998a) SDS, 65°C from a P. chabaudi Sau3A 
genomic library 
7 OJ- 4/5 (Holloway et at. RFLP HindH 1 x SSC, 0.1 % SDS, 5' terminus of the P. 
tubulin 1989, Holloway et 50°C falciparum aI tubulin gene 
at. 1990) (1.9 kb in EcoRI site of 
pBR322) 
8 Ag3035 5 (Favaloro 1993, RFLP AtuI 0.5 x SSC, 0.1 % P. chabaudi cDNA(1.3 kb in 
Favaloro et at. SDS, 65°C EcoRl site of pGEX-2T) 
1993) 
9 DNA 5 (Ridley et al. 199 1) RFLP RsaI 1 x SSC, 0.1 % SDS, Conserved region from P. 
p015 50°C falciparum DNA polymerase 
gene (1 kb in EcoRI of 
PUBS; clone pUBS 0/5) 
10 P.29 5 (Canton et al. RFLP AluI 0.5 x SSC, 0.1 % Anonymous marker isolated 
1998a) SDS, 65°C from a P. chabaudi Sau3A 
genomic library 
11 Ag3024 5 (Favaloro 1993, RFLP DraI 0.5 x SSC, 0.1 % Uncharacterised P. chabaudi 
Favaloro et al. SDS, 65°C cDNA clone (insert size not 
1993) determined; in EcoRl site of 
pGEX-2T) 
12 P.12 6 (Canton etal. RFLP Sau3A 0.5 x SSC, 0.1 % Anonymous marker isolated 
1998a) SDS, 65°C from a P. chabaudi Sau3A 
genomic library 
13 DNA 6 (Ridley etal. 199 1) RFLP AluI 1 x SSC, 0.1 % SDS, Conserved region of P. 
pola 50°C falciparum DNA polymerase 
a gene 
14 DHFR 7 (Cowman and Lew MS- N/A SER-specific: P. chabaudi dhfr gene. AJ 
1989) PCR 94°C/30 s, 46°C/30 allele detected with the 
s, 65°C/30 s x35, primer pair SER and DHFR1, 
ASN-specific: AS (50SIP) allele detected 
94°C/30s, 43°C/30s, with ASN and DHFR4 (Table 
65°C/30s x 35. 2). 
15 P.23 7 (Carlton et al. RFLP AsnI 0.5 x SSC, 0.1 % Anonymous marker isolated 
1998a) SDS, 65°C from a P. chabaudi Sau3A 
genomic library 
16 MSP-1 8b (Deleersnijder et RFLP N/A 94°C /30s, 56°C /30, P. chabaudi merozoite 
at. 1990) 65°C /60s x 35 surface protein, MSP-1 
genomic DNA (5.4 kb in 
EcoRI site of pBluescript; 
clone pBS RX4) 
17 hsp86 8 (Su and Wellems RFLP HindII i x SSC, 0.1 % SDS, P.falciparum heat shock 
1994) 50°C protein 86 gene (2 kb in NsiI 
site of pcDNA II) 
18 Ag3027 9 (Favaloro 1993, RFLP RsaI 0.5 x SSC, 0.1 % P. chabaudi cDNA(1.3 kb in 
Favaloro et al. SDS, 65°C EcoRl site of pGEX-2T) 
1993) 
19 AMA-] 9 (Marshall et al. RFLP SspI 0.5 x SSC, 0.1 % Complete P. chabaudi apical 
1989) SDS, 65°C membrane antigen gene (2.6 
kb in BamHIIEcoRI site of 
pBluescript) 
20 cDNA bc (Silveira etal. RFLP AluI 0.5 x SSC, 0.1 % Uncharacterised P. chabaudi 
121 1984, Sharkey et SDS, 65°C cDNA clone (190 bp in PstI 
al. 1988) site pBR322) 
21 EF-1a 11 D. Williamson, RFLP HindH 1 x SSC, 0.1 % SDS, P.falciparum clone 
National Institute 50°C containing linked pfPK5 
for Medical (yeast cdc-2 gene homologue) 
Research, Mill Hill, and elongation factor 1-a 
London, Genbank genes (4.3 kb in Hindffl site 
accession no. of EMBL8, clone pPF-1; 451 
X60488 bp EF1-(x gene in PvuH site) 
CN 
22 PCNA 11 (Kilbey et al. 1993) RFLP HindII 1 x SSC; 0.1 % SDS, P. falciparum proliferating 
45°C cell nuclear antigen (PCNA) 
gene (800 bp in 
HindIII/EcoRI site of 
pBluescript 
23 P.22 11 (Canton et at. RFLP AsnI 0.5 x SSC, 0.1 % Anonymous marker isolated 
1998a) SDS, 65°C from a P. chabaudi Sau3A 
genomic library 
24 mdri 12 P. Cravo, MS- N/A AS-specific: P. chabaudi multi-drug 
University of PCR 94°/30s, 48°C /30s, resistance gene (mdri). 
Edinburgh, 65°C/30s x35. 
Edinburgh, UK. AJ-specific: 
94°c/30s, 50°C/30s, 
65°C x35. 
25 aldol 13 '  (Meier et al. 1992) RFLP Hindll 1 x SSC, 0.1 % SDS, P. berghei aldolase-1 (a/do-i) 
60°C gene (900 bp NcoI fragment) 
26 cDNA 13 (Silveira etal. RFLP Dral 0.5 x SSC, 0.1 % P. chabaudi 37 kDa antigen 
148 1984, Sharkey et SDS, 65°C gene (330 bp in PstI site 
al. 1988) pBR322) 
27 G6PD 13'  (O'Brien etal. RFLP AluI 1 x SSC, 0.1 % SDS, P.falciparum glucose-6- 
1994) 50°C phosphate dehydrogenase 
(G6PD) gene (588 bp in 
EcoRI site of pGEM) 
28 Pfcrk3 13 C. Doerig RFLP AluI 1 x SSC, 0.1 % SDS, P.falciparum mitogen- 
INSERM, Paris, 50°C activated protein kinase- 1 
France. gene (500 bp in EcoRI site of 
pCR H) 
29 Ag3040 14 (Favaloro 1993, RFLP RsaI 0.5 x SSC, 0.1 % P. chabaudi cDNA(1.3 kb in 
Favaloro et al. SDS, 65°C EcoRl site of pGEX-2T) 
1993) 
00 
30 PccglO 14 P.Hunt & RFLP EcoRVI 94°C /30s, 50°C/i P. chabaudi gene homologue 
P.Donleavy, HindIII mm, 620C/2 min for of the P. falciparum 
University of 35 cycles chioroquine resistant 
Edinburgh, transporter (CRT) (cgio) 
Edinburgh, UK. 
a Chromosomal location determined by Canton et at. (I 998a). 
b As determined by Janse et al. (1994). 
As determined by Sharkey et at. (1988). 
d Chromosomal location determined through inheritance of alleles in the progeny of the AJ x AS (3CQ) (Canton et at. 1998a) and AJ 
x AS (50SIP) crosses. 
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2.1 0.2 Polymorphisms detected by PCR 
Mutation-specific PCR and allele-specific PCR, used to determine dhfr, mdrl 
and msp-1 genotypes were performed as described in Sections 2.5.2-2.5.4. 
Polymorphisms between the AS (50S/P) and AJ P. chabaudi cglO gene were 
detected by PCR and restriction digestion. The PccglO primers were designed by P. 
Hunt and P. Donleavy (University of Edinburgh) and the cycling parameters were: 
94°C for 30s, 50°C for 60s and 62°C for 120s for 35 cycles. Products were digested 
with EcoRVIHindllI and run on a 1.5% agarose gel to detect RFLPs as described. 
2.11 Hybridisation of labelled DNA to Southern blots 
2.11.1 Restriction digests of genomic DNA 
P. chabaudi genomic DNA was digested following standard procedures 
(Sambrook et al. 1989). Briefly, 2.5-3 jig of DNA was incubated overnight at the 
desired temperature in 5-10 units of the appropriate restriction enzyme and buffer 
(Roche Diagnostics). 
2.11.2 Southern blotting 
DNA digests were mixed with an appropriate volume of 5 x gel loading 
buffer and electrophoresed on 1-1.5 % agarose gels in 1 x TBE buffer. After 
electrophoresis, gels were depurinated in 0.25 M HC1 for 15 minutes and Southern 
blotted (Southern 1975) onto Hybond-N+ (Amersham-Pharmacia) by alkaline 
transfer using a vacuum transfer system (Anachem) (Sambrook et al. 1989). 
2.11.3 DNA radiolabelling 
DNA to be used for probing was labelled with [(X12  P]dATP (Amersham-
Pharmacia) by random hexamer priming (High Prime DNA Labelling kit, Roche 
Diagnostics) following the manufacturer's protocol. 
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2.11.4 Hybridisation 
Southern blots were placed in screw-capped glass hybridisation bottles 
(Hybaid) and incubated in pre-hybridisation solution (Appendix I) at the desired 
hybridisation temperature (see Table 3) for at least one hour. Blots were incubated 
inside a Maxi-Oven (Hybaid) with continuous rotation. 
0.1 mg sheared salmon sperm DNA (Anachem) were added to the labelled 
probe, the volume made up to 1 ml with sterile H 20 and the solution boiled for 5 
minutes. After leaving on ice for a further 5 minutes, the probe was added to the pre-
hybridising blots and hybridised overnight for at least 12 hours. 
2.11.5 Washing Southern blots 
Hybridisation solutions were carefully disposed of and blots were washed 
once at room temperature in 2 x SSC (Appendix I), 0.1% SDS for 5 minutes. Blots 
hybridised with homologous probes were then washed with 0.5 x SSC, 0.1% SDS at 
65°C for at least one hour with one change of solution. Blots hybridised with 
heterologous probes were washed at a stringency appropriate to the degree of 
conservation between the probe and P. chabaudi (see Table 3). 
2.11.6 Exposing and developing X-ray film 
Southern blots were wrapped in cling film and exposed to autoradiography 
film (Kodak XAR-5) overnight at -70°C in an autoradiography cassette. The X-ray 
film was developed in an autoradiographer developer (Exograph). If signals were 
weak, the membranes were exposed to film for longer periods of time. 
2.11.7 Stripping Southern blots 
Southern blots were stripped of probe in 100 mM NaOH for at least 30 
minutes at room temperature with agitation and at least one change of solution. Blots 
were washed briefly in 5 x SSC, wrapped in cling film and stored at 4°C. 
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2.12 Linkage analysis 
Linkage was assessed by comparing the inheritance pattern of each 
chromosome-specific marker with the inheritance of the SIP resistance phenotype 
(Lander and Botstein 1989). Linkage ratios were determined as the ratio of the 
number of progeny showing linkage of S/P susceptibility with an individual marker 
to the total number of progeny analysed. 
Resistance to SIP may be a complex trait, involving the additive effects of 
two or more genes. Therefore the data were analysed in order to map the trait to 
discrete quantitative trait loci (QTL). Quantitative trait data analysis was carried out 
by calculating the mean difference in log parasitaemias, on day 6 following treatment 
with either 25/1.25 mg/kg SIP, 50/2.5 mg/kg SIP or 10 mg/kg pyrimethamine, 
between groups of progeny clones inheriting the AS (50S/P) allele of the marker and 
groups inheriting the AJ allele of the marker. The mean difference in log 
parasitaemias could also be calculated for day 8 following treatment with 50/2.5 
mg/kg SIP. The Student's t-test was used to see whether differences in the means 
were significant (Appendix II). 
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3. Results: Selecting for Resistance to 
Sulfonamide Drugs 
3.1 Susceptibility of AS (SENS) and AS (PYR) to sulfonamide drugs 
3.1.1 Susceptibility of AS (SENS) and AS (PYR) to sulfadoxine 
The most useful starting material for identifying genes determining resistance 
is resistant mutants selected from sensitive clones. Direct examination of the 
sensitive and resistant forms can then be made to search for mutations in candidate 
genes which cause the resistance. In order to select for mutants of P. chabaudi 
resistant to sulfonamide drugs, it was first necessary to assess the level of sensitivity 
in the starting material, the clones AS (SENS) and AS (PYR). This allowed an 
appropriate drug dose for selection to be determined. However, the susceptibility of 
the parasites to sulfadoxine depends on levels of Para-aminobenzoic acid (PABA) in 
the host diet, since the drug competes with PABA for the active site of the DHPS 
enzyme. A PABA- and folate-deficient mouse diet was therefore obtained (ICN) so 
that the levels of the antagonists could be adjusted as required. The sulfadoxine 
responses of parasites in mice on normal diets and mice on the PABA- and folate-
deficient diet were then compared. 
Groups of CBA/Ca mice were fed either on normal diet ad libitum 
supplemented with 0.05% PABA in their drinking water or on a PABA- and folate-
deficient diet ad libitum with no PABA in their drinking water. Mice were kept on 
this regime for one week before being infected with either AS (SENS) or AS (PYR), 
and treated with varying doses of sulfadoxine in a 4 day test as described in section 
2.3.2. Both AS (SENS) and AS (PYR) parasites were found to be resistant to 5 
mg/kg sulfadoxine in mice fed on a normal diet (Table 4). In these mice, a dose of 
25 mg/kg sulfadoxine had little effect on the growth of AS (SENS), but AS (PYR) 
growth was delayed relative to the undrugged control. A dose of 125 mg/kg 
sulfadoxine cleared AS (PYR) initially, but parasites started to recrudesce on day 7, 
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Table 4. The effect of PABA on the sulfadoxine sensitivities of AS (SENS) and AS (PYR). 
The sulfadoxine susceptibilities of AS (SENS) and AS (PYR) were compared in mice fed on normal diet to infections in mice 
maintained on a folate- and PABA-deficient diet with no PABA in the drinking water. 
Normal Diet PABA-and folate-deficient diet 
Sulfadoxine Day 4 	 Day 7 Day 4 Day 7 
Clone 	 Dose (mg/kg) Parasitaemiaa 	 Parasitaemiaa Parasitaemiaa Parasitaemiaa 
AS (SENS) 0 ++++ 	 pp PP 
5 pp - - 
+++ 	 pp - - 
+++ pp - - 
25 pp - - 
++++ 	 pp - - 
+++ pp - - 
125 + - - 
± 	 ++++ 
AS (PYR) 	 0 +++ 	 pp 






125 - ++ 	 - 	 - 
aparas itaemia  scoring: - = no visible parasites; ± <0.5>0.1 parasites/500 rbcs; i-> 0.5 parasites/500 rbs; ++ > 2 parasites/500 rbcs; 
++++> 10 parasites/500 rbcs; +++++> 50 parasites/500 rbcs; ++++++> 200 parasites/500 rbcs; pp, post-peak of infection. 
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while AS (SENS) was resistant to 125 mg/kg sulfadoxine but peaked two days later 
than the undrugged control. Taken together, these results show that AS (PYR) is 
more sensitive to sulfadoxine than AS (SENS). In mice maintained on the folate-
and PABA-deficient regime, AS (SENS) and AS (PYR) were sensitive to all doses of 
sulfadoxine, including the lowest dose, 5 mg/kg (Table 4). This test confirmed that 
susceptibility to sulfadoxine is antagonised by a high level of PABA and/or folic acid 
in the host diet. 
In the next tests, the PABA- and folate-deficient diet was supplemented with 
0.005% PABA in the rodents' drinking water. The sulfadoxine susceptibility tests 
were then repeated on this regime to assess an appropriate dose for selecting for 
resistance to sulfadoxine (Table 5). All subsequent sulfadoxine tests, unless 
otherwise stated, were in mice on this diet. As expected, the presence of 0.005% 
PABA in the drinking water resulted in both AS (SENS) and AS (PYR) having 
decreased sensitivity to sulfadoxine. When treated with 2 or 10 mg/kg sulfadoxine, 
AS (SENS) showed little reduction in its growth compared to the undrugged control; 
when treated with 50 mg/kg sulfadoxine, it was cleared at first, but started to 
recrudesce on day 9. AS (PYR) showed a reduction in its growth rate relative to the 
undrugged control when treated with 2 mg/kg and 10 mg/kg sulfadoxine, although 
the parasites recrudesced on day 6 and 9 respectively; all AS (PYR) parasites were 
eradicated by 50 mg/kg sulfadoxine. 
The dose required to select for resistance must eradicate all parasites under 
normal circumstances. These results suggested that a dose higher than 50 mg/kg 
sulfadoxine would be needed to select for sulfadoxine resistance from clone AS 
(SENS). Subsequently, a dose of 75 mg/kg sulfadoxine was chosen in attempts to 
select for resistance. Since 50 mg/kg sulfadoxine eradicated all AS (PYR) parasites 
and 10 mg/kg sulfadoxine showed a marked reduction in its growth rate, 40 mg/kg 
sulfadoxine was chosen as an appropriate dose to select for sulfadoxine resistance in 
AS (PYR). 
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Table 5. The sulfadoxine susceptibilities of AS (SENS) and AS (PYR). 
Mice were maintained on a folate- and PABA-deficient diet supplemented with 











AS (SENS) 0 pp pp pp 
2 pp pp pp 
+++ pp pp pp 
+++++ pp pp pp 
10 +++ pp pp pp 
++ pp pp pp 
++++ pp pp pp 
50 - - pp 
- ± ++++ pp 
- ± +++++ pp 
AS (PYR) 0 pp pp pp 
2 ± PP PP 
- - ++ pp 
± ++++ pp pp 
10 - - ++ pp 
- + ++ pp 
- - ++ pp 
50 - - - - 
aparas itaea  scoring: - = no visible parasites; ± <0.5>0.1 parasites/500 rbcs; + > 0.5 
parasites/500 rbs; +± > 2 parasites/500 rbcs; ++++> 10 parasites/500 rbcs; +++++> 50 
parasites/500 rbcs; pp, post-peak of infection. 
3.2 Selection for resistance to sulfadoxine 
3.2.1 Results of sulfadoxine selection 
One hundred mice on a PABA- and folate-deficient diet supplemented with 
0.005% PABA in the drinking water, were injected (ip) with 106  parasites of clone 
AS (SENS) and 75 mg/kg sulfadoxine was administered to the mice, from day 3, for 
a total of 4 days (section 2.3.3). A further 100 mice were injected with AS (PYR) 
and similarly drugged with 40 mg/kg sulfadoxine. The mice infected with AS (PYR) 
failed to develop parasites in their circulation, while 15 of the mice injected with AS 
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(SENS) developed patent parasitaemias by day 18. Parasites were collected and 
frozen from all 15 mice and are referred to here as sulfadoxine-selected lines. 
3.2.2 Sulfadoxine responses of the sulfadoxine-selected lines 
The sulfadoxine-selected lines were analysed for their responses to sulfadoxine 
and compared to that of AS (SENS). All 15 selected lines showed drug responses 
identical to AS (SENS) (data not shown). Selection for resistance therefore had not 
been successful. 
3.3 Selection for resistance to sulfadoxine/pyrimethamine 
3.3 Susceptibility of AS (SENS) and AS (PYR) to SIP 
Before selecting for resistance to the S/P combination, the sensitivities of AS 
(SENS) and AS (PYR) were investigated. All S/P tests were in mice fed on normal 
diets supplemented with the standard amount of PABA (0.05%) in the drinking 
water. AS (SENS) was found to be totally sensitive to 25/1.25 and 50/2.5 mg/kg S/P, 
and growth was reduced relative to the undrugged control when treated with 5/0.25 
mg/kg S/P (Table 6). A dose of 50/2.5 mg/kg S/P was thus chosen as appropriate to 
select for resistance in AS (SENS). 
A dose of 5/0.25 mg/kg S/P had little effect on the growth of AS (PYR) and 
while doses of 50/2.5 and 75/3.75 mg/kg S/P cleared parasites initially, recrudesces 
were observed on day 14 (Table 6). A higher dose was therefore needed to eradicate 
all AS (PYR) parasites; 125/6.25 mg/kg S/P was thus chosen as an appropriate dose 
to select for S/P resistance in this parasite. 
The synergistic activity between sulfadoxine and pyrimethamine can clearly 
be seen in Table 6. AS (PYR) is resistant to a dose of 2.5 mg/kg pyrimethamine, 
while 50 mg/kg sulfadoxine results in approximately a 3 day delay to reach peak 
parasitaemia on normal diet. However, when these two doses are combined, AS 
(PYR) is eliminated from the circulation, recrudescing on day 14. 
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Table 6. Susceptibility of AS (SENS) and AS (PYR) to sulfadoxinel 
pyrimethamine (SIP) 
Clone Drug Dose Day 8 Day 10 Day 14 
Parasitaemiaa Parasitaemiaa Parasitaemiaa 
AS (SENS) 0 pp pp pp 
50 mg/kg SDX pp pp 
2.5 mg/kg PYR - - - 
5/0.25 mg/kg SIP ++ pp 
++ +++++ pp 
± ++++ pp 
25/1.25 mg/kg S/P - - - 
50/2.5 mg/kg S/P - - - 
AS (PYR) 0 pp pp pp 
50 mg/mg SDX ± .4-+++ pp 
2.5 mg/kg PYR pp pp pp 
5/0.25 mg/kg S/P +++++ pp pp 
++++ pp pp 
+++++ pp pp 
25/1.25 mg/kg S/P ++ pp 
++ +++++ pp 
+++ pp 
50/2.5 mg/kg S/P - - - 
- - + 
75/3.75 mg/kg S/P - - ± 
- - + 
aparas itaea  scoring: ± < 0.5 >0.1 parasites/500 rbcs; +> 0.5 parasites/500 rbs; ++> 2 
parasites/500 rbcs; ++++> 10 parasites/500 rbcs; +++++> 50 parasites/500 rbcs; ++++++> 
200 parasites/500 rbcs. SDX, sulfadoxine; PYR, pyrimethamine; pp, post-peak of infection. 
3.3.2 Results of sulfadoxinelpyrimethamine selection 
One hundred mice on normal diet, were injected with AS (PYR) and selected 
with 125/6.25 mg/kg S/P (section 2.3.3). Fifteen out of the 100 mice infected with 
AS (PYR), developed patent parasitaemias on day 18, 15 days after the last 
administration of S/P. Parasites were collected and frozen from all 15 mice; these are 
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referred to here as SIP-selected lines. A further 52 mice were injected with AS 
(SENS) and treated with 50/2.5 mg/kg SIP. Fourteen out of the 52 mice infected 
with AS (SENS) developed patent parasitaemias on day 18. These parasites were 
preserved, but not characterised further in the present work. The remainder of this 
work involves the characterisation of the SIP-selected lines that were derived from 
AS (PYR). 
3.3.3 Sulfadoxine/pyrimethamine responses of the SIP selected lines 
The growth patterns of each of the SIP-selected lines were compared under 
SIP pressure to that of the parent clone, AS (PYR). Eight lines showed increased 
resistance to SIP, while the remaining seven had drug responses comparable to that 
of AS (PYR). Six of the eight resistant lines showed reductions in their growth rates 
compared to the undrugged control following 50/2.5 mg/kg SIP treatment, but all 
grew more quickly than AS (PYR). These lines were classified as SIP resistant (R). 
The remaining two lines grew quickly under 50 mg/kg SIP and recrudesced after 
treatment with 75/3.75 mg/kg SIP. These parasites were denoted as having high-level 
SIP resistance (HR). 
One R and one HR line were chosen for further analysis. These lines were 
cloned by limiting dilution (section 2.2.6). The SIP resistant clone was then denoted 
as AS (50SIP) while the clone with high-level SIP resistance was denoted as AS 
(75S/P). The SIP susceptibilities of AS (75SIP) and AS (50SIP) are shown in Figure 
7. 
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Figure 7. 	Assessment of the sulfadoxine/pyrimethamine (SIP) 
sensitivities of the clones AS (PYR), AS (50SIP) and AS (75S1P). The S/P 
sensitivities of AS (50S/P) JO and AS (75S1P) 	were compared to AS (PYR)U 
following treatment in a 4 day drug test with 50 mg/kg S/P. The data points are the 
mean ± S.E. of three mice from a representative experiment. 
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3.3.4 Sulfadoxine susceptibilities of the SIP resistant clones 
In tests for response to 5 mg/kg sulfadoxine, AS (50SIP) grew more quickly 
than the clone with high-level S/P resistance, AS (75S1P), while AS (PYR) was 
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Figure 8. Assessment of the sulfadoxine sensitivities of the clones AS 
(PYR), AS (50SIP) and AS (7551P). The sulfadoxine sensitivities of AS (50SIP) 
and AS (75S/P) were compared to AS (PYR) M following treatment with 5 
mg/kg sulfadoxine in mice fed on PABA- and folate-deficient diet supplemented 
with 0.005% PABA in the drinking water. The data points shown are the mean ± 
S.E. of three mice from a representative experiment. 
61 
Results: Selecting for Resistance to Sulfonamide Drugs 	 Chapter III 
3.3.5 Pyrimethamine resistance 
AS (50S/P) grew faster under pyrimethamine pressure than clone AS (75S1P), 
which showed a similar growth rate to AS (PYR) following 10 mg/kg 
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Figure 9. Assessment of the pyrimethamine resistance of the clones 
AS (PYR), AS (50SIP) and AS (7551P). The pyrimethamine resistance of AS 
(50S/P) 0 and AS (75S/P) 0 were compared to AS (PYR) LI following treatment 
in a 4 day drug test with 10 mg/kg pyrimethamine. The data points shown are the 
mean ± S .E. of three mice from a representative experiment. 
3.4 Stability of resistance in the absence of drug 
To investigate the stability of resistance in the absence of drug, the resistant 
parasites were passaged weekly to uninfected mice without drug pressure. Each 
week, the parasites were also sub-inoculated into groups of CBA/Ca mice and 
analysed for their responses to S/P. AS (755/P) retained resistance after nine weekly 
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passages in the absence of drug, while AS (50S/P) remained resistant after 20 weekly 
passages without drug pressure. AS (50S/P) was successfully transmitted through 
mosquitoes and the subsequent sporozoite-induced infection was found to have a 
drug-resistance phenotype identical to AS (50SIP). Thus, SIP resistance in AS 
(5051P) is stable in the absence of drug and after mosquito transmission. AS (755/P) 
was eventually transmitted through mosquitoes, but the drug-resistant phenotype of 
the resulting parasites was not determined. 
3.5 Summary of drug responses 
Two SIP resistant clones, AS (5051P) and AS (75S/P), were selected from AS 
(PYR) and chosen for further analysis. AS (PYR) parasites were eliminated by SIP 
treatment, whereas AS (50SIP) and AS (75SP) recrudesced following S/P pressure. 
However, each mutant possessed a different drug resistant phenotype. The AS 
(7551P) clone always recrudesced before the AS (50SIP) clone following treatment 
with SIP, while AS (50SiP) always appeared before AS (75S/P) when treated with 
either sulfadoxine or pyrimethamine alone. The drug responses of these clones are 
summarised in Table 7. 
Table 7. Summary of drug sensitivities of the parent clone AS (PYR) 
and the S/P-selected clones, AS (50SIP) and AS (5051P) 
Drug' 	 AS (PYR) b 	AS (SOS/P) b 	AS (75S/P) b 
50/2.5 mg/kg SIP 	 S 	 R 	 HR 
10 mg/kg pyrimethamine 	R 	 HR 	 R 
5 mg/kg sulfadoxine 	S 	 HR 	 R 
a  Drug-susceptibilities as measured by the 4-day test described in section 2.3.2. 
b  5, sensitive; R, resistant; HR, highly resistant. 
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4. Results: The dihydropteroate synthase and 
dihydrofolate reductase genes of P. chabaudi. 
4.1 Isolation of the P. chabaudipppk-dhps 
4.1.1 Cloning and sequencing the P. chabaudipppk-dhps gene 
Mutations in the gene coding for dihydropteroate synthase (DHPS) have been 
implicated in the mechanism of S/P resistance in P. falciparum (Triglia et al. 1998). 
Therefore, to identify any possible mutations associated with resistance to SIP, the P. 
chabaudi homologue was cloned and sequenced. The dhps gene was then sequenced 
from AS (PYR) and from all the SIP selected lines. 
To isolate P. chabaudi dhps, degenerate oligonucleotide primers were used to 
amplify a portion of the gene from clone AS (SENS). The resulting PCR product of 
about 100 bp showed significant homology to the P. falciparum dhps sequence. The 
full length sequence coding for the P. chabaudi PPPK-DHPS was subsequently 
obtained through the technique of 'PCR-walking' using Vectorette genomic DNA 
libraries. 
4.1.2 Analysis of the nucleotide and predicted amino acid sequence 
A region of 2489 bp was fully sequenced and compared to the P. falciparum 
pppk-dhps sequence (Brooks et al. 1994, Triglia and Cowman 1994). Based on the 
structure of the P. falciparum gene, the P. chabaudi homologue is predicted to have 
three open reading frames from 24-130, 368-2164 and 2317-2432 bp (Figure 10). 
The two introns contain multiple stop codons and their positions relative to introns in 
the P. falciparum pppk-dhps gene are highly conserved. However, the comparison 
suggests that approximately 30 nucleotides coding for the first 10 amino acids, 
including the start codon, are missing from the 5' end of the P. chabaudi pppk 
sequence. Stop codons and the absence of a start codon upstream of the first codon 
shown in Figure 10, suggest that an additional intron may be present at the 5' end of 
the gene. 
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1 	ctcagatagtctattaaatgtaaGAA AAC AAC AAA GGG AAT ATT GTT GTT TTA AAC TTT GGA ACA ACT GAC AAA ACA AAT GCT GTA ACA 
1 
E N N K G N I V V L N F G T T D K T N A V T 
90 ATT TTA GAA ACG GCA TTA TAT CTT ACT GAG AAG TAT ATA Ggttagataaaagcagacaagtaaataacaaataaatgacattcataaggcatgtgatt 
23 I L E T A L Y L T E K Y I 
vec PFFK4 	 v!_­ PFPK? 
188 
301 tatgtaaatgcatatcctttccatcttttcttattttgattattttattatttttatcaacttgcagGAAAA ATA ATA AP1T ACT TCG TAT ATG TAC GAA 
36 	
G K I 	I N T S Y M Y E 
400 ACT GTT CCA GAG TAT ATT GTA CTT GAC AAA AGT AAT ATA CCG AAT AAT ATA ATA GGA GAA GAT CAT CCA TAT GAT GTA AGT AGT 
47 T V P E Y I V L D K S N I P N N I I G E D D P Y D V S S 
484 TTA AAC GAA TTG GTA AAT GGT TTG GAA AAT TCG AAA TAT GAG AAT GTG TTT CAA GAG GAT GAA AGT TTA GTT TCA CAA TGT GAPL 75 L N E L V N G L E N S K Y E N V F Q E D E S L V S Q C E 
568 GAA TAT GAA ATA TTT TTA AAT AAT AAA GAT TTA TTT GAPL AAT AAA ATA AAA CAG ATT AGT GTC GAA GAA TAC AAA ACT GAG GCT 
103 E Y E I F L N N K D L F E N K I K Q I S V E E Y K T E A 
FiPK1 
652 AGT AAT ATA ATA AAG GAA AAT GAT GAA ATA ATG AAA ATT APLT TTA GAA AAG CAT AAA AAT AAA TAC TAC ZCA AAT TAT TTT TAT 
131 S N I I K E N D E I M K I N L E K H K N K Y Y T N Y F Y 
PFPK2 
736 AAT TTA G4CC GTA GTT TTT AAA AGT TTC ATT CAT CAT CCG CTA CAC TTA TTA GTA ATA TTA AAA TAT ATA GAG CAT CTA ATG AAA 
159 N L A V V F K S F I D D P L H L L V I L K Y I E H L M K 
820 AGPk AAA AAT TCT AAA GAG GTT GAPL AAA TTT GAA AAC CGG TTG ATA GAC ATC GAT ATA TTA TTT TTT AAT AAT TAT ACT ATC TTT 
187 P. K N S 	K E V E K F E N P. L 	I 	D 	I 	D 	I 	
L 	F 	F N N Y T 	I 	F 
vecPPPK2 vecPPPKl 
904 GAA AAA AAT ATA AAT TTA ACA AAA GAT LGT  1:  	
GCA ATT ATG TGT AAA TAT AT AAT ATA GAA TGT GAC GAT AAT TGT AAT 
215 E K N I N L T K D S L Y A I M C K Y I N I E C D D N C N 
988 AAA CGG TTA AAA GAT ATT GAG CAA ATA AAG CAT AAT ATA AAA TTT CTT TCT ATT CCT CAT GTA TAT ACA AAA CAT AGA TAT AGT 
243 K P. L K D I H Q I K D N I K F L S I P H V Y T K H R Y S 
1072 ATA CTG TTA TGC TTA AAT GAT ATT ATA CCA AAT TAT AAG CAC AAT ACT TTA AAA GAA ACT ATA AAT AAT TTA TAT GAA GAA TTT 
271 I L L C L N D I I P N Y K H N T L K E T I N N L YE E F 
1156 ATT ACT AAC TTT TCA AAA CTA TAT AAT ACA TGT ATC AAA AAA TAT AAC AAA CGA TTA TAT GTT C AAPL APkT GM GTA TG TAT 
299 I T N F S K L Y N T C I K K Y N K P. L Y V L K N E V L Y 
Figure 10. Nucleotide and predicted amino acid sequence of the PPPK-DHPS of P. chabaudi. The nucleotides are 
numbered from the first nucleotide in the sequence. Lower case letters indicate non-coding nucleotides and an asterisk marks the 
position of the predicted stop codon. The black arrows indicate the boundaries of the oligonucleotides used in either Vectorette PCR 
to extend the sequence, or to amplify the pppk-dhps for sequencing. Blue arrows indicate the junction of the PPPK and DHPS 
domains. 
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Figure 10. continued 
DHPS3 v cDHPS4 
1240 TTA AAA GAA AAA ACA AAT ATA GTT GG ATA TTA AAT ACC AAT TAT AAT TCT TTT TCG GAT GGT CGT TTA TTT GTT AAA C G GAT 
327 L K E K T N I V C I L N T N Y N S F S D G G L F V K P D 
  
vecDHPS2 
1324 04icW4 4  GTA CG   OATA TTT CAA ATG ATA AAT GAA GGT GTA GAT ATT ATA GAT ATA GGT GGT GAG TCC TCT GCT CCT TTT GTT 
355 I A V R R I F Q M I N E G V D I I D I G G E S S A P F V 
1408 TCT CAT AAT CCA GAA ATT AAA GAA CGT GAT TTG GTA ATT CCT GTA PTA GAA TTA TTT GAA CAG GAG TGG AAT AAA ATG TTA CAA 
383 S H N P E I K E R D L V I P V L E L F E Q E W N K M L Q 
1492 ATT TGT AAA AAT GAA AAA ATA GAT AAA GAA GAA AAG GGA ATC GAG AAA CAG AAT GAT AAA TTA AAT CAA AAT AAC CTA TCT TTA 
411 I C K N E K I D K E E K G I E K Q N D K L N Q N N L S L 
1576 CAA ACA AAA ACA TCA ACT ATT TAT AAA CCG CCT ATA AGT ATA GAT ACC ATG AAC TAT GAT TTA TTC AAA GAA TGT GTT GAC AAA 
439 Q T K T S T I Y K p p i s I D T M N Y D L F K E C V D K 
1660 AAT TTA GTT GAT ATA CTT AP.T GAT ATA AGT GCA TGT ACA AAT GAC CCC CAA ATA ATT AAG PTA TTA AAG AAA AAA AAT AAA TAT 
467 N L V D I L N D I S A C P N D P Q I I K L L K K K N K Y 
DHPS6 
1744 TAT AGT GTT GTT TTA ATG CAT AAA AGA GGA GAT CCA CAT ACT ATG GAC ATG TTA ACA CAA TAT GAG CAT GTT GTA TAT tAT ATT 
495 Y S V V L M H K R G D P H T M D M L T Q Y E D V V Y D I 
DHPS4 
1828 AAA AAA TAT TTA GAG GkA AGA TTA ?AT TTT CTA ACT TTA AAT GtC ATA CCT AGG TAT AGA ATT ATA PTA CAT ATC GGT TTA GGT 
523 K K Y L E H R L N F L T L N C I P R Y F. I I L D I C L C 
1912 TTT GCA AAG AAG CAT GAT CAA TCA APT AAA TTA TTA CAA AAC ATA CAT GTT TAT GAP CAT TAT CCT CTT TTT ATT CCC TAT TCA 
551 F A K K H D Q S I K L L Q N I H V Y D D Y P L F I G Y S 
1996 AGG AAG AGA TTT ATA TCG CAT ACT TTC GCA CAA ACG TGC CTT GAA ATA TGT CCT AAT ACT APT CCC CAA kAT GAA AAT ATT CAA 
579 R K R F I S H T L A Q T C V E I C P N P I A Q N H N I Q 
2080 AAT GAT CAA TCT GAT AAA AAC GGA TTT ACA GTT AGC AAT ATA AGA AAG GAC AAA GAC CAC TAT CTT TAT CAA AAA AAT ATA TTA 
607 N D E S D K N G F T V R N I F. K D K D Q Y L Y Q K N I L 
vecDHPS7 
2164 Ggtatttttattctgttttatgcttttgtatatacataaattagctcattcttgtgctataatag occttatatatttgccttatttttgttgagttgcatgcatatattagc 
635 G 
vecDHPS8 
2275 tttataatatttttaattatttacattttttttcatacacagGT CCA TTA CCC ATT GC TCA TAT TGC TTT GAA AAA AAA GTT GAA ATG ATA 
636 	 C L A I A S Y C F E K K V E M I 
DKFS5 
2367 AGA GTT CAT CAT GTT TTT GAA ACT AGA TGT CTT CTA CAT ATG ATC AAA AAA TTC CAC CAA AAT CAA taaac4atgcaattgtcgaaga 
652 R V H D V F E T R C V L D M H K K L H Q N E * 
2454 aaaaaatatattatcataattagtaaactatcttca 
ON 
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Extensive sequencing upstream failed to locate the start codon, or a region 
with homology to the 5 end of the P. falciparum sequence. Assuming that there are 
still another 10 amino acids to be identified, the coding sequence predicts a mature 
polypeptide of 683 amino acids, with an approximate molecular mass of 80,305 kDa. 
The P. chabaudi pppk-dhps sequence was used to screen the Malaria Genome 
Sequence Tag Project database at the University of Florida (http://parasite. 
vetmed.ufl.edu/) . A partial DNA sequence of 300 bases with significant homology 
to the pppk gene was identified from the P. vivax genome sequence survey (GSS) 
project (UFL 267PvH07) and two sequences, one with significant homology to the 
pppk gene and one with homology to the dhps gene, were identified in the P. berghei 
expressed sequence tag (EST) project (UFL 055PbEO9, UFL 228PbG09). 
4.1.3 Analysis of the predicted dihydropteroate synthase (DHPS) 
amino acid sequence 
As reported previously for other protozoan DHPS enzymes, the P. chabaudi 
DHPS is part of a bifunctional protein, containing both the DHPS and PPPK enzyme 
domains (Walter and Konigk 1980). Comparison with the P. falciparum pppk-dhps 
gene shows that the region from amino acids 323-673 encodes the P. chabaudi 
DHPS enzyme while residues 1-322 encode the PPPK enzyme. There is no junction 
region between the two protein domains; the only bifunctional protozoan PPPK-
DHPS known to have a junction region is that of Toxoplasma gondii (Pashley et al. 
1997). 
Comparison of the predicted P. chabaudi DHPS amino acid sequence with 
other available DHPS sequences (Figure 11) indicated that it has highest homology 
with a fragment of the P. berghei homologue. These sequences were 92% identical 
and 95% similar at the amino acid level, if conservative substitutions are allowed. 
Similarity with the P. falciparum DHPS was also high; 63% identical and 75% 
similar. The P. chabaudi DHPS has a 29 amino acid insertion (amino acids 476-505) 
relative to the P. falciparuni protein. Identity with other DHPS proteins was lower; 
30% with the Pneumocystis carinii DHPS, 27% with the T. gondii DHPS, 24% with 
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1 	 88 
ENNKGNIW- LNFGTTDKTN AVI ILETALY LTEKYI -GKI INTSYMYETV PEYIVLDKSN I PNNI IGEDD PYDVSS LNEL 
TIQELILS EENKTNIAV- LNLGTNDRRN AVLILETALI -I LVEKYL-GKI INTSYLYETV PEYIVLDKKE SCEKINKDCR IYDVNYINEL 
ENTKGNIW- LNFGTTDKTN AV1'ILETALY LTEKYI-GKI INTSYMYETV PEYVVLDKSD IP}IIGEDD PYDVSSLNDL 
GKI INSSYIYETV PEYIVLDEEN KIGEVTEGEP PRDISWIGDL 
MP.EED PGKEYATA-Y IALGSNLQGD ARLGIIEEAI SELGRCLGPI LGTSCLYETV PAF ------- ---------- ----------  
SSNNYIKS ENSIDNEAVY ISLGSNLGNR IKFILD-AIE }a1S-IKGIKV LKTSMLYESK PMY 
LSSSQNTPIE G}TWKRA-F LAFGSNIGDR FF-IIQM-ALQ LLSREKTVKL RNISSIFESE PMY 
MTVA-Y IAIGSNLASP LEQVNA-ALK ALGDIPESHI LTVSSFYRTP PLG ------- ---------- ---------- 
89 	 174 
VNGLENSKYE NVFQEDESLV SQCEEYEIFL NNKDLFENKI KQISVEEYKT EASNIIKEND EIMKINLEKH KNKYYTNYFY NLAWFKSFI 
MQNLEESKYE ----ENKELI DKCEEYETFL KNGKVDNSIL KEVNVENYLL ECNNIIV}D EIMKNNLSKY KDKYYTSYFY NLTVVVKTFV 
VKGLEKSKYE 
IPTVENSRYE ----ESEDLI YECKELEVFL }aEKINESII REVSVEDYEN EARRIIKRND EIMKKNLEQ 
DVCPKGVVHD VFHPFYLNAV VKLRTPITDP WWLEILIL EA-KTGRPLP T-PEDMEAAL NDCTSSGEAT 
-- ---------- ---------- ---------- ---------- -- FKDQPAFY NAVCKVQTSL 
-- ---------- ---------- ---------- ---------- -- FOQTPFM NGCVEVETLL 
-- ---------- ---------- ---------- ---------- -- PQDQPDYL NAAVALETSL 
175 	 261 
DDPLHLLVIL KYIE-HLMKR }eSKEVEKFE -NRLIDIDI- LFFNNYTIFE KNINLTKDSL YAIMCKYINI ECD-----DN CNKRL--KDI 
NDPLSMLVVI KYIE-ELNKR ENVKEKEKFE -NRIIDIDI- LFFNDFTIFM KNflCEKNMI YKILSKYIIiL ERDIIC'GNDN MSIWNMDKDI 
NEDVPGQGNK GASRKGDWKE ALO(DKYVRG APRLLDVDL- LFFDGRS 
H-PEQLLFEL QLIEKELG-R --VKVIDK-G -PRCIDLDI- VFYGRKII 
T-PSELLKLC KKIEYEELQR --VKHFDN-G -PRTIDLDIV MFLNSA 
A-PEELLNFIT QRIELQQG-R --VRPERWG -PRTLDLDI- MLFGNEVI 
P. chaba udi: 





















Figure 11. Alignment of five known PPPK-DHPS's and the predicted P. chabaudi, P. berghei and P. vivaxPPPK-
DHPSs. The PPPK-DHPS from P. chabaudi, P. 1falciparum (U07706), P. vivax (University of Florida Gene Sequence Survey 
Project), P. berghei (University of Florida Gene Sequence Tag Project), i: gondil (U81497), N. carinli (M86602), S. cerevisiae 
(ORF 848 in X96722) and E. coil (L06495 and X68776) were aligned using the Gap and PileUp programmes of the UWGCG. 
GeneBank accession numbers are shown in brackets. Amino acids are designated by the single letter code. The sequences are 
numbered with respect to the P. faIciparurn sequence. A dash indicates a gap introduced to obtain optimal alignment. Conserved 
residues are shown in blue while positions within the P. .faiciparum sequence that have been implicated in sulfadoxine resistance are 
shown in red. The sequences to which degenerate oligonucleotides were made for PCR amplification are marked with arrows. The 
highly conserved DHPS motif is boxed. 
00 
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262 	 350 
P. chabaudi: 	---------- ---------- ---------- ---------- ----- EQIKD NIKFLSIPHV YTKHRYSILL CLND-IIPNY KHNTLKETIN 
P. falciparum: NLNNNNNIKK }NNDIDCDC VDQKMNNHVN NKNYINSFRD PQEIINNMVD NIEFLSIPHV YTTHP.YSILL CLND-MIPEY KHNVLNNTIR 
T. gc'ndii: 	---------- ---------- ---------- --------- V VIHPDVRPVD KQWPLTLPHP RIITRNFVLF PLCDL-DPEY IHPVEGMSVK 
Pn. carinii: ---------- ---------- ---------- ---------- ---------- NSESLIIPHP RVLERSFVLK PLLD-ISGDL VHPVTGLSIA 
S. cerevisiae: ---------- ---------- ---------- ---------- GEDII --- VN EP-DLNIPHP IUILERTFVLE PLCELISPVH LHPVTAEPIV 
coli: 	---------- ---------- ---------- ---------- ---------- NTERLTVPHY DMKNRGFW PLFE-IAPEL VFPDGEMLRQ 
351 	 PPPK_domain 380 
P. chabaudi: 	NLYEEFITNF SK--------LYNTCIKKYN VRLYVL} -- ---------- ---------- ---------- ---------- ----------  
P. falciparum: CLYNKYVSP.M KE--------QYNINIKENN KRIY\LKD -- ---------- ---------- ---------- ---------- ----------  
gondii: 	ELLRINLEP.R RIHLLNAAEE ARQTQELAA- KTNSETSGDH IAC--SHRCA PPASLHFVMN YRIDGSLAIP RRCFAATTEE LWLGGDAGI 
Pn. ca.rinii: SYFEKIVDHD 1K -------- PVLPFLY-KN KSI ------- -- D-F ----- ---------- ---------- ----------- ---------  
S. cerevisiae: DHLKQLYDKQ I-IDEDTLWKLV P-LPYRSGVE PRFLKFKTAT KLDEF ----- ---------- ---------- ----------- ---------  
coli: 	ILHTPAFDKL NKW* 
381 DHPS_domain 	 DRPS1 	 423 
P. chabaudi: 	---------- ---------- ---------- ---------- -- EVLYLKE( TNIVGILNVN YNSFSDGGLF VK-----PDI AVP.RIFQMIN 
P. falciparum: ---------- ---------- ---------- ---------- -- P.ISYLKEK TNIVGILNVN YDSFSDGGIF yE ----- P} AVQRMFEMIN 
gondii: 	VDTLLYIEDV KIHADQIIKV GGEEALSEVQ RTQLLRLQP.L EKTLREEH-P LKLMGILNVS PDSFTDHFAS SV ------ DE AVAPAEAMVT 
Pn. carinii: ---------- ---------- ---------- ---------- SFR-SY-@P TYIMAILNLT PDSFFDGGII-i -s ----- TDS VLIDVEKFIN 
S. cerevisiae: ---------- ---------- ---------- ------- TGE TNRITV--SP TYIMPIFNAT PDSFSDGGEH FADIESQLND IIKLCKDALY 
coli: 	 SSK-AN-MAK TVICGIINVT PDSFSDGGTH NS-----LID AVKHP.NLMIN 
424 	DHP.c2 	 480 
P. chabaudi: 	EGVD-IIDIG GESSAPFVSH NPEIK-ERDL --VIPVLELF EQEWN}4LQI CKNEKIDKEE KGIEKQNDKL NQNNLSLQTK TSTIYKPPIS 
P. falciparum: EGAS-VIDIG GESSGPFVIP NPKIS-ERDL --VVPVLQLF QKEWNDIKNK IVKCDA ---- ---------- ---------- ----- KPIIS 
gondii: 	DGD-WDVG GEATNPFRVA G-EVPLAVER ERVVPW--- QKILDGNP V --------- ---------- ---------- ------- us 
Pn. carinii: AG1T-IIDIG GQSTRPGSYI IP-L--EEEI FRVIPAIKYL QKTYPDI --- ---------- ---------- ---------- ------- LIS 
S. cerevisiae: LHESVIIDVG GCSTRPNSIQ A---SEEEEI RRSIPLIK7U RESTELPQDK V --------- ---------- ---------- ------- ILS 
E. coli: 	AGPT-IIDVG GESTBPGAAE V----SVEEEL QRVIPVVEAI AQRF-EV --- ---------- ---------- ---------- ------- WIS 
0' 
Figure 11 continued. 
481 	 564 
P. chabaudi: 	IDTMNYDLFK ECVDILVDI LNDISACTND PQII}LKKK N-KYYSV'TLM HKRGDPHTMD MLTQYEDVVY -DIKKYLEER ---LNFLTL- 
P. falcipa rum: IDTINYNVFK ECVDMDLVDI LISACTNN PEIIKLLKKK N-KFYSVVLM HKRGNPHTMD KLTNYDNLVY -DIF0YLEQR ---LNFLVL- 
P. berghei: 	NYDLFK ECVDKNLVDI LNDISACTND PKIIKLLKKK N-KYYSVVLN I{KRGNPHTMD MLTQYEDVVY -DIKKYLEDR ---LNFLTL- 
T. gondii: VDT4K7EVAR DAVTAG-ADW VNDQTGESRK GGEGDPLSFV VGNSTTVVLM H}GTPDTFD GYQDYD-DVV HEVGSWLASM SEALQR- 
Rn. carinii: 	IDTFRSEVAE QAVKAG-ASL VNDISGGRYD PKMFNTVARL K --- VPICIM RMRGNFLNMD NLTDYGTDII EQITIELEK- --LLNSAEK- 
cerevisiae: IDTYRSNVAK EAIKVG-VDI INDISGGLFD SNMFAVIAEN PE--ICYILS HTRGDISTMN RLAHYEN--F P.LGDSIQQEF VHNTDIQQLD 
E. coli: 	VDTSKPEVIR ESAKVG-AHI IIRSLSEP GPLEA-AET G --- LPVCLM HMQGNPKTMQ EAPKYD-DVF AEVNRYFIE- --QIARCEQ- 
565 607 
P.chabaudi: ---------- ---------- --- NGIPRYR IILDIGLGFA K-K-HDQSIK LLQNIHVYD - ---------- ---------- - DYPLFEGYS 
P. falciparum: ---------- ---------- --- NGIPRYR ILFDIGLGFG K-K-HDQSIK LLQNIHVYD - ---------- ---------- - EYPLFIGYS 
P. berghei: ---------- ---------- --- NGIPRYR IILDIGLGFA K-K-HDQSIK LLQNIQVYD - ---------- ---------- - DCPLFLGYS 
 gondii: ---------- ---------- --- GGVGRWR ILADPGLGIS KNP-EQSFE- LVRGVHGIRQ MLPT ------ ---------- - GIPQLLGFS 
Pn. carinii: ---------- ---------- --- SGIPRWN IILDPGLGFS KTL-HQNIE 	LLRRFNELKS KNC ------- --------- F NGLPWLLGPS 
 cerevisiae: DLKDKTVLIR NVGQEERYIK AIDNGVKRWQ ILIDPGLGFA K'IW-KQNLQ- IIR}IPIL --KNYSFTMN SNNSQVIVNL RNMPVLLGPS 
E. ccli: ---------- ---------- --- AGIAKEK LLLDPGFGFG KNLSHNYS-- LLARLAEFHH ---------- --------- F N-LPLLVGMS 
608 694 
P. chabaudi: RFISHTLA QTCVEICPNT IAQNE--NIQ N--DESDK-N GFTVRNIRKD RDQYLYQ1I LGGLAIASYC ---FEKKVEM IRVHD FETR 
P. falciparum: RIFIAHCMN DQNVVINTQQ KLHDEQQNEN }IVDKSHNW MFQNNYMRKD KDQLLYQKNI CGGLAIASYS ---YYKKVDL IRVHDILETK 
P. berghei: R1GFISMTLA QTCPLEICPNT ISENE--NVQ N--DESGK-N TFAVRNIRQD }CQYLYQKNI L 
 gondii: RKRLVGWG -- ---------- - VGESAQD-R KGPPTTATVE ------ GRR - ---------- WGGAAIAAW- CAANTDAVTV VRTRDIKDTR 
Pn. carinii: RKRFTGFITG ---------- DNNPKDR --- ---------- ---------- --------- I WGTVAAVVAS ---ISGGCDI IRVHDIYEMY 
 cerevisiae: RIQ(FIGHIT - ---------- ---------- ---------- -------- RD VDAK--QR-D FATGA-VVAS C--IGFGSDM VRVED 	CS 
E. ccli RKSMIGQLL - ---------- NVGPSER --- ---------- ---------- --------- L SGSLACAVIA --- ANQGAHI IRVHD TV 
C 
P. chabaudi: 
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the Saccharomyces cerevisiae DHPS, and 28% to the equivalent Escherichia coli 
protein. The P. chabaudi sequence contains the conserved DHPS motif 
(L/V)R(V/T)HDV, found in all DHPS proteins, at positions 651-656 (Pashley et al. 
1997). 
4.1.4 	Analysis of the predicted hydroxymethyldihydropterin 
pyrophosphokinase (PPPK) amino acid sequence 
The region from amino acids 1-322 is predicted to encode the P. chabaudi 
PPPK enzyme, although approximately 10 amino acids predicted to occur at the 
amino-terminus are missing. Alignment of the P. chabaudi PPPK sequence with 
available PPPK sequences (Figure 11) showed that it is much less conserved than the 
DHPS domain. While a few residues are absolutely conserved, there are no 
conserved motifs. The predicted P. chabaudi PPPK protein had highest homology 
with the predicted P. berghei PPPK; the sequences were 92% identical and 95% 
similar at the amino acid level. Identity with other Plasmodium PPPK proteins was 
lower; 51 % with the P. falciparum PPPK and 50% identity with predicted P. vivax 
PPPK. Comparison of the P. chabaudi sequence with that from other organisms 
revealed 38% identity to T. gondii, 31% to Pn. carinii, 24% to S. cerevisiae and 28% 
to the equivalent E. co/i protein. The Plasmodium PPPK proteins have a large 
insertion relative to those from other organisms; in P. falciparum the PPPK has a 79 
amino acid insertion (positions 222-301), while in the P. chabaudi PPPK, the 
insertion is only 34 amino acids. 
It is interesting to note that the P. berghei pppk sequence also appears to have 
an additional intron at the 5' end of the gene. As seen in the P. chabaudi translated 
sequence, the absence of a region with homology to the 5' end of the P. falciparum 
sequence, suggests that an additional intron may be present at the 5' end of both 
rodent malaria genes. All other intron positions in the Plasmodium pppk-dhps genes 
are highly conserved. 
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4.1.5 Sequencing the pppk-dhps alleles of the drug-selected lines 
The dhps sequences (nucleotides 1270-2432) were determined from all lines 
that survived drug selection, including AS (50S/P) and AS(75S1P). Sequence 
analysis of these lines did not reveal any polymorphisms when compared to the dhps 
sequence of AS (PYR); all sequences were identical to that shown in Figure 10. In 
addition, the entire pppk-dhps sequence (nucleotides 25-2432) was sequenced from 
AS (PYR), AS (50SIP) and AS(75S1P) and a drug-sensitive clone AJ. Again, the 
sequences were identical to that shown in Figure 10. Taken together, these results 
suggest that resistance to SIP is not conferred by mutations in pppk-dhps in these 
lines. 
4.2 Sequencing the dihydrofo/ate reductase-thymidylate synthase 
(DHFR-TS) alleles of the drug-selected lines 
The gene encoding dihydrofolate reductase (DHFR) has been strongly 
implicated in the mechanism of SIP resistance in P. falciparum (Watkins et al. 1997, 
Basco et al. 1998b, Plowe et al. 1998). Parasites resistant to S/P in the current work 
were selected from a P. chabaudi clone, AS (PYR), already resistant to 
pyrimethamine. The pyrimethamine resistance is conferred by the presence of an 
asparagine rather than a serine at position 106 in its DHFR (Cowman and Lew 1990, 
Cheng and Saul 1994). To investigate the possibility that additional mutations in the 
dhfr gene were responsible for S/P resistance, the dhfr gene was sequenced from AS 
(PYR) and all the drug-selected lines, including AS (50SIP) and AS(75S1P) (Figure 
12). The DHFR is also a bifunctional enzyme, containing both DHFR activity and 
the thymidylate synthase (TS) domain (Garrett et al. 1984). The ts domain was 
sequenced from AS (PYR), AS (50SIP) and AS(75S1P). There were no sequence 
differences in the respective genes of any of the clones. These results show that 
resistance to S/P is not conferred by additional mutations in dhfr-ts in these lines. 
This is the first report of the sequence of ts from the P. chabaudi chabaudi 
subspecies. As previously reported, the TS domain is more highly conserved than 
the DHFR domain (Hyde 1990). The DHFR domains from the two P. chabaudi 
subspecies, P.c chabaudi and P. c. adami, are 98% identical to one another, while the 
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1 DHFRI 	 58 
DS: MEDISEIFDIYAICACCKVLNSNEKASCFSNKTFKGLGNEGGLPWKCNSVDMIcJ-IFSSV 
AS: 	 AICACCKVLNSNEKAGCFSNKTFKGLGNEGGLPWKCNSVDMKHF'SSV 
59 	 116 
ASN 	SER flRRR5 
DS: TSYVNETNYMRLKWKRDRYMEKNNVKLNTDGI PSVDKLQNIVVMGKASWES I FSKFKP 














291 	TS domain 	 348 
DS: NSIKYKHHPEYQLNIIYDIIMHGNKQDDRTGVGVLSKFGYMMKFNLSEyFpLLTTKK 
AS: NSIKYKHHPEYQYLNI IYDI IMHGNKQDDRTGVGVLSKFGYMMKFNLSEYFPLLTTKK 
349 	 TS1 	406
30 
DS: LFVRGIIEELLWFIRGETNGNTLLEKNVRIWEANGTREFLDNRKLFHREVNDLGpIyG 
AS: LFVRGI IEELLWFIRGETNGNTLLEKNVRIWEANGTREFLDNRKLFHREVNDLGPIYG 













Figure 12. Amino acid sequence alignment of the P. chabaudi DHFR-
TS. The complete amino acid sequence of P. chabaudi adami clone DS (accession 
number M30834) and the P. chabaudi chabaudi clone AS (SENS) are shown. The 
differences are shown in blue and the site of the serine to asparagine mutation 
associated with pyrimethamine resistance in AS (PYR), AS (50S/P) and AS (75S1P) 
is shown in red. The arrows indicated the boundaries of the oligonucleotides used in 
the PCR to amplify the dhfr gene for sequencing. 
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TS domains show 100% identity. All polymorphisms within the gene are in the 
regions encoding the DHFR domain or the junction region. 
4.3 Summary of sequencing results 
The analysis of the dhfr and dhps sequences from the S/P-selected lines did 
not reveal any polymorphisms when compared to the respective sequences of the AS 
(PYR) genes. The pppk and ts sequences were also determined from AS (PYR), AS 
(50S/P) and AS (75S/P). There were no sequence differences in the respective genes 
of any of the clones. Taken together, these data suggest that SIP resistance in P. 
chabaudi is not conferred by additional mutations in the dhfr or dhps genes. 
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5. Results: The Crosses and Linkage Analysis 
5.1 The crosses 
In order to determine the genetic basis of resistance to SIP, the resistant 
clones were crossed with the drug sensitive clone, AJ. The crosses were repeated to 
increase the numbers of different meiotic products analysed and the crosses 
performed are shown in Table 8. Rats were infected with AJ mixed with either AS 
(50S/P) or AS (75 SIP) and mosquitoes for each cross permitted to feed on the rats on 
day 3 or 4, when mature gametocytes were present (described in section 2.9). Ten 
days after mosquito infection, a sample of mosquitoes from each cage were dissected 
and examined for the presence of oocysts. The mosquito infection rates are shown in 
Table 9. Oocysts were found on the midguts of mosquitoes that had been fed on rats 
infected with AJ, AS (50SIP) and AJ x AS (5051P). No oocysts were seen on 
midguts of mosquitoes that had been fed on rats infected with AS (75S1P) alone. 
Sporozoite-induced infections were established in mice either by allowing infected 
mosquitoes to feed on mice on days 15, 17 and 21 (crosses 1 and 3) or by removing 
salivary glands from mosquitoes by dissection and injecting the contents into mice 
(ip) (crosses 2 and 4). Approximately 100 mosquitoes were used for each feed or 
injection. 
Table 8. The crosses performed in this work 
Cross Number 	Crosses 	Sporozoitesa 
1 	AJ x AS (50SIP) Feed 
2 	AJ x AS (50S/P) 	Injection 
3 	AJ x AS (75S/P) Feed 
4 	AJ x AS (755/P) 	Injection 
aSporozojte.iflduced infections were established in mice by mosquito feeds, 
permitting infected mosquitoes to feed on mice, or by injection by removing 
salivary glands from mosquitoes and injecting (ip) the contents directly. 
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Table 9. Oocyst rates of mosquitoes from crosses 
Crosses 1 & 3 Crosses 2 & 4 
Line Mosquito Oocystsa Line Mosquito Oocyst? 
AJ 1 27 AJ 1 0 
2 1 2 0 
3 0 
AS(5OSIP) 1 6 4 0 
2 0 5 0 
3 0 6 6 
4 0 7 0 
5 0 8 0 
6 0 
AS (50SIP) 1 0 
AS(75S1P) 1 0 2 5 
2 0 3 1 
3 0 4 0 
4 0 5 0 
5 0 
6 0 AS(75S/P) 1 0 
7 0 2 0 
3 0 
AJxAS(50S/P) 1 0 4 0 
2 0 5 0 
3 0 6 0 
4 0 7 0 
5 4 8 0 
6 3 9 0 
7 0 10 0 
8 7 11 0 
12 0 
AJxAS(75S1P) ND ND 13 0 






AJ x AS (75S1P) 	ND ND 
'Number of oocysts per mosquito midgut are shown. ND, not determined. 
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5.2 The progeny of the AJ x AS (5051P) crosses 
5.2.1 Identification of recombinants in the cross progeny 
The uncloned progeny of AJ x AS (50SIP) and AJ x AS (7551P) crosses were 
examined for the presence of the two parent alleles of mspl by allele-specific PCR, 
and for dhfr by mutation-specific PCR (described in section 5.3.3). The mspl marker 
was chosen as it is unlikely that there would be selection against these alleles, while 
the dhfr was chosen in order to identify recombinant forms following pyrimethamine 
treatment. For mspl, a band of approximately 300 bp was observed in AS (50SIP), 
while in AJ it was approximately 30 bp larger; the two alleles could easily be 
distinguished after electrophoresis. The results for the crosses are given in Table 10. 
Both parental mspl and dhfr genes were found in the uncloned AJ x AS 
(50SIP) progeny from crosses 1 and 2, even though transmission of AS (50SIP) alone 
was unsuccessful in cross 1. The uncloned progeny from both crosses 1 and 2 were 
treated with pyrimethamine and examined for mspl and dhfr. Both parental mspl 
alleles were found in the progeny that survived treatment, showing that 
recombination between the dhfr and msp] had occurred, confirming that AJ and AS 
(50S/P) gametes had undergone crossing in mosquitoes. In the absence of crossing, 
only the mspl allele of the drug-resistant parent would have been present in the drug-
treated progeny. In contrast, progeny that had inherited the AJ dhfr allele were 
eliminated by drug treatment as no AJ alleles were present in the progeny that 
survived drug treatment. This confirmed the role of this gene in resistance to 
pyrimethamine. 
Only the AJ alleles of mspl and dhfr were found in the progeny of the AJ x 
AS (75S1P) from both crosses 3 and 4. This suggested that AS (75S1P) had not been 
transmitted through mosquitoes, which was consistent with the absence of oocysts on 
midguts of mosquitoes fed AS (75S/P)-infected rats (Table 9). 
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Table 10. Analysis of the crosses with dhfr and mspl 
Parasite 	Cross 	Treatment 	 Marker 




None 	 AJ 	 AJ 
AS (5OSIP) 
	
None 	 AS 	 AS 
Uncloned Progeny 
AJ x AS (505/P) 
uncloned progeny 
AJ x AS (50S/P) 
uncloned progeny 
AJ x AS (50S/P) 
uncloned progeny 
AJ x AS (5 OS/F) 
uncloned progeny 
1 	None 	AS&AJ 	AS&AJ 
1 	10mg/kg 	AS 	AS&AJ 
pyrimethamine 
for 4 days 
2 	None 	AS&AJ 	AS&AJ 
2 	10mg/kg 	AS 	AS&AJ 
pyrimethamine 
for 4 days 
AJ x AS (75S/P) 	3 	None 	AJ 	 AJ 
uncloned progeny 
AJ x AS (75 S/P) 	4 	None 	AJ 	 AJ 
uncloned nroenv 
a  Numbers in brackets refer to the probe number as shown in Table 3. 
bAJ AJ-type allele; AS, AS-type allele. 
5.2.2 Cloning from the progeny of the cross 
In order to perform further genetic analysis, clones were made from the 
progeny of the AJ x AS (50SIP) crosses. In total, 33 clones were isolated by limiting 
dilution from the uncloned progeny of both crosses; 14 from cross 1 and 19 from 
cross 2. Each clone was tested for its response to S/P and pyrimethamine as 
previously described. DNA was purified from each clone for analysis of the 
inheritance of markers that distinguished the parent clones. No analyses of the AJ x 
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AS (75S1P) crosses were carried out, in view of the absence of the AS alleles of mspl 
and dhfr which indicated that, at least in these crosses, AS (75S1P) was infertile. 
5.3 Genome markers 
5.3.1 Chromosome-specific markers 
Thirty chromosome-specific DNA markers were used to detect 
polymorphisms between parent clones AS (50SIP) and AJ. Twenty-six of the 
polymorphisms were detected by restriction fragment length polymorphism (RFLP) 
on Southern blots of genomic DNA. Twenty of the RFLP markers were known 
genes from Plasmodium species (Canton et al. 1998a), and the remaining six were 
anonymous markers isolated from a P. chabaudi DNA library (Canton et al. 1998a). 
Four polymorphisms were detected either by allele-specific PCR (mspl, dhfr and 
mdrl) or PCR amplification followed by digestion of the product to produce an 
RFLP (cg]O). 
5.3.2 Development of mutation-specific PCR for Pcdhfr 
Two allele-specific amplification assays were designed that were able to 
detect either the wild-type dhfr allele, or the presence of the allele containing the 
mutation at nucleotide 319. The AS (50S/P) allele has a G to A mutation, resulting 
in the change from serine to asparagine at position 106, which confers resistance to 
pyrimethamine (Cowman and Lew 1990, Cheng and Saul 1994). Following the 
method of Wang et al. (1995), mutation-specific primers were designed by 
incorporating a deliberate mismatched base at the 3' end of the primer. Wang et al. 
(1995) found that this single mismatch was not always sufficient to prevent mutation-
specific primers annealing to and amplifying both alleles, and so a deliberate T/T 
mismatch was introduced at the penultimate base at the 3' end of the primer. This 
resulted in the destabilisation of the 3' end of the primer on the non-target sequence 
such that amplification did not occur. A mismatch at the penultimate base was also 
incorporated into the 3' end of the P. chabaudi dhfr mutation-specific primers. 
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5.3.3 Genotyping the dhfralleles of the cloned progeny of the cross 
using mutation-specific PCR 
The mutation-specific PCR was used to genotype the dhfr alleles of the 
cloned progeny of the cross. Figure 13 shows the results of genotyping the progeny 
from cross 1. The asparagine-specific primers amplified a product of 281 bp from 
DNA extracted from AS (50SIP), while no amplification product was seen when AJ 
DNA was used as the template. The serine-specific primers amplified a product of 
314 bp from AJ DNA, while no product was generated with DNA from AS (50SIP). 
a. 
U) 
<0 <_ << 




Figure 13. Genotyping the dhfralleles of the progeny of cross I using 
mutation-specific PC R. Two allele-specific amplification assays were designed, 
serine-specific and asparagine-specific, that were able to detect either the wild-type 
AJ dhJr allele, or the mutant AS (50SIP) allele respectively. 
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Progeny clones 1108/8, 1108/11, 1110/6, 1110/8 and 1110/13 AS/AJ were 
determined to have the AJ-allele of dhfr due to the presence of a band when 
amplification was performed with the serine-specific primers, but not with the 
asparagine-specific primers (Figure 13). Only a very faint band was produced with 
the serine-specific primers from 1110/10 AS/AJ DNA. Further MS-PCR 
amplifications confirmed that this clone had inherited the AJ-allele of dhfr. It was 
concluded that clones 1107/10, 1107/14, 1108/10, 1109/2, 1109/11 and 1110/4 
AS/AJ had inherited the AS-allele of dhfr following the production of a band with 
the asparagine-specific primers, but not the serine-specific primers, (Figure 13). 
To check that mixtures could be easily detected, amplification was performed 
on template containing both AS (50SIP) and AJ DNA with both sets of primers. As 
expected, a product was generated each primer pair. Subsequently, progeny 'clones 
1111/3 and 1111/10 AS/AJ were found to be mixtures containing both the AS and 
AJ-alleles of dhfr, and were thus excluded from further analysis. Similar 
amplifications were performed using DNA from the clones of the second cross (cross 
2). 
5.3.4 Identification of independent recombinants 
Thirty-three clones were made from the progeny of the AJ x AS (505/P) 
crosses. Six of the 33 clones examined were found to be mixtures, two were AJ-
parental type, and one AS-parental type. Eight recombinants had genotypes identical 
to at least one other clone as determined from inheritance of data of 20-30 markers. 
These were considered to derive from duplicate cloning events, and thus excluded 
from further analysis. In total sixteen of the original 33 clones were thus found to be 
independent recombinants; eight from cross 1 (1107/10, 1107/14, 1108/8, 1109/11, 
1110/4, 1110/8, 1110/10 and 1110/13 AS/AJ) and 8 from cross 2(1351/2, 1384/10, 
1385/2, 1396/1, 1398/14, 1538/12, 1538/14 and 1539/1 AS/AJ). These were used in 
the linkage analysis studies. 
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5.4 Phenotyping the parents and progeny of the crosses 
5.4.1 Growth rates of the parental clones 
In the absence of treatment, the parental clones AJ and AS (50SIP) grew 
rapidly in CBA/Ca mice. Figure 14 shows a typical growth curve for the clones AJ, 
AS (PYR) and AS (50SIP) following inoculation of 106  parasitised red blood cells. 
In this experiment, AJ reached an average parasitaemia of 49.2% on day 6, while AS 
(PYR) and AS(50SIP) reached average parasitaemias of 33.8% and 36.2% 
respectively. The difference in day 6 parasitaemias between AJ and AS (50S/P) is 
significant (P<0.01), as is the difference between AJ and AS (PYR) (P<0.01). No 
significant difference was seen between the AS (50SIP) and AS (PYR) parasitaemias. 
The importance of the different growth characteristics of the parent clones, regarding 
the progeny, is analysed further in section 5.5.3. 
50 
C 
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Day of Infection 
Figure 14. The course of infection of clones AJ, AS (PYR) and 
AS(5051P). Each data point represents the average parasitaemia of two mice taken 
from a representative experiment ± 1 S.E.I = AJ,S = AS(PYR),O =AS (50SIP) 
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5.4.2 Sulfadoxine/pyrimethamine susceptibility tests 
The growth rates of each progeny clone treated with two different doses of 
SIP were compared with each of the two parents and with AS (PYR) (Table 11). 
Each clone was tested in at least two separate experiments. Blood smears were taken 
on days 6, 8 and 10 and examined for the presence of parasites. 
Ten progeny clones had growth rates similar to AS (50SIP) and were 
classified as S/P resistant (R). These clones reached peak parasitaemias by day 8 
after treatment with 25/1.25 mg/kg SIP. Following treatment with 50/2.5 mg/kg SIP, 
the resistant progeny clones were usually found at detectable levels in the 
bloodstream on day 6, reaching peak parasitaemias between days 9-11. Some 
resistant progeny (1110/4 and 1539/1 AS/AJ) grew faster than the resistant parent 
following treatment with 25/1.25 mg/kg SIP, reaching higher peak parasitaemias, two 
days earlier than AS (50S/P). The difference in day 6 parasitaemias between AS 
(50SIP) and 1110/4 ASIAJ and AS (505/P) and 1539/1 AS/AJ were highly 
significant (P<0.01). 1110/4 ASIAJ also reached higher parasitaemias than either 
parent in the undrugged controls. 
Five clones showed a drug response similar to AJ. These clones were cleared 
by treatment with both doses of S/P and were typed as S/P sensitive (5). One clone 
showed a growth pattern similar to AS (PYR). 1385/2 AS/AJ recrudesced after 
treatment with 25/1.25 mg/kg S/P but was cleared by treatment with the higher dose 
of S/P. It was classified as having low-level S/P resistance (LR). 
5.4.3 Pyrimethamine susceptibility tests 
The growth rates of each progeny clone treated with 10 mg/kg pyrimethamine 
were compared with each parent and with AS (PYR) treated similarly (Table 12). 
Blood smears were examined on days 6, 8 and 10. Each clone was tested in at least 
two independent experiments. 
Five progeny clones showed a pyrimethamine response similar to AJ. These 
clones were cleared by treatment with pyrimethamine and typed as pyrimethamine 
sensitive (5). Eleven progeny clones had growth rates similar to AS (50S/P) under 
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Table 11. Sulfadoxine/pyrimethamine phenotypes of 16 progeny clones 




























AJ 40.2 (±3.3) 0.0(-+0.0) 0.0(+-0.0) 0.0 (±0.0) 0.0(+-0.0) 0.0(-+0.0) 0.0(-+0.0) S 
AS (PYR) 29.6 (±3.3) 0.3(-+0.2) 4.0 (±2.4) 11.6 (±3.2) 0.0(+-0.0) 0.1(-+0.1) 0.9(-+0.7) LR 
AS (50S/P) 31.4 (±3.3) 14.3 (±3.4) 34.2 (±4.2) pp 3.5 (±1.3) 16.1 (±4.2) pp R 
1107/10 44 (±9.8) 1.9(±1.9) 20.2(±20.2) pp 0.0(+-0.0) 1.6 (±1.6) 8.5 (±8.5) R 
1107/14 27.8 (±5.4) 9.6 (±3.2) 37.8 (±6.4) pp 0.8(+-0.8) 12.8 (±12.6) 24.1 (±15.9) R 
1108/8 38.3 (±8.5) 0.0(+-0.0) 0.0 (±0.0) 0.0(-+0.0) 0.0(+-0.0) 0.0(-+0.0) 0.0(-+0.0) S 
1109/11 46.2 (±3.7) 23.0 (±22.3) pp pp 0.2(+-0.2) 4.6 (±4.6) 7.3 (±7.0) R 
1110/4 58.6(±1.3) 40.9(±2.1) pp pp 7.8(±7.8) 8.9(±6.8) pp R 
1110/8 52.6 (±0.5) 0.0(+-0.0) 0.0 (±0.0) 0.0 (±0.0) 0.0(-+0.0) 0.0(+-0.0) 0.0(+-0.0) S 
1110/10 36.7 (±15.0) 0.0(+-0.0) 0.0(-+0.0) 0.0(-+0.0) 0.0(-+0.0) 0.0(-+0.0) 0.0(-+0.0) S 
1110/13 35.4 (±11.6) 0.0(-+0.0) 0.0(+-0.0) 0.0(-+0.0) 0.0(-+0.0) 0.0(-+0.0) 0.0(-+0.0) S 
1351/2 18.5 (±7.8) 0.0(-+0.0) 0.0(-+0.0) 0.3(-+0.3) 0.0(-+0.0) 0.0(+-0.0) 0.0(-+0.0) S 
00 
Day 6 Day 8 Day 10 Day 6 Day 8 Day 10 
Clone Day 6 25/1.25 25/1.25 25/1.25 50/2.5 50/2.5 50/2.5 SIP 
Undrugged mg/kg SIP mg/kg S/P mg/kg SIP mg/kg SIP mg/kg S/P mg/kg S/P Phenotype 
Drugged Drugged Drugged Drugged Drugged Drugged 
1384/10 17.7 (±9.3) 10.0 (±6.6) 31.5 (±9.6) pp 0.0(-+0.0) 1.6 (±1.6) 8.3 (±6.3) R 
1385/2 37.1 (±11.1) 0.2(-+0.2) 5.8 (±4.6) 25.9 (±12.2) 0.0(-+0.0) 0.0(-+0.0) 0.0(-+0.0) LR 
1396/1 43.3 (±9.0) 19.9 (±1.4) 51.1 (±0.3) pp 0.0(-+0.0) 12.9 (±12.9) 19.6 (±19.1) R 
1398/14 39.5 (±7.6) 14.6 (±10.0) pp pp 0.9(-+0.9) 14.1 (±14.1) 20.7 (±18.5) R 
1538/12 28.2(±2.4) 17.7(±1.1) pp pp 1.7(±1.7) 17.4(±15.1) 31.6(±8.4) R 
1538/14 26.2 (±7.0) 24.5 (±1.5) pp pp 2.0 (±2.0) 20.9 (±20.9) pp R 
1539/1 40.9 (±7.4) 39.2 (±0.9) pp pp 2.9 (±2.9) 18.5 (±18.5) 28.3 (±8.7) R 
Figures shown are mean parasitaemias from at least two separate experiments and figures in brackets are standard errors. Infections 
that have already peaked are indicated by pp. SIP, sulfadoxine/pyrimethamine; R, resistant; 5, sensitive; LR, low level resistance. 
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AJ 40.2 (±3.3) 0.0(-+0.0) 0.0(-+0.0) 0.0(+-0.0) S 
AS(PYR) 29.6(±3.3) 3.8(±2.7) 6.0(±4.7) 14.3 (±4.1) R 
AS(5OSP) 31.4(±3.3) 15.0(±3.1) 46.2(±3.8) pp R 
1107/10 44(±9.8) 10.3(±1.65) 54.4(±9.7) pp R 
1107/14 27.8(±5.4) 18.4(±15.9) pp pp R 
1108/8 38.3 (±8.5) 0.0(-+0.0) 0.0(-+0.0) (0.0) (±0.0) S 
1109/11 46.2 (±3.7) 24.0 (±21.4) 36.6 (±0.4) pp R 
1110/4 58.6(±1.3) 13.3(±4.6) pp pp R 
1110/8 52.6 (±0.5) 0.0 (±0.0) 0.0(+-0.0) (0.0) (±0.0) S 
1110/10 36.7 (±15.0) 0.0 (±0.0) 0.0 (±0.0) 0.1 (±0.1) S 
1110/13 35.4(±11.6) 0.0(±0.0) 0.0(±0.0) 0.0(±0.0) S 
1351/2 18.5 (±7.8) 0.0(-+0.0) 0.0 (±0.0) 0.0(+-0.0) S 
1384/10 17.7 (±9.3) 5.3(-+0.5) 36.9 (±2.5) pp R 
1385/2 37.1(±11.1) 29.8(±23.6) pp pp R 
1396/1 43.3(±9.0) 56.6(±3.2) pp pp R 
1398/14 39.5 (±7.6) 32.3 (±1.7) pp pp R 
1538/12 28.2(±2.4) 11.1(±6.7) 48.9(±11.9) pp R 
1538/14 26.2 (±7.0) 13.3 (±2.1) 59.1 (±1.6) pp R 
1539/1 40.9(±7.4) 32.8(±1.0) pp pp R 
Figures shown are mean parasitaemias from at least two separate experiments and 
figures in brackets are standard errors. Infections that had already peaked are 
indicated by pp. PYR, pyrimethamine; R, resistant; 5, sensitive. 
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pyrimethamine pressure and were classified as pyrimethamine resistant (R). These 
clones reached peak parasitaemias by day 8 following treatment. As with SIP, some 
progeny clones (e.g. 1396/1 and 1539/1 AS/AJ) grew faster than the resistant parent 
following treatment with pyrimethamine, reaching peak parasitaemias two days 
earlier than AS (50S/P). The difference in day 6 parasitaemias between AS (50SIP) 
and 1396/1 AS/AJ, and between AS (50SIP) and 1539/1 AS/AJ, were highly 
significant (P<0.01). No intermediate phenotypes were observed. 
5.5 Linkage Analysis 
5.5.1 Inheritance of chromosome-specific markers 
A total of 361 polymorphic sites were analysed among the progeny clones, 
most of which exhibited an approximately even distribution. 211 (58%) of all loci 
were inherited from the AJ parent and 150 (42%) from the AS (50SIP) parent (180.5 
expected), compared to the 50:50 ratio expected if there is an equal chance of 
inheriting markers from either parent. There was a skewed inheritance of markers 
associated with chromosome 9. Out of 28 polymorphic sites for this chromosome, 25 
(14 expected) of these were inherited from the AJ parent. In addition, no AS (50S/P) 
type alleles of marker 18 (Ag 3027) on chromosome 9 were detected among the 
progeny. 
5.5.2 Simple analysis for linkage between markers and SIP resistance 
The inheritance patterns of the 30 chromosomal markers and the SIP and 
pyrimethamine responses among the 16 progeny are shown in Figure 15. Linkage 
was assessed by comparing the inheritance pattern of each chromosome-specific 
marker with inheritance of the SIP phenotype. Linkage ratios were determined as the 
ratio of the number of progeny showing linkage of S/P susceptibility with an 
individual marker to the total number of progeny analysed. For this analysis, 
sensitive and low-level resistant progeny were pooled. Markers showing a linkage 
ratio of 12/16 or greater were crudely taken as showing linkage to resistance; due to 
the small number of markers, the very high probability that they are not evenly 
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Figure 15a. Inheritance of 15 chromosomal markers (chromosomes I-Vu) among 16 progeny clones from two 
AJ x AS (50SIP) crosses. Progeny clones are listed vertically, Roman numerals refer to chromosome number and each 
chromosome marker has been allocated the same probe number as in Table 3. Red boxes indicate inheritance of AS (SOS/P)-type 
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Figure 15b. Inheritance of 15 chromosomal markers (chromosomes VIII-XIV) among 16 progeny clones from 
two AJ x AS (50S/P) crosses. Progeny clones are listed vertically, Roman numerals refer to chromosome number and each 
chromosome marker has been allocated the same probe number as in Table 3. Red boxes indicate inheritance of AS (50S/P)-type 
alleles, blue boxes indicate inheritance of AJ-type allele, boxes indicate data not available. 
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distributed among the genome and that little is known of recombination rates in P. 
chabaudi, it was difficult to apply statistical analyses to these linkage ratios. 
Therefore, the only statistical analysis of linkage was that performed in the 
quantitative trait analysis (section 5.5.3). 
The dhfr marker (marker 14) on chromosome 7 showed strongest co-
segregation with SIP resistance, with a linkage ratio of 15/16. Figure 15 shows that 
dhfr is almost perfectly linked to the S/P resistance phenotype in both crosses; all the 
sensitive progeny clones have inherited the AJ dhfr allele, while all the resistant 
progeny clones have the AS dhfr allele. The dhfr would show perfect linkage (16/16) 
had clone 1385/2 AS/AJ been classified with the resistant progeny. 1385/2 AS/AJ, 
which shows intermediate SIP resistance, was grouped with the sensitive progeny 
since it was the resistant SIP phenotype that was under investigation. This 
intermediate SIP resistance was similar to that conferred by mutant dhfr alone in AS 
(PYR). It appears therefore, that while 1385/2 AS/AJ had inherited the mutant dhfr 
from AS (50S/P), it had not inherited the additional gene(s) required for resistance to 
S/P. As expected, dhfr (marker 14) is perfectly linked to pyrimethamine resistance in 
both crosses (Figure 15). 
Other markers showing segregation with S/P resistance were pBSJJO (marker 
3) on chromosome 3 with a linkage ratio of 11/15, P.1 (marker 5) on chromosome 4 
with a linkage ratio of 7/10, Ag3024 (marker 11, 10/13) on chromosome 5 and P.22 
(marker 23) on chromosome 11 with a linkage ratio of 11/14. Markers on 
chromosomes 13, the location of dhps (Carlton et al, 1998b), showed linkage ratios 
of 10/16 or less. These ratios do not differ from markers showing a random 
distribution, indicating that dhps is not tightly linked to resistance. 
Unexpectedly, five markers showed a linkage ratio indicative of linkage with 
inheritance of the AJ-allele and SiP resistance. These were Ag3035 (marker 8, 3/15) 
and DNA po15 (marker 9, 3/16) on chromosome 5, and aldol (marker 25, 3/10), 
G6PD (marker 27, 2/15) and Pfcrk3 (marker 28, 3/15) on chromosome 13. Markers 
on all other chromosomes showed a random distribution expected for normal linkage 
equilibrium. 
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5.5.3 Quantitative trait loci analysis 
Since resistance to SIP may be a complex trait, involving the additive effects 
of two or more genes, the data were analysed in order to map the trait to discrete 
quantitative trait loci (QTL). Details of the analysis are given in Appendix H. The 
results of the QTL analysis are shown in Table 13. The data were normalised by 
taking log,,, transformations. The differences between the mean log parasitaemias of 
grouped progeny clones inheriting the AS (50S/P) versus AJ allele of each marker are 
shown for day 6 parasitaemias for progeny treated with either 25/1.25 mg /kg SIP, 
50/2.5 mg/kg SIP or 10 mg/kg pyrimethamine. The difference in mean log 
parasitaemias of progeny treated with 50/2.5 mg/kg SIP on day 8 are also shown. 
Days 8 and 10 for the remaining drug treatments could not be included as some of the 
resistant progeny reached peak parasitaemias on day 7, and so were difficult to assess 
accurately on subsequent days. Positive integers indicate that the AS (505/P) marker 
allele is segregating with resistance, while negative integers indicate that the AJ 
allele is segregating with resistance. 
The strongest linkage of the S/P resistance phenotype was to dhfr (marker 14) 
on chromosome 7. On days 6 and 8, the differences between the mean log-
parasitaemias of the two groups of progeny clones inheriting either the AJ or AS 
(50SIP) dhfr allele were highly significant (25/1.25 mg/kg S/P and 10 mg/kg 
pyrimethamine, P<0.001; 50/2.5 mg/kg S/P (day 6), 0.01<zP<z0.05; 50/2.5 mg/kg S/P 
(day 8) P<0.001). Other possible loci with linkage to S/P resistance were P.1 
(marker 5) on chromosome 4 (25/1.25 mg/kg S/P. 0.001<P<0.01), AMA-] (marker 
19) on chromosome 9 (50 mg/kg S/P (day 8), 0.001<P<0.01) and Ag3024 (marker 
11) on chromosome 5 (50 mg/kg S/P (day 8), 0.001<P<0.01). The same marker on 
chromosome 5 also segregated with pyrimethamine resistance (0.01<P<0.05). 
The inheritance of AJ-type alleles on chromosomes 5 and 13 showed a 
significant linkage with both S/P and pyrimethamine resistance. AJ-type alleles 
segregating with resistance to 25/1.25 mg/kg S/P were Ag3035 (marker 8) 
(0.01<P<0.05) and DNA p01 5 (marker 9) (0.001<P<0.01) on chromosome 5 and 
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Table 13. Analysis for linkage between inheritance of markers and 
sulfadoxine/pyrimethamine and pyrimethamine resistance. 
Chromosome Marker No. of Day 6 Day 6 Day 8 Day 6 
Progeny 25/1.25 50/2.5 50/2.5 10 mg/kg 
Analysed mg/kg SIP mg/kg SIP mg/kg SIP PYR 
(n) Treated Treated Treated treated 
1 1 12 -0.08 0.04 -0.03 -0.32 
2 2 13 0.43 0.21 0.20 0.35 
3 3 15 0.40 0.16 0.30 0.64 
4 12 0.48 0.19 0.56 0.82 
4 5 10 0.86** 0.24 0.61 0.57 
6 5 -0.14 -0.09 -0.06 0.38 
4/5 7 3 
5 8 15 0.91* -0.23 -0.66 1.07** 
9 16 0.83** -0.12 0.84** -0.62 
10 14 0.80 0.27 0.81 0.78 
11 13 0.52 0.02 0.71** 079* 
6 12 14 0.01 0.24 0.44 0.24 
13 14 0.18 -0.02 0.41 0.27 
7 14 16 1.13*** 0.29* 0.84*** 1.28*** 
15 12 0.50 0.25 0.27 0.50 
8 16 15 -0.09 -0.07 0.12 -0.15 
17 10 -0.21 -0.12 0.04 -0.39 
9 18 16 
19 12 0.91 0.09 0.95** 0.73 
10 20 9 0.18 -0.03 0.32 1.02 
11 21 9 -0.09 -0.02 -0.16 -0.61 
22 7 0.09 -0.05 -0.17 -0.13 
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Chromosome Marker No. of Day 6 Day 6 Day 8 Day 6 
Progeny 25/1.25 50/2.5 50/2.5 10 mg/kg 
Analysed mg/kg SIP mg/kg SIP mg/kg SIP PYR 
(n) Treated Treated Treated treated 
12 24 9 -0.27 -0.47 -0.36 -0.31 
13 25 10 -0.39 -0.09 -0.11 -0.72 
26 9 -0.45 -0.14 -0.10 -0.38 
27 15 1.00** -0.25 0.71** 1.17*** 
28 15 -0.57 0.70** -0.07 
14 29 10 0.56 0.39 0.04 0.29 
30 16 0.18 0.08 -0.08 0.15 
Figures represent the mean difference in log parasitaemia between progeny clones 
inheriting the AS (50SIP) versus the AJ allele of each marker. The analysis could not 
be carried out for marker 7 and marker 18 because no progeny inherited the AS 
(50SIP) allele of this locus. SIP, sulfadoxine/pyrimethamine; PYR, pyrimethamine. 
* P <0.05, ** P <0.01, ***P <0.001 
G6PD (marker 27) (0.001<Pcz0.01) on chromosome 13. AJ-type alleles showing 
linkage to 50/2.5 mg/kg SIP were Pfcrk3 (marker 28) (day 6; 0.001<P<0.01) and 
G6PD (marker 27) (day 8; 0.001<P<0.01) on chromosome 13 and DNA p01 8 
(marker 9) (day 8, 0.001<Pcz0.01) on chromosome 5. Ag3035 (marker 8) 
(0.001<P<0.01) on chromosome 5 and G6PD (marker 27) (P<0.001) and Pfcrk3 
(marker 28) (P<0.001) also showed highly significant segregation with resistance to 
pyrimethamine. Figure 16 shows the mean day 6 log parasitaemias, for four markers, 
for each drug treatment; one representative marker (mspl) showing no linkage with 
resistance and three markers (dhfr, P.1 and G6PD) that showed significant between- 
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Figure 16. Marker contrasts for four loci. Graphs show the mean day 6 log 
parasitaemia between progeny clones inheriting the AS (50S/P) (grey bars) 	versus 
the AJ allele (white bars) 	of four markers. Progeny were treated with either 
25/1.25 mg/kg SIP (25S/P), 50/2.5 mg/kg SIP (50S/P) or 10 mg/kg pyrimethamine 
(10 PYR). Inheritance of mspl (marker 16) shows random distribution indicative of 
normal linkage equilibrium, the AS (50SIP)-type dhfr (marker 14) is strongly linked 
to S/P and pyrimethamine resistance, while P.1 (marker 5) shows linkage with 
resistance to 25/1.25 mg/kg SIP. Inheritance of the AJ-type allele of marker 27 
shows significant linkage with 25/1.25 mg/kg S/P and pyrimethamine resistance. 
Error bars are ± 1 S.E. * P <0.05, ** P <0.01, ***P <0.001. 
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allele difference in parasitaemia, showing that these markers are segregating with the 
drug-resistant phenotype. 
Some markers showed a large difference in mean parasitaemias between 
progeny clones inheriting the AS (50S/P) versus the AJ allele, but the difference was 
not found to be significant. This is due to a large variance about the mean 
parasitaemia and possibly small sample size. Therefore, these loci cannot be ruled 
out as analysis of more progeny clones may reveal linkage to S/P resistance. 
5.5.4 Quantitative trait loci analysis of the fast growth phenotype 
The growth characteristics of the parent clones differed significantly (Figure 
14), AJ growing faster than AS (505/P) and reaching a higher peak parasitaemia. 
QTL analysis was carried out for the day 6 undrugged controls to see if growth rate 
was linked to any of the loci examined. The differences between the mean log-
parasitaemias of grouped progeny clones inheriting the AS (505/P) versus the AJ 
allele of each marker are shown in Table 12. The inheritance of two AS-type alleles 
were weakly associated with fast growth rate; Ag3020 (marker 1) on chromosome 1 
(0.01<P<0.05) and DNA pol 5 (marker 9) on chromosome 5 (0.01<P<0.05). No AJ-
type alleles segregated with fast growth rate. 
This finding showed that the inheritance of genes determining fast growth 
rate from the AJ parent, does not account for the linkage between drug-resistance and 
the inheritance of AJ-type alleles on chromosomes 5 and 13. 
5.5.5 Summary of linkage analysis 
Taken together, these results suggest that mutant dhfr is a major determinant 
of SIP resistance in P. chabaudi. However, at least one other gene is required, and 
these results suggest that other loci for S/P resistance are present on chromosomes 4, 
5 and 9. In addition, inheritance of loci on chromosomes 5 and 13 from the drug-
sensitive parent appear to contribute to the level of resistance observed. 
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Table 14. 
Analysis for linkage between inheritance of markers and growth rate. 
Chromosome Marker No of Day 6 
Progeny Undrugged 
Analysed 
1 1 12 0.18* 
2 2 13 0.13 
3 3 15 -0.06 
4 12 -0.03 
4 5 10 -0.07 
6 5 0.02 
4/5 7 3 
5 8 15 0.03 
9 16 0.15* 
10 14 0.03 
11 13 0.01 
6 12 14 -0.08 
13 14 -0.08 
7 14 16 0.01 
15 12 -0.14 
8 16 15 -0.13 
17 10 -0.03 
9 18 16 
19 12 -0.02 
10 20 9 0.02 
11 21 9 -0.04 
22 7 0.09 
23 14 -0.02 
12 24 9 0.00 
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Chromosome Marker No. of Day 6 
Progeny Undrugged 
Analysed 
13 25 10 -0.03 
26 9 0.03 
27 15 -0.07 
28 15 0.08 
14 29 10 0.04 
30 16 0.02 
Figures represent the mean difference in log parasitaemia between progeny clones 
inheriting the AS (50S/P) versus the AJ allele of each marker. The analysis could not 
be carried out for marker 7 and marker 18 because no progeny inherited the AS 
(SOS/P) allele of this locus. * P <0.05, ** P <0.01, ***p  <0.001 
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6. Discussion 
6.1 Summary of results 
In order to identify the genes conferring resistance to sulfadoxine/ 
pyrimethamine (SIP), resistant mutants of P. chabaudi were derived from AS (PYR) 
by treating infected mice with high doses of SIP. Two representative S/P resistant 
lines were cloned and chosen for further analysis. AS (PYR) parasites were 
eliminated by SIP treatment, whereas AS (5051P) and AS (75SIP) recrudesced at 
different rates following SIP pressure. Parasites of the AS (75S1P) clone always 
recrudesced earlier than those of the AS (5051P) clone. However, AS (5051P) always 
recrudesced before AS (75S1P) when treated with the individual components, 
sulfadoxine or pyrimethamine, alone. The resistance of AS (50S/P) and AS (75S1P) 
was stable after multiple blood passages in the absence of drug, and stable in AS 
(50SIP) following mosquito transmission. 
The P. chabaudi pppk-dhps gene was cloned by homology and sequenced. 
Analysis of this gene and the dhfr-ts of AS (7551P) and AS(50S/P) did not reveal any 
sequence changes when compared to the respective sequences of the AS (PYR) 
genes. Therefore, the mechanism of resistance to S/P in these drug-selected lines 
does not involve additional mutations in dhfr-ts and pppk-dhps. 
To determine the genetic basis of SIP resistance in P. chabaudi, AS (505/P) 
was crossed with an unrelated, drug sensitive clone, AJ. Sixteen independent 
recombinant progeny clones were phenotyped for their susceptibility to S/P and 
pyrimethamine and genotyped for the inheritance of 30 chromosome-specific 
markers. Linkage analysis showed that mutant dhfr is a major determinant of SIP 
resistance in P. chabaudi. However at least one other gene is involved. Quantitative 
trait analysis suggested that other loci for SIP resistance could be present on 
chromosomes 4, 5 and 9. In addition, loci on chromosomes 5 and 13 appear to 
contribute to the level of resistance observed. No association was found between S/P 
susceptibility and the inheritance of the dhps gene. 
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6.2 Selection for resistant parasites 
SIP resistant mutants of P. chabaudi were obtained following single-step 
selection by the drug combination on a clone already resistant to pyrimethamine, AS 
(PYR). Pyrimethamine resistance in AS (PYR) is conferred by the presence of 
asparagine at position 106 in its DI{FR, equivalent to the serine to asparagine change 
at position 108 conferring resistance to pyrimethamine in P. falciparum (Peterson et 
al. 1988, Cowman and Lew 1990, Cheng and Saul 1994). A clone already resistant 
to pyrimethamine was chosen as the starting material because in P. falciparum 
pyrimethamine resistance and hence mutations in dhfr, were already widespread 
when SIP was introduced in the field (Peters 1987). 
The drug responses of the S/P selected lines were of two types; intermediate 
and high resistance, suggesting that the resistant phenotypes are conferred by 
different genetic mechanisms. Furthermore, the ease with which resistance was 
selected (single step, high-pressure selection) suggests that single point mutations 
could have caused each type of resistance. Interestingly, the clone with high 
resistance to SIP, AS (755/P), showed lower resistance to the individual components 
sulfadoxine and pyrimethamine, than AS (505/P). This suggests that the mechanism 
of resistance to the individual drugs may be different from the mechanism of 
resistance to the combination. If the same is true of P. falciparum, in vitro resistance 
assays for pyrimethamine and sulfadoxine individually may be of little relevance in 
predicting SIP response. 
This is the first report of S/P resistance in malaria parasites, selected by 
single-step drug treatment in the laboratory, which shows stable resistance in the 
absence of drug. Stable pyrimethamine-resistant mutants of P. chabaudi have been 
produced by exposure of sensitive forms to this drug alone (Walliker et al. 1975, 
Cowman and Lew 1990), and MacLeod (1977) produced sulfadiazine resistant 
mutants of P. chabaudi in a similar way. With regard to other rodent malaria species, 
S/P resistant parasites have been selected using a continuous low-dose method in P. 
berghei and P. yoelii (Merkli and Richle 1980, Merkli and Richle 1983, Peters and 
Robinson 1984). The resistant phenotypes of these parasites were not stable in the 
99 
Discussion 	 Chapter VI 
absence of drug; once drug pressure was removed, parasites reverted to the sensitive 
phenotype. No sequence data of the dhfr and dhps genes of these parasites are 
available, but as resistance was not stable, resistance was probably due to 
physiological adaptations, where genes that are not normally expressed become 
active in the presence of the drugs. Parasites then reverted to their normal sensitive 
phenotype once drug pressure was removed. 
There are two methods of selecting drug resistant mutants in the laboratory; i) 
high-dose, single-step selection or ii) continuous, low-drug pressure selection. The 
single step selection method was used in this study because in P. falciparum, 
resistance to SIP arose quickly and independently at various geographical locations. 
The ease with which resistance developed is indicative of a simple mutation being 
responsible for conferring resistance, as seen in pyrimethamine resistance. This is 
unlike the evolution of chloroquine resistance. Resistance to chloroquine emerged 
from two locations in the late 1960's, 20 years after it was first introduced and has 
gradually been spreading from these two sites (Payne 1987). This suggests that 
chioroquine resistance is a multigenic trait, the result of an additive effect of 
mutations in many genes (Cowman and Foote 1990). Selection for stable 
chloroquine resistance in rodent malarias was only successful using the continuous, 
low drug pressure selection procedure, over many passages (Powers et al. 1969, 
Rosario 1976a, Padua 1980). However, work done by Merkli and Richle (1980) and 
Peters and Robinson (1984) has shown that the low-dose, continuous pressure 
method does not produce S/P mutants with stable resistance, suggesting that this 
method only selects for physiological adaptations to SIP. 
While resistance to SIP is likely to be a multigenic trait, and therefore 
resistance in P. falciparum might have been expected to have taken a long time to 
emerge, this work and that of others, has shown that mutant dhfr is a major 
determinant (Watkins et al. 1997). Since resistance to pyrimethamine, and therefore 
mutant dhfr alleles, was already widespread in P. falciparum when SIP was 
introduced, resistance required only one (or very few) more mutation(s) at other loci, 
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which were easily selected for. Whether or not the second locus is dhps is still a 
much debated topic, but this work points to the role of other loci. 
Selection on high numbers of parasites parallels the situation encountered in 
the therapeutic use of S/P in man. The 20:1 ratio of sulfadoxine to pyrimethamine 
has also been maintained, and is the only study on rodent malaria to do so. Both 
Merkli and Richle (1980) and Peters and Robinson (1984) used ratios of 3:1. 
However, one major drawback is that no pharmacological data are available for the 
half-life of sulfadoxine in mice, so it is not clear if the same ratio was appropriate. In 
general, mice metabolise drugs much faster than humans; the half-life of 
pyrimethamine is approximately 95 hours in man, but only 24 hours in mice 
(Weidekamm et al. 1982). Sulfadoxine has an estimated half-life of 184 hours in 
humans (Weidekamm et al. 1982) and because sulfadoxine and pyrimethamine have 
similar half-lives in humans, this work has assumed that sulfadoxine also has a half-
life similar to that of pyrimethamine in mice. S/P was administered to infected mice 
daily and appropriate doses for P. chabaudi were chosen by identifying a dose which 
eradicated all sensitive parasites. However, without pharmacological data, it is not 
clear whether this exposure of P. chabaudi to S/P is analogous to the exposure of P. 
falciparum parasites in treated humans. 
In selecting for S/P resistance, 100 mice were infected with 106  parasites and 
the first drug dose was administered four days later. It is estimated that there were 
approximately 10 parasites per mouse at the time of the first drug administration. 
Therefore, approximately 1011  parasites were subjected to S/P selection. Eight of the 
selected lines showed an increase in resistance, giving an approximate mutation rate 
of 0.8 x 10'°. This is comparable to the mutation rates of 2.4 - 4.3 x 10'° observed 
during selection for pyrimethamine resistance from rodent malaria parasites (Morgan 
1974), but is lower than that calculated for other organisms such as S. cerevisiae 
which has an estimated mutation rate of between 2 x 106  and 1 x 10 (Drake 1991). 
This is probably because other parasites that were selected for mutations for 
resistance to S/P either harboured deleterious mutations and/or were eliminated by 





If a higher dose had been used in the selection, or selection pressure applied 
for a longer period of time, parasites with even higher resistance to SIP might have 
been obtained. This has important implications in the linkage analysis. A parasite 
with higher resistance to S/P would have been easier to distinguish from parasites 
with pyrimethamine resistance alone and the progeny phenotypes may have been 
more discrete. However, transmission through mosquitoes of the clone with high-
level resistance to SIP, AS (75S/P), proved difficult. The parasite was eventually 
transmitted, but it was not characterised further in this work. In addition, the AS 
(5051P) clone was found to have a reduced infectivity to mosquitoes. It was 
transmitted on its own through mosquitoes on the second attempt, but it produced 
fewer oocysts in mosquito midguts that the sensitive clone, AJ. It may be that the 
AS-type parasites have reduced infectivity to mosquitoes as a result of multiple blood 
passages, or it may be that drug-resistance confers a fitness cost in these parasites. 
This may be particularly relevant to pyrimethamine and SIP resistant mutants, since 
these parasites have one or more mutations in the genes encoding enzymes in the 
folate biosynthesis pathway. Changes in DHFR resulting in decreased 
pyrimethamine binding also result in a decrease in catalytic activity (Siriwarapom 
and Yuthavong 1984). Therefore, the parasite may be less efficient at pyrimidine 
synthesis, resulting in slower DNA synthesis and replication. When this hypothesis 
was tested, pyrimethamine-resistant P. berghei were found to undergo slower 
sporogonic development in the mosquito than the pyrimethamine-sensitive clone 
from which they were derived, leading to the conclusion that, in the absence of drug, 
pyrimethamine-resistant parasites are less fit than sensitive parasites, although the 
mechanism of resistance in these parasites was not determined (Shinondo et al. 
1994). An additional mutation in the folate pathway to overcome S/P inhibition 
might result in an even greater fitness cost. However, selection for S/P resistance in 
AS (50S/P) also resulted in increased resistance to pyrimethamine and the loss of the 
PABA-sensitivity phenotype, suggesting that in selecting for resistance to SIP, the 
parasites have overcome the cost of having a DHFR with reduced catalytic activity. 
The potential mechanisms for this are discussed in section 6.6. 
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Attempts to select for sulfadoxine-resistant parasites were unsuccessful. 
While some parasites emerged after selection, they were not resistant to the drug and 
the reverted to the normal sensitive phenotype once drug pressure was removed. 
Like the previously obtained SIP resistant parasites (section 6.2), the ability to 
survive in high levels of drug was probably due to physiological adaptations. 
6.3 Sequencing the dhps and dhfr genes 
6.3.1 Isolation of the P. chabaudipppk-dhps 
Mutations in the gene coding for dihydropteroate synthase (DHPS) have been 
implicated in the mechanism of S/P resistance in P. falciparum (Triglia et al. 1998). 
Therefore, to identify any possible mutations associated with resistance to S/P in P. 
chabaudi, the homologue was isolated using degenerate oligonucleotide primers. The 
full length sequence coding for the P. chabaudi PPPK-DHPS was subsequently 
obtained through the technique of 'PCR-walking' using Vectorette genomic DNA 
libraries. 
The approximate Mr calculated from the predicted amino acid sequence 
(80,305 kDa) is half that of the measured Mr of the native bifunctional protein 
(190,000 kDa) (Walter and Konigk 1980). This suggests that the P. chabaudi PPPK-
DHPS forms a dimer in vivo, as proposed for the P. falciparum and T. gondii proteins 
(Brooks et al. 1994, Pashley et al. 1997). Comparison with the PPPK and DHPS 
amino acid sequences of other organisms showed that the P. chabaudi PPPK-DHPS 
has highest homology with the P. berghei homologue, identified in the P. berghei 
EST project. Residues that are absolutely conserved in all PPPK and DHPS enzymes 
are those that have been shown to be involved in substrate binding and catalysis in 
DHPS enzymes of other organisms (Achari et al. 1997, Hampele et al. 1997, Hennig 
et al. 1999). 
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6.3.2 Sequencing the pppk-dhps and dhfr-ts genes from AS (5051P) 
and AS (7551P) 
The dhps and dhfr genes were sequenced from all the lines that survived SIP 
selection. Furthermore, the full length sequences of dhps-pppk and dhfr-ts were 
determined from AS (50SIP) and AS (75S1P). Sequence analysis did not reveal any 
polymorphisms when compared to the pppk-dhps and dhfr-ts sequences of AS 
(PYR). The mechanism of resistance to SIP in these drug-selected lines is not 
therefore conferred by additional mutations in the dhfr or dhps genes. 
Due the presence of an intron at the 5' end of the gene coding for the P. 
chabaudi PPPK-DHPS, the first 10 amino acids of the PPPK domain are still to be 
determined. While it is possible that an amino acid change in the amino terminus 
region of the PPPK could result in structural changes in the DHPS, resulting in sulfa 
drug resistance, such a mechanism has never been described. Additionally, the pppk-
dhps gene was not linked to resistance in the AJ x AS (50SIP) cross. 
Increased expression of dhfr has been shown to confer low-level resistance to 
pyrimethamine (Inselberg et al. 1987, Cowman and Lew 1989, Cowman and Lew 
1990, van Dijk et al. 1994). Stable resistance would require a permanent increase in 
expression, caused by a mutation in the promoter region, or a gene duplication event. 
While expression studies were not completed in this work, again the pppk-dhps gene 
was not linked to resistance in the cross, indicating that increased expression is not 
the mechanism of S/P resistance in the P. chabaudi mutants described here. 
6.4 The AJ x AS (5051P) crosses 
6.4.1 The genetic basis of resistance to S/P 
The inheritance of S/P susceptibility was examined among 16 progeny clones 
from two AJ x AS (50SIP) crosses. Five progeny clones were clearly sensitive to S/P 
and ten clearly resistant. One clone was classified as having low-level S/P resistance, 
similar to the S/P response of AS (PYR). This clone had also inherited the mutant 
dhfr allele, suggesting that mutant dhfr alone is able to confer low-level resistance. 
This is supported by the quantitative trait loci (QTL) analysis that shows mutant dhfr 
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to be a major determinant of SIP resistance. However, at least one other gene is 
required, which is present in the ten SIP resistant progeny, but absent from the 
progeny clone with low-level resistance. The quantitative trait analysis suggest that 
other loci for S/P resistance are present on chromosomes 4, 5 and 9. 
The inheritance of the loci conferring resistance can be explained by a variety 
of mechanisms. As a progeny clone with low-level resistance is present among the 
progeny, a simple genetic model can be predicted: 
Two genes confer resistance to S/P in AS (50SIP) 
If two genes confer resistance to SIP, one mutant dhfr and the other present 
on either chromosome 4, 5 or 9, each mutant gene may confer a low-level of 
resistance, but show an additive effect together, resulting in the high level of 
resistance in AS (50S/P). The progeny of the cross between AS (50SIP) (DHFR R) 
and AJ (dhfr +) would show three S/P phenotypes; (i) sensitive, (ii) low-level 
resistance and (iii) resistant (Figure 19). This would suggest a ratio of 1:2:1 of 
sensitive: low-level resistant: resistant progeny. This does not fit with the 16 progeny 
characterised where the ratio of sensitive: low-level resistance: resistant was 5:1:10. 
However, it is difficult to draw conclusions from these ratios due to the small number 
of progeny analysed. The isolation of more progeny clones may reveal an increased 
proportion of progeny with low-level resistance, or alternatively, these progeny may 
have been selected against in either the mosquito or in mice. 
Two genes confer resistance, but mutant dhfr is epistatic to the unknown gene 
A variation of the two-gene hypothesis is that both are involved in resistance, 
but that dhfr is epistatic to the unknown gene, i.e. the latter has no effect in the 
absence of mutant dhfr, but increases the level of resistance to S/P when it is present 
(Figure 18). This is similar to the proposed role of the mdr gene in chloroquine 
resistance in P. falciparum (Foote et al. 1990). Since the unknown gene does not 
confer resistance on its own, the ratio of sensitive: low-level resistance: resistant in 
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S/P resistant 	Low-level SIP 	Low-level SIP 	S/P sensitive 
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PYR resistant 	PYR resistant 	PYR sensitive 	PYR sensitive 
Predicted phenotypes 
Figure 17. Diagram illustrating the two-gene hypothesis. Upper case 
letters indicate that the allele has been inherited from the resistant parent AS (505/P), 
lower case letters or + indicate that the allele was inherited from the sensitive parent. 
SIP, sulfadoxine/pyrimethamine; PYR; pyrimethamine. 
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AS (5OSIP) 



























Figure 18. Diagram illustrating inheritance of resistance if dhfr is 
epistatic to R. Upper case letters indicate that the allele has been inherited from 
the resistant parent AS (50S/P), lower case letters or + indicate the allele was 
inherited from the sensitive parent. SIP, sulfadoxine/pyrimethamine; PYR; 
pyrimethamine. 
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the progeny clones is 2:1:1. This is more in agreement with the proportions of the 
progeny phenotypes found in this study. 
3) Two genes confer resistance in AS (5051P), but mutant dhfr is epistatic to the 
unknown gene and the inheritance of an additional gene from AJ contributes to the 
level of resistance 
The association between resistance and the inheritance of loci on 
chromosomes 5 and 13 from the sensitive parent can be explained by the inheritance 
of genes that contribute to the level of resistance observed. This model can be 
combined with either the two-gene hypothesis, or the two-gene epistasis hypothesis. 
The latter is shown in Figure 19. Here, dhfr is epistatic to the unknown gene, both of 
which are inherited from the AS (50SIP) parent and a third gene (A), inherited from 
the AJ parent contributes to the level of resistance, for example by influencing 
growth rate under drug pressure. This results in a ratio of 2:1:1 of sensitive: low-
level resistance: resistant, with one resistant progeny genotype also inheriting a fast 
growth rate, contributing to the level of resistance observed. It is not possible to 
draw conclusions from the observed numbers of clones of each phenotype because of 
the small number of progeny analysed, but an excess of resistant parasites may have 
been selected for due to their fast growth rate. 
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Figure 19. Diagram illustrating inheritance of resistance if dhfr is 
epistatic to R, and an additional gene, A inherited from AJ contributes 
to the level of resistance observed. SIP, sulfadoxine/pyrimethamine; PYR; 
pyrimethamine. 
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6.4.2 The quantitative trait loci analysis 
The QTL analysis assumes that the drug resistance phenotype results from the 
sum of the effects of the individual QTLs. It also relies on the hypothesis that the SIP 
resistant genes are inherited from the AS (50S/P) parent. However, the inheritance of 
multiple loci on chromosomes 5 and 13 from the sensitive parent AJ are significantly 
linked to the resistant phenotype in the progeny. It is unlikely that these are false 
positives as linkage is observed with both the resistance to S/P and pyrimethamine 
and with different doses of SIP. Markers 27 and 28 on chromosome 13 show highly 
significant linkage to pyrimethamine resistance. The reason for this is not clear; AJ 
is sensitive to both pyrimethamine and SIP. 
The pppk-dhps gene has been mapped to chromosome 13 in P. chabaudi 
(Carlton et al. 1998b). No sequence polymorphisms were observed between the AS 
(50SIP) and AJ alleles, but it is estimated that approximately 30 bp are missing from 
the 5' end of the pppk sequence. One explanation for linkage of drug-resistance to 
loci inherited from chromosome 13 of the sensitive parent, is that the AJ DHPS may 
confer innate resistance to sulfonamides. This could be due to amino acid changes in 
the amino terminus of PPPK that were not detected, resulting in structural changes in 
the DHPS. Therefore, when the AJ dhps is inherited along with the AS (50SIP) dhfr 
allele and the other gene(s) conferring resistance, a level of resistance higher than 
that of the resistant parent is observed. However, attempts to develop an RFLP 
marker to distinguish the AS and AJ dhps alleles have been unsuccessful (Carlton 
1995), suggesting that the pppk-dhps sequences in the two parasite clones are 
identical. 
If the inheritance of loci from AJ contributes to the level of resistance 
observed, it is unclear why all the resistant progeny have inherited these loci from the 
AJ parent and the majority of the sensitive progeny have inherited the corresponding 
alleles from the resistant parent. This association may be due to chance, and analysis 
of more progeny may break down this association. Alternatively, resistance may 
confer a fitness cost that is compensated by the inheritance of genes from the 
sensitive parent, e.g. determining growth rate. Selection on the progeny may have 
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then occurred either in mosquitoes, during the exo-erythrocytic stage in the mice, or 
during growth in the blood, such that only the resistant progeny that had inherited the 
loci on chromsomes 5 and 13 from the AJ parent survived to be cloned. Analysis of 
more progeny may break down this association. 
The parasitaemias from the day 6 undrugged control were analysed to see if 
growth rate was linked to the loci on chromosomes 5 and 13. No AJ-type alleles 
segregated with fast growth rate. Therefore, the inheritance of genes determining fast 
growth rate from the AJ parent do not account for the linkage between drug-
resistance and the inheritance of AJ-type alleles on chromosomes 5 and 13. Canton 
et al. (1998a) found a weak association between growth rate between days 4 and 6 
and the inheritance of loci on chromosomes 11 and 14 in the AJ x AS (3CQ) cross. 
No such association was found in the AJ x AS (5051P) crosses, but the analysis used 
in this work looked at parasitaemia on day 6 only, so loci controlling growth between 
days 4 and 6 may have been overlooked. 
QTL analysis also assumes that each QTL locus has an additive effect to the 
phenotype under investigation. For example, SIP resistance may have been caused 
by an additive effect of mutant genes at two loci, each able to confer low SIP 
resistance (Figure 17). Alternatively, one gene may be epistatic to the other, i.e. one 
locus has no effect on drug resistance in the absence of the other, but increases the 
resistance level when it is present (Figure 18). Genes with epistatic effects are much 
harder to map as they do not confer any low-level of resistance on their own. 
The progeny clones that grow faster than the resistant parent under SIP and 
pyrimethamine pressure, due to the inheritance of loci from the sensitive as well as 
the resistant parent, are of interest as this has important implications in the field. 
Recombination between drug-sensitive and drug-resistant P. falciparum may result in 
drug-resistant parasites with increased virulence. Therefore, clinical failures must be 
treated with an effective drug, if available, as soon as possible. The AJ x AS (50SIP) 
cross provides the opportunity to map the loci determining growth rate/virulence. 
The genes aldo-] and G6PD are found in conserved synteny groups on chromosome 
13 in P. chabaudi and chromosome 14 in P. falciparum (Carlton et al. 1998b). On 
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completion of the genome project, it will clearly be of interest to see what other 
genes are present on chromosome 14 in P. falciparum. 
The inheritance patterns of the markers show that extensive recombination 
and reassortment has occurred among the chromosomes during meiosis. The markers 
are numbered according to Carlton (1995), such that the number of crossovers per 
chromosome in the AJ x AS (3CQ) cross were minimal. Su et al. (1999) estimate a 
rate of one crossover per 1.67 x 106  bp per meiosis in the P. falciparum Dd2 x HB3 
cross. As marker coverage is less than optimal in this work, if the gene conferring 
resistance and the marker are far apart in the AJ x AS(50SIP) cross, there is a high 
probability that a crossover event will separate them. As seen in the inheritance of 
markers 14 and 15 on chromosome 7, recombination breaks down the association of 
the AS-allele of P.23 and the AS-allele of dhfr; no linkage is seen between P.23 and 
pyrimethamine or S/P resistance. Therefore, QTLs on chromosomes with few 
markers may easily be overlooked. In addition, due to the number of markers tested, 
false positives can be expected. The inheritance of 30 markers was analysed for 
linkage to four different drug-resistant phenotypes, resulting in 120 marker contrast 
analyses. With an estimated false positive rate of 5%, i.e. that there is a 5% chance 
that a marker may be linked to resistance just by chance, it can be estimated that 1 in 
24 QTL are false positives. Alternatively, it can be assumed that only QTLs that are 
highly significant (P <0.001) are genuinely linked to a quantitative trait. 
A major problem with genome mapping in P. chabaudi is the current lack of 
chromosome-specific markers. It is likely that an insufficient number of progeny 
from the AJ x AS (50 SIP) cross were phenotyped and genotyped in order to identify 
real QTLs. Carlton et al. (1998a) estimate that for a single marker 9, 17 or 32 
progeny clones are required if the nearest marker is 0, 10 or 20 centiMorgans (cM) 
respectively away from the gene (genetic distance between two loci is measured in 
cM, with one cM equivalent to a crossover rate of 1%; a recombination rate of 1% 
indicates tight linkage, whereas a frequency of 50% indicates that the loci are far 
apart). Although the recombination rate in P. chabaudi is unknown, based on that 
calculated for P. falciparum (Su et al. 1999), 16 progeny should be sufficient to 
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identify a single gene effect. However, when 25 markers are used, the increased 
probability of obtaining a false positive increases the number of progeny required to 
14, 27 or 52. Therefore the ability to detect loci other than those closely linked to a 
genetic marker was not optimal, in particular for any loci which may be present on 
the larger chromosomes that only have one or two markers. Only one locus was 
examined on chromosome 12 and while two loci were examined on chromosome 14, 
they appear to be very tightly linked. Therefore, if a QTL is present on chromosome 
14, recombination may have broken down the linkage between the QTL and the 
chromosome 14 markers and hence linkage to resistance was not detected. In 
addition, there are no markers for the extra-chromosomal DNA; the 6 kb 
mitochondrial element and the 35 kb apicoplast genome. Therefore, if resistance is 
linked to changes in genes present on the extra-chromosomal DNA, they will not 
have been detected. 
Only 16 progeny were phenotyped due to the time and expense of obtaining 
progeny clones, phenotyping and RFLP genotyping. Lander and Botstein (1989) 
suggest that growing a large number of progeny, but only genotyping those with the 
most extreme phenotypes (selective genotyping) can minimise the number of progeny 
that need to be scored with genetic markers. Such methods can be applied to QTL 
mapping in P. chabaudi in future work. 
6.4.3 The inheritance of chromosome-specific markers 
The inheritance data indicates that certain genotypes were indeed selected 
during the crosses. Out of the polymorphic loci analysed, 58% of all loci were 
inherited from the AJ parent, compared to the 50:50 ratio expected if there is an 
equal chance of inheriting markers from either parent. The advantage that the AJ 
clone appears to have over AS-type parasites has been reported in other work. An 
excess of AJ-parental type clones was found among the progeny of the AJ x AS 
(30CQ) crosses (Rosario 1976a, Rosario 1976b, Carlton 1995 and the AJ x AS 
(30CQ) cross (Padua 1980). In the AJ x AS (3CQ) and AJ x AS (30CQ) crosses, 
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there was also evidence that recombinant progeny with an AJ genetic background 
were at an advantage (Padua 1980, Canton 1995). 
There was no excess of AJ-parentals in the progeny of the AJ x AS (50SIP) 
crosses in this work, but while only a relatively small number of progeny have been 
characterised, it is interesting to note that once again, the AJ genetic background 
appears to be favoured among the progeny. It was notable that all progeny inherited 
the AJ-type allele of Ag3027 on chromosome 9. A possible explanation for this is 
that the AJ-type allele of Ag3027 may confer a growth advantage in the mosquito or 
in mice. However, the AS-type allele of Ag3027 is present in the progeny of the AJ x 
AS(3CQ) cross (Canton et al. 1998a), so the reasons for the skewed inheritance in 
the current cross are unclear. Carlton et al. (1998a) also noted a bias towards the 
inheritance of AJ-type markers associated with chromosome 5 and skewed RFLP 
distributions have also been observed in the P. falciparum crosses (Walker-Jonah et 
al. 1992). In the P. falciparum HB3 x Dd2 cross, where 35 progeny were mapped for 
the inheritance of 901 markers, biased inheritance was found in seven marker groups 
(Su et al. 1999); most of chromosome 2 and terminal regions of chromosomes 9 and 
13 showed significant excesses of Dd2 markers, while regions on chromosomes 3 
and 8 carried an excess of HB3 markers. Therefore, skewed inheritance is not 
unusual in Plasmodium genetics, at least in the comparatively few crosses carried out 
so far. 
6.4.4 The sulfadoxine/pyrimethamine susceptibility tests 
The pyrimethamine and S/P drug tests used in this work were based upon 
parasite recrudescence following drug treatment of 25/1.25 mg/kg SIP, 50/2.5 mg/kg 
S/P or 10 mg/kg pyrimethamine for 4 days. Resistant parasites appeared on or before 
day 8, whereas sensitive parasites were completely eliminated by these doses. All 
tests were repeated on at least two independent occasions to minimise the effect of 
environmental noise, but there were variations in parasitaemias and the day of 
recrudescence between repeated tests of the same clone. In particular, variations 
were seen in clones following treatment with 50/2.5 mg/kg SIP. In the QTL analysis, 
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loci showing linkage to 50/2.5 mg/kg S/P did not always show linkage to 25/1.25 
mg/kg SIP and vice versa. It may be that different genes are involved in resistance to 
50/2.5 mg/kg from those conferring resistance to 25/1.25 mg/kg SIP, but a more 
likely explanation is that the phenotyping is not optimal for the 50/2.5 mg/kg drug 
dose. This is apparent in the size of the variance of the mean parasitaemias on days 
6, 8 and 10 following treatment with 50/2.5 mg/kg SIP. In some experiments, 
resistant progeny reached peak parasitaemias on day 8, while during other tests the 
same clones reached peak parasitaemias between days 9 and 12. This 'noise' could be 
overcome by improving the test, perhaps by altering the dose given, the time between 
treatments or the duration of the drug treatment. Alternatively, analysis could take 
into account only the presence or absence of parasites. For example, if three mice 
have day 8 parasitaemias of 0, 1 and 40% respectively, in the QTL analysis, the 
difference between 1 and 40% is highly significant, where as the difference between 
0 and 1% may not be significant. However, in vivo the difference between a 0 and 
1% parasitaemia is much more important. The mouse with no parasites may never 
develop an infection, while the mouse with a 1% parasitaemia will have a peak 
parasitaemia within 2 or 3 days. if the quantitative trait analysis could be modified to 
look at the presence or absence of parasites following drug treatment, environmental 
noise may be reduced, resulting in more of the variation being due to the individual 
QTLs. 
Environmental noise has been noted by others analysing P. chabaudi genetic 
crosses (Rosario 1976a, Padua 1981, Carlton 1995). The age, sex and strain of the 
mouse used, as well as the host diet have all been shown to have an effect on the 
outcome of infection (Stevenson et al. 1982). To minimise the effect of these 
variables, all drug tests were carried out using 6-9 week old male inbred CBAJCa 
mice, maintained on a constant diet with drinking water supplemented with 0.05% 
PABA, except where described for sulfadoxine susceptibility tests. Variation can also 
be due to the immune status of the individual mice (Carlton 1995). This is 
particularly relevant for sulfadoxine as it is a 'static' drug, i.e. it does not actually kill 
the parasite, but it inhibits DNA synthesis and hence replication. Its activity relies on 
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either the spleen or immune system to clear the developmentally arrested parasites. 
In addition, the antifolates and sulfonamides also act on a wide range of micro-
organisms. Therefore, any concurrent infection in the mice may also metabolise the 
drugs, decreasing the concentration of drug acting on P. chabaudi. While unwanted 
infections were kept to a minimum, their presence cannot be ruled out. 
6.5 Mechanisms of sulfadoxine/pyrimethamine resistance 
Which genes are conferring resistance to S/P in P. chabaudi? As a rule, 
microbial resistance to a single drug can be expected to be due to a variety of genetic 
mechanisms. Such mechanisms include variation in the target (modification, 
amplification or bypassing of the pathway) or variations in drug levels by decreased 
uptake, increased expulsion, compartmentalisation or failure to activate a prodrug. 
Any of these mechanisms could be acting independently, or in conjunction with 
mutations in dhfr and dhps. While pyrimethamine-resistant parasites are known have 
an increased requirement for PABA (Jacobs 1964), early work on sulfonamide 
selected P. berghei showed that sulfa-resistant parasites have a reduced requirement 
for PABA (Jaswant-Singh et al. 1954, Ramakrishnan et al. 1956). The authors 
suggest that sulfa-resistant parasites may have acquired the ability to synthesise 
PABA de novo. While AS (PYR) has an increased requirement for PABA and is 
more sensitive to sulfadoxine on a PABA-deficient diet, after selection with SIP, the 
SIP resistant parasites have a reduced requirement for PABA, confirming that sulfa-
resistant parasites may have either acquired the ability to synthesise PABA or are 
able to by-pass the pathway completely. Uptake of PABA and hence sulfadoxine has 
been shown to be reduced in sulfadoxine resistant parasites, suggesting that resistant 
parasites are able to use an alternative pathway (Tan-Ariya and Brockelman 1983, 
Dieckmann and Jung 1986). The presence of the shikimate pathway, necessary for 
PABA biosynthesis, has recently been confirmed in malaria parasites (Roberts et al. 
1998). Therefore, sulfadoxine-resistant parasites may have the ability to obtain all of 
their required PABA for growth from this pathway, while sensitive parasites also 
need to take up exogenous PABA from their host. The polymorphisms observed in 
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the P. falciparum dhps gene may be due to natural variation, as seen in Pneumocystis 
carinii (Lane et al. 1997) before sulfa-resistant Pn. carinii were identified (Heiweg-
Larsen et al. 1999) or may have been selected for by widespread use of sulfa drugs 
for other infections. 
6.5.1 Folate uptake 
Wang et a! (1999) explain the synergy between sulfadoxine and 
pyrimethamine by showing that pyrimethamine has a second site of action, in 
addition to inhibiting DHFR. Pyrimethamine blocks the utilisation of exogenous 
folate, which forces the parasite to use the endogenous folate pathway, rendering it 
extremely susceptible to sulfadoxine inhibition. The mechanism by which this 
occurs is unknown, but it is likely that since pyrimethamine is a structural analogue 
of folic acid, it inhibits either the uptake or processing of exogenous folate (Wang et 
al. 1999). A mechanism to overcome pyrimethamine inhibition of folate uptake 
would allow the parasite to process exogenous folate in the presence of 
pyrimethamine and when combined with a mutant dhfr, would reverse inhibition of 
the folate pathway. Since the parasite no longer relies on the endogenous folate 
pathway, and the reaction catalysed by DHPS precedes DHFR in the folate pathway, 
inhibition of DHPS by sulfadoxine becomes irrelevant, resulting in resistance to SIP. 
Therefore, while mutations in dhps cause resistance to sulfadoxine in vitro (Triglia et 
al. 1998), they may not contribute to resistance to SIP in vivo. 
A gene influencing the use of exogenous folate has been mapped to 
chromosome 4 in P. falciparum, closely linked to dhfr (Wang et al. 1997a). The 
chromosome location of different genes is highly conserved between P. falciparum 
and P. chabaudi (Carlton et al. 1998b) where the dhfr gene is found on chromosome 
7 (Cowman and Lew 1989). Therefore, a locus linked to an equivalent folate effect 
in P. chabaudi, which may modulate the response to SIP, may also be present on 
chromosome 7. Unfortunately, the QTL analysis is unable to detect the presence of 
another QTL, in addition to dhfr, on chromosome 7 due to poor marker coverage. 
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6.6 Relevance of this work to SIP resistance in P. falciparum 
Mutant dhfr was found to be a major determinant of SIP resistance in P. 
chabaudi. This agrees with pharmacokinetic data showing that inhibition of P. 
falciparum DHFR by SIP treatment is more important than the inhibition of DHPS, 
leading to the hypothesis that mutations in dhfr are sufficient to confer resistance to 
SIP (Watkins et al. 1997). This work shows that dhfr is a major determinant, but also 
points to the presence of other loci. To identify the gene(s) at these loci, it will first 
be necessary to develop many more chromosome-specific markers. While over 800 
polymorphic microsatellite markers have been developed for P. falciparum (Su et al. 
1999), it has been reported that there are a limited number of microsatellites in the 
genomes of rodent malaria parasites (van Belkum et al. 1992). This has yet to be 
confirmed by extensive genome sequencing, but other methods for detecting 
polymorphisms, such as amplified fragment length polymorphisms (AFLP), a rapid 
method for detecting large numbers of DNA polymorphisms (Vos et al. 1995), and 
typing using anchored polyA and polyT oligonucleotides (APADs) (Su and Canton 
2000) can easily be applied to P. chabaudi genetic analyses. This would permit the 
identification of the gene(s) conferring resistance to SIP in P. chabaudi. With the 
completion of the genome project, the P. falciparum homologue can be rapidly 
identified and sequenced from field isolates to see if the mechanism of resistance in 
P. falciparum is similar to that in P. chabaudi. Transfection of candidate genes into 
drug-sensitive clones can then be carried out to confirm a causal relationship with 
resistance (van Dijk et al. 1995, Wu et al. 1996). Molecular analysis of several 
pyrimethamine resistant rodent clones has shown that the mechanisms of 
pynimethamine resistance are remarkably similar to those seen in P. falciparum, 
therefore it might be expected that drug-resistant P. chabaudi are a good model for 
studying drug-resistance in P. falciparum (Cowman and Lew 1990, Cheng and Saul 
1994). 
Fine mapping of the loci for SIP resistance present on chromosomes 4, 5 and 
9 may take some time, and time is running out for S/P in Africa. It is estimated that 
at the current rate of spread of resistance, SIP will be ineffective within five years 
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(White et al. 1999). In order to develop strategies to slow the spread of resistance, it 
may be possible to identify these loci in P. falciparum, since some genes present on a 
single chromosome in P. chabaudi, were also found to be on a single chromosome in 
P. falciparum (Canton et al. 1998b). For example, the genes crk-4 and csp were both 
found to be located on chromosome 4 in P. chabaudi, and in P. falciparum, they 
were found together on chromosome 3, while AMA-] and RAN were found together 
on chromosome 9 in P. chabaudi and chromosome 11 in P. falciparum (Carlton et 
al., 1998b). The complete sequence of chromosome 3 of P. falciparum is already 
available and it is predicted to encode 215 proteins, including three transporters and 
at least 10 open-reading frames with unknown function (Bowman et al. 1999). To 
identify the genes at the putative QTL on chromosome 4 in P. chabaudi, candidate 
genes from P. falciparum chromosome 3 could be used to probe pulse-field gels, to 
identify chromosomal location, and Southern blots of genomic DNA to identify 
RFLPs between AS (50S/P) and AJ. if polymorphic markers are identified, the QTL 
analysis can be repeated. if this approach is successful, the gene underlying the 
quantitative trait on chromosome 3 may be identified and the P. falciparum 
homologue can be rapidly sequenced from field isolates to see if the locus also 
contributes to S/P resistance in P. falciparum. 
This work suggests that the mechanism of resistance to sulfadoxine alone 
may be different to the mechanism of resistance to the SIP combination, if the same 
is true of P. falciparum, in vitro assays for sulfadoxine may be of little relevance in 
predicting S/P response. Taken together, these results suggests that caution must be 
taken when using polymorphisms in dhfr and dhps in epidemiological studies to 
estimate the frequency of S/P-resistant parasites and that all molecular surveys should 
be validated with some kind of in vitro test for SIP resistance. 
6.7 The future of QTL mapping in Plasmodium 
The sequencing of the P. falciparum genome is well underway, with 
chromosomes 2 and 3 finished and many of the other 12 chromosomes nearing 
completion (Gardner et al. 1998, Bowman et al. 1999). With the completion of the 
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genome sequence, positional cloning of genetic determinants, which was previously 
very expensive and time consuming, will become much easier. Recent advances in 
microarray technology and proteomics permit rapid identification in changes in gene 
expression in thousands of genes under different physiological conditions, such as 
drug exposure (Hayward et al. 2000, Yates 2000). Both methods will detect an 
increase in expression, such is seen in mdr duplication in mefloquine resistance, 
while proteomics can detect shifts in molecular weight due to insertions or deletions 
and in isoelectric point (p1) due to a single amino acid substitution. As the cost of 
genome sequencing is continually reducing, it looks increasing likely that the rodent 
malarias will also benefit from a sequencing project, allowing these techniques to be 
applied to P. chabaudi (van Lin et al. 2000). The rodent malarias have an important 
advantage over P. falciparum for this type of work due to the ability to select 
isogenic drug-resistant clones from sensitive parasites, making the detection of 
changes in a single mRNA or protein much easier. These high throughput 
technologies will revolutionise candidate gene studies, identify new drug and vaccine 
targets and aid our understanding of malaria biology and pathology, all of which are 
essential to malaria control, and may be, eventually, eradiction of the disease. 
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Appendix I: The composition of solutions 
All solutions were sterilised by autoclaving or filtration, unless otherwise stated. 
Calf serum/Ringer 
50% (v/v) calf serum 
50% (v/v) Ringer solution 
20 units heparin/ml mouse blood 
Not sterilised and made fresh. 
Citrate saline 
0.9% (w/v) NaCl 
1.5% (w/v) sodium citrate 
Deep-freeze solution 
28% (v/v) glycerol 
3% sorbitol 
0.65% (v/v) NaCl 
DNA lysis solution 
10 mM Tris 
50 mM EDTA 
0.1% SDS 
Gel-loading buffer (5X) 
30% (v/v) glycerol 
70% (v/v) dH 20 
0.25% (w/v) bromophenol blue 
Not sterilised 
Luria-bertani (LB) medium 
10 g bacto-typtone 
5 g bacto-yeast extract 
lOgNaCl 
Made up to 800 ml with dH 20, 
pH adjusted to 7.5 and solution 
made up to 1000 ml with dH20. 
Phosphate buffered saline (PBS) 
137 m NaCl 
2.7 mM KC1 
4.3 mM Na2HPO4 
1.47 MM  KH2PO4 
PCR dNTP solution (100X) 
6.25 mM dGTP 
6.25 mM dATP 
6.25 mM dTTP 
6.25 mM dCTP 
Pre-hybridisation solution 
10% (w/v) dextran sulphate 
10% (v/v) 10% SDS 
5.8 % (w/v) NaCl 
Made up to 1000 ml with dH 20 
Mixed at 65°C for 40 mins, autoclaved, 
aliquoted and stored at -20°C. 
Ringer solution 
27 mM CaCl 2 
0.15 M NaCl 
Saline-sodium citrate (SSC) (20X) 
3MNaC1 
0.3 M sodium citrate 
Sequencing gel loading buffer (5X) 
83 % (v/v) deionised formamide 
25 mM EDTA pH 8.0 
50 mg/ml blue dextran 
Not sterilised and made fresh. 
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Tris/boratelEDTA (TBE) buffer (1X) 
O.O9MTris 
0.09 M boric acid 
0.002 M EDTA 
TrisIEDTA (TE) buffer 
10 mlvi Tris-HC1 pH 8.0 
1 mM EDTA pH 8.0 
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Appendix II: The Student's t test 
The Student's t-test is used for comparing the means of two small samples. 
The mean difference between the two samples is divided by the standard error of the 
difference, which takes in account the small sample size. The answer is then 
compared with the distribution of t at the appropriate degrees of freedom, where t 
equals: 
(Z - x2) 
t = J[(nj- 1  )S1 + (n2- i)s21 (n 1_+_n2\ 
(n1+n2-2) 	.1 n1n2  ) 
where Tc =I x s = / (x 
)2  and the degrees of freedom are (n 1 + n2)-2. 
n 	"1 	n-i 
For example, the value for t for the differences between mean log 
parasitaemias of grouped progeny clones inheriting the AS (50SIP) versus the AJ 
allele of marker 1, on day 6 following treatment with 25/1.25 mg/mg S/P, was 
calculated as follows: 
Table 15. Mean parasitaemias of progeny grouped according to the 
inheritance of marker I 
Mean day 6parasitaemias following 2511.25 mg/kg SIP 
Progeny inheriting the Logioa Progeny inheriting the Log10 a 
AS (50S/P)-type allele (mean +1) AJ-type allele (mean +1) 
1.9 0.46 0.0 0.00 
9.6 1.02 10.0 1.04 
0.0 0.00 0.2 0.06 
23.0 1.38 19.9 1.32 




Z 4.47 	 13.62 
X10.64 x2 = 0.72 
s 1 =0.69 	 s2 =0.64 
St 2 = 0.48 s 2 = 0.41 
a The data were normalised by taking logo transformations 
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Substituting in the formula for t: 
(0.64 - 0.72) 
t = /[(7-1)0.48+(5-1)0.41 (
7x5 )
7+5 
(7+5-2) 	j  
-0.08 
= / 2.88 + 1.64 x 0.34 
10 
-0.08 	 -0.08 
= "1 0.45 x 0.34 	 = 	0.392 
= -0.21 
The values of -0.08 and 0.392 in the final step are the difference between the 
mean log parasitaemia and the standard error of the difference respectively. 
Consulting a table of the distribution of t, a value of 0.21 is lower than the tabulated 
value of 1.812 at P = 0.05 for 10 (12-2) degrees of freedom. Therefore, it can be 
concluded that there is no statistically significant difference between the means and 




Achari, A., Somers, D. 0., Champess, J. N., Bryant, P. K., Rosemond, J., and 
Stammers, D. K. 1997. Crystal structure of the anti-bacterial sulfonamide 
drug target dihydropteroate synthase. Nature Structural Biology 6, 490-497. 
Altschul, S. F., Madden, T. L., Schäffer, A. A., Zhang, J., Zhang, Z., Miller, W., and 
Lipman, D. J. 1997. Gapped BLAST and PSI-BLAST: a new generation of 
protein database search programs. Nucleic Acids Research 25, 3389-3402. 
Arnold, C. and Hodgson, I. J. 1991. Vectorette PCR: a novel approach to genome 
walking. PCR -Methods and Applications 1, 39-42. 
Babiker, H. A., Ranford-Cartwright, L. C., Currie, D., Charlwood, J. D., Billingsley, 
P., Teuscher, T., and Walliker, D. 1994. Random mating in a natural 
population of the malarial parasite Plasmodium falciparum. Parasitology 
109,413-421. 
Babiker, H. A. and Walliker, D. 1997. Current views on the population structure of 
Plasmodium falciparum: implications for control. Parasitology Today 13, 
262-267. 
Basco, L. K. and Ringwald, P. 1998a. Molecular epidemiology of malaria in 
Yaounde, Cameroon I. Analysis of point mutations in the dihydrofolate 
reductase-thymidylate synthase gene of Plasmodium falciparum. American 
Journal of Tropical Medicine and Hygiene 58, 369-373. 
Basco, L. K., Tahar, R., and Ringwald, P. 1998b. Molecular basis of in vivo 
resistance to sulfadoxine-pyrimethamine in African adult patients infected 
with Plasmodium falciparum malaria parasites. Antimicrobial Agents in 
Chemotherapy 42, 1811-1814. 
Bloland, P. B., Lackritz, E. M., Kazembe, P. N., Were, J. B. 0., Steketee, R., and 
Campbell, C. C. 1993. Beyond chloroquine: implications of drug resistance 
for evaluating malaria therapy efficacy and treatment policy in Africa. 
Journal of Infectious Diseases 167, 932-937. 
Botstein, D., White, R. L., Skolnick, M., and Davis, R. W. 1980. Construction of a 
genetic linkage map in man using restriction fragment length polymorphisms. 
American Journal of Human Genetics 32, 314-331. 
Bowman, S., Lawson, D., Basham, D., Brown, D., Chillingworth, T., Churcher, C. 
M., et al. 1999. The complete nucleotide sequence of chromosome 3 of 
Plasmodiumfalciparum. Nature 400, 532-538. 
125 
References 
Bray, R. S. and Garnham, P. C. C. 1953. Effect of milk diet on Plasmodium 
cynomolgi infections in monkeys. British Medical Journal 1, 1200-1201. 
Bray, R. S. 1957a. Studies on malaria in chimpanzees. American Journal of Tropical 
Medicine and Hygiene 6, 514-519. 
Bray, R. S. 1957b. Studies on malaria in chimpanzees. X. The presumed second 
generation of the tissue phase of Plasmodium ovale. American Journal of 
Tropical Medicine and Hygiene 6, 638-649. 
Brooks, D. R., Wang, P., Read, M., Watkins, W. M., Sims, P. F. G., and Hyde, J. E. 
1994. Sequence variation of the hydroxymethyldihydropterin pyrophosphate 
kinase:dihydropteroate synthase gene in lines of the human malaria parasite, 
Plasmodium falciparum, with differing resistance to sulfadoxine. European 
Journal of Biochemistry 224, 397-405. 
Bruce-Chwatt, L. J. 1985. Essential malariology. 2nd edition. William Heinemann 
Medical Books, London. 
Canton, J. M. R. 1995. The genetics of chloroquine resistance in the rodent malaria 
Plasmodium chabaudi. PhD Thesis University of Edinburgh. 
Carlton, J., Mackinnon, M., and Walliker, D. 1998a. A chloroquine resistance locus 
in the rodent malaria parasite Plasmodium chabaudi. Molecular and 
Biochemical Parasitology 93, 57-72. 
Carlton, J. M. R., Vinkenoog, R., Waters, A. P., and Walliker, D. 1998b. Gene 
synteny in species of Plasmodium. Molecular and Biochemical Parasitology 
93, 285-294. 
Carlton, J. M. R., Galinski, M. R., Barnwell, J. W., and Dame, J. B. 1999. Karyotype 
and synteny among the chromosomes of all four species of human malaria 
parasite. Molecular and Biochemical Parasitology 101, 23-32. 
Carter, R. and Walliker, D. 1975. New observations on the malaria parasites of 
rodents of the Central African Republic - Plasmodium vinckei petteri 
sbsp.nov. and Plasmodium chabaudi Landau, 1965. Annals of Tropical 
Medicine and Parasitology 69, 187-196. 
Carter, R. 1978. Studies on enzyme variation in the murine malaria parasites 
Plasmodium berghei, P. yoelii, P. vinckei and P. chabaudi by starch gel 
electrophoresis. Parasitology 76, 241-267. 
Cheng, Q. and Saul, A. 1994. The dihydrofolate reductase domain of rodent 
malarias: point mutations and pyrimethamine resistance. Molecular and 
Biochemical Parasitology 65, 361-363. 
126 
References 
Chongsuphajaisiddhi, T., Subchareon, A., Puangpartk, S., and Harinasutra, Y. 1979. 
Treatment of falciparum malaria in Thai children. Southeast Asia Journal of 
Tropical Medicine and Public Health. 12, 418-421. 
Chulay, J. D., Watkins, W. M., and Sixsmith, D. G. 1984. Synergistic antimalarial 
activity of pyrimethamine and sulfadoxine against Plasmodium falciparum in 
vitro. American Journal of Tropical Medicine and Hygiene 33, 325-330. 
Cornelissen, A. W. C. A. and Walliker, D. 1985. Gametocyte development of 
Plasmodium chabaudi in mice and rats: evidence for host induction of 
gametocytogenesis. Parasitology Research 71, 297-303. 
Cowman, A. F. and Lew, A. M. 1989. Antifolate drug selection results in duplication 
and rearrangement of chromosome 7 in Plasmodium chabaudi. Molecular 
and Cellular Biology 9, 5182-5188. 
Cowman, A. F. and Foote, S. J. 1990. Chemotherapy and drug resistance in malaria. 
International Journal for Parasitology 20, 513. 
Cowman, A. F. and Lew, A. M. 1990. Chromosomal rearrangements and point 
mutations in the DHFR-TS gene of Plasmodium chabaudi under antifolate 
selection. Molecular and Biochemical Parasitology 42, 21-30. 
Cowman, A. F., Karcz, S., Galatis, D., and Culvenor, J. G. 1991. A P-glycoprotein 
homologue of Plasmodium falciparum is localised on the digestive vacuole. 
Journal of Cell Biology 113, 1033-1042. 
Cowman, A. F., Galatis, D., and Thompson, J. K. 1994. Selection for mefloquine 
resistance in Plasmodiumfalciparum is linked to amplification of the pf,ndr-1 
gene and cross-resistance to halofantrine and quinine. Proceedings of the 
National Academy of Sciences of the USA 91, 1143-1147. 
Creasey, A. M., Ranford-Cartwright, L. C., Moore, D. J., Williamson, D. H., Wilson, 
R. J. M., Walliker, D., and Carter, R. 1993. Uniparental inheritance of the 
mitochondrial gene cytochrome b in Plasmodium falciparum. Current 
Genetics 23, 360-364. 
Curtis, J., Duraisingh, M. T., and Warhurst, D. C. 1998. In vivo selection for a 
specific genotype of dihydropteroate synthase of Plasmodium falciparum by 
pyrimethamine-sulfadoxine but not chlorproguanil-dapsone treatment. 
Journal of Infectious Diseases 177, 1429-1433. 
Dallas, W. S., Gowen, J. E., Ray, P. H., Cox, M. J., and Dev, I. K. 1992. Cloning, 
sequencing, and enhanced expression of the dihydropteroate synthase gene of 
Escherichia coli MC4100. Journal of Bacteriology 174, 5961-5970. 
127 
References 
Deleersnijder, W., Hendrix, D., Bendahman, N., Hanegreefs, J., Brijs, L., Hamers-
Casterman, C., and Harriers, R. 1990. Molecular cloning and sequence 
analysis of the gene encoding the major merozoite surface antigen of 
Plasmodium chabaudi chabaudi IP-PCI. Molecular and Biochemical 
Parasitology 43, 231-244. 
Denny, P., Preisner, P. R., Williamson, D., and Wilson, I. 1998. Evidence for a single 
origin of the 35 kb plastid DNA in apicomplexans. Protist 149, 5 1-59. 
Dieckmann, A. and Jung, A. 1986. Mechanisms of sulfadoxine resistance in 
Plasmodium falciparum. Molecular and Biochemical Parasitology 19, 143-
147. 
Diggens, S. M. 1970. Single step production of pyrimethamine-resistant Plasmodium 
berghei. Transactions of the Royal Society of Tropical Medicine and Hygiene 
64, 9. 
Diourté, Y., Djimde, A., Doumbo, 0. K., Sagara, I., Coulibaly, Y., Dicko, A., Diallo, 
M., Diakité, M., Cortese, J. F., and Plowe, C. V. 1999. Pyrimethamine-
sulfadoxine efficacy and selection for mutations in Plasmodium falciparum 
dihydrofolate reductase and dihydropteroate synthase in Mali. American 
Journal of Tropical Medicine and Hygiene 60, 475-478. 
Drake, J. W. 1991. A constant rate of spontaneous mutation in DNA-base microbes. 
Proceedings of the National Academy of Sciences of the USA 88, 7160-7164. 
Duraisingh, M. T., Curtis, J., and Warhurst, D. C. 1998. Plasmodium falciparum: 
Detection of polymorphisms in the dihydrofolate reductase and 
dihydropteroate synthetase genes by PCR and restriction digestion. 
Experimental Parasitology 89, 1-8. 
Dzekunov, S. M., Ursos, L. M. B., and Roepe, P. D. 2000. Digestive vacuolar pH of 
intact intraerythrocyctic Plasmodium falciparum either sensitive or resistant 
to chioroquine. Molecular and Biochemical Parasitology 101, 107-124. 
Egan, T. J., Ross, D. C., and Adams, P. A. 1994. Quinoline antimalarial drugs inhibit 
spontaneous formation of 3-haematin (malaria pigment). FEBS Letters 352, 
54-57. 
Favaloro, J. M. 1993 Antigens of Plasmodium chabaudi. PhD Thesis, Monash 
University. 
Favaloro, J. M., Culvenor, J. G., Anders, R. F., and Kemp, D. J. 1993. A Plasmodium 
chabaudi antigen located in the parasitophorous vacuole membrane. 
Molecular and Biochemical Parasitology 62, 263-270. 
128 
References 
Ferdig, M. T. and Su, X.-Z. 2000. Microsatellite markers and genetic mapping in 
Plasmodium falciparum. Parasitology Today 16, 307-312. 
Fermér, C., Kristiansen, B.-E., Sköld, 0., and Swedberg, G. 1995. Sulfonamide 
resistance in Neisseria meningitidis as defined by site-directed mutagenesis 
could have its origin in other species. Journal of Bacteriology 177, 4669-
4675. 
Fidock, D. A., Nomura, T., Cooper, R. A., Su, X.-Z., Talley, A. K., and Wellems, T. 
E. 2000a. Allelic modification of the cg2 and cg] genes do not alter the 
chioroquine response of drug-resistant Plasmodium falciparum. Molecular 
and Biochemical Parasitology 110, 1-10. 
Fidock, D. A, Nomura, T., Talley, A. K., Cooper, R. A., Dzekunov, S. M., Ferdig, M. 
T., Ursos, L. M. B., Singh, A. B., Naudé, B., Deitsch, K. W., Su, X.-Z., 
Wootton, J. C., Roepe, P. D., and Wellems, T. E. 2000b. Mutations in the 
Plasmodiumfalciparum digestive vacuole transmembrane protein PfCRT and 
evidence for their role in chioroquine resistance. Molecular Cell 6, 861-871. 
Foley, M. and Tilley, L. 1997. Quinoline antimalarials: mechanisms of action and 
resistance. International Journal for Parasitology 27, 231-240. 
Foote, S. J., Thompson, J. K., Cowman, A. F., and Kemp, D. J. 1989. Amplification 
of the multidrug resistance gene in some chioroquine-resistant isolates of 
Plasmodium falciparum. Cell 57, 921-930. 
Foote, S. J., Kyle, D. E., Martin, R. K., Oduola, A. M., Forsyth, K., Kemp, D. J., and 
Cowman, A. F. 1990. Several alleles of the multi-drug resistance gene are 
closely linked to chloroquine resistance in Plasmodium falciparum. Nature 
345, 255-258. 
Foster, S. D. 1991. The pricing, distribution and use of antimalarial drugs. Bulletin of 
the World Health Organisation. 69, 349-363. 
Fulton, J. D. and Grant, P. T. 1956. The sulpha requirement of the erythrocytic form 
of Plasmodium knowlesi. Biochemistry Journal 63, 274-282. 
Gardner, M. J., Carucci, D. J., Cummings, L. M., Aravind, L., Koonin, E. V., 
Shallom, S., Mason, T., Yu, K., et al. 1998. Chromosome 2 sequence of the 
human malaria parasite Plasmodiumfalciparum. Science 282, 1126-1132. 
Gardner, M. J. 1999. The genome of malaria parasites. Current Opinion in Genetics 
and Development 9, 704-708. 
129 
References 
Garrett, C. E., Coderre, J. A., Meek, T. D., Garvey, E. P., Claman, D. M., Beverly, S. 
M., and Santi, D. V. 1984. A bifunctional thymidylate synthetase-
dihydrofolate reductase in protozoa. Molecular and Biochemical 
Parasitology 11, 257-265. 
Garnham, P. C. C. 1966. Malaria parasites and other haemosporida. Blackwell 
Scientific Publications, Oxford. 
Garnham, P. C. C. 1988. Malaria parasites of man: life cycles and morphology, in 
Wernsdorfer, W. H. and McGregor, I. Malaria: principles and practice of 
malariology, pages 61-96. 1988. Churchill Livingston Press, Edinburgh. 
Gervais, G. W., Trujillo, K., Robinson, B. L., Peters, W., and Serrano, A. E. 1999. 
Plasmodium berghei: Identification of an mdr-like gene associated with drug 
resistance. Experimental Parasitology 91, 86-92. 
Goldberg, D. E., Slater, A. F., Cerami, A., and Henderson, G. B. 1990. Hemoglobin 
degradation in the malaria parasite Plasmodium falciparum: an ordered 
process in a unique organelle. Proceedings of the National Academy of 
Sciences of the USA 87, 2931-2935. 
Greenberg, J., Taylor, D. J., and Trembley, H. L. 1954. The effect of milk diets on 
the course of sporozoite-induced Plasmodium gallinaceum infections in 
chicks. American Journal of Hygiene 60, 99-105. 
Harinasuta, T., Migasen, S., and Boonag, D. 1962. Chioroquine resistance in 
Plasmodiumfalciparum in Thailand. UNESCO First Regional Symposium on 
Scientific Knowledge of Tropical Parasites, Singapore University, Singapore. 
Hampele, I. C., D'Arcy, A., Dale, G. E., Kostrewa, D., Nielsen, J., Oefner, C., Page, 
M. G. P., Schönfeld, H.-J., Stüber, D., and Then, R. L. 1997. Structure and 
function of the dihydropteroate synthase from Staphylococcus aureus. 
Journal of Molecular Biology 268, 21-30. 
Hayward, R. E., DeRisi, J. L., Alfadhli, S., Kaslow, D. C., Brown, P. 0., and Rathod, 
P. K. 2000. Shotgun DNA microarrays and stage-specific gene expression in 
Plasmodiumfalciparum malaria. Molecular Microbiology 35, 6-14. 
Hawking, F. 1953. Milk diet, p-aminobenzoic acid, and malaria (Plasmodium 
berghei). British Medical Journal 1, 1201-1202. 
Heiweg-Larsen, J., Benfield, T. L., Eugen-Olsen, J., Lundgren, J. D., and Lundgren, 
B. 1999. Effects of mutations in Pneumocystis carinii dihydropteroate 




Hennig, M., Dale, G. E., DArcy, A., Dane!, F., Fischer, S., Gray, C. P., Jo!idon, S., 
Muller, F., Page, M. G. P., Pattison, P., and Oefner, C. 1999. The structure 
and function of the 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase 
from Haemophilus influenzae. Journal of Molecular Biology 287, 211-219. 
Holder, A. A. 1999. Malaria vaccines. Proceedings of the National Academy of-
Sciences of the USA 96, 1167-1169. 
Holloway, S. P., Sims, P. F. H., Delves, C. J., Scaife, J. G., and Hyde, J. E. 1989. 
Isolation of cx-tubulin genes from the human malaria parasite Plasmodium 
falciparum: sequence analysis of ct-tubu!in. Molecular Microbiology 3, 1501- 
15 10. 
Holloway, S. P., Gerousis, M., Delves, C. J., Sims, P. F. G., Scaife, J. G., and Hyde, 
J. E. 1990. The tubulin genes from the human malaria parasite Plasmodium 
falciparum, their chromosomal location and sequence analysis of the a-
tubulin II gene. Molecular and Biochemical Parasitology 43, 257-270. 
Hyde, J. E. 1990. The dihydrofolate reductase-thymidylate synthetase gene in the 
drug resistance of malaria parasites. Pharmacology and Therapy 48, 45-59. 
Inselberg, J., Bzik, D. J., and Horii, Y. 1987. Pyrimethamine resistant Plasmodium 
falciparum: overproduction of dihydrofolate reductase by a gene duplication. 
Molecular and Biochemical Parasitology 26, 121-134. 
Jacobs, G. H., Oduola, A. M., Kyle, D. E., Milhous, W. K., Martin, S. K., and 
Aikawa, M. 1988. Ultrastructure study of the effect of chioroquine and 
verapamil on Plasmodium falciparum. American Journal of Tropical 
Medicine and Hygiene 39, 15-20. 
Jacobs, R. L. 1964. Role of p-aminobenzoic acid in Plasmodium berghei infection in 
the mouse. Experimental Parasitology 15, 213-225. 
Janse, C. J., Canton, J. M. R., Walliker, D., and Waters, A. P. 1994. Conserved 
location of genes on polymorphic chromosomes of four species of malaria 
parasites. Molecular and Biochemical Parasitology 68, 285-296. 
Jaswant-Singh, Ramakrishnan, S. P., Prakash, S., and Bhatnagar, V. N. 1954. Studies 
on Plasmodium berghei, Vincke and Lips, 1948. XX. A physiological change 
observed in a suiphadiazine resistant strain. Indian Journal of Malariology 8, 
301-307. 
Jeffreys, A. J., Wilson, V., and Them, S. L. 1985. Hypervariable minisatellite regions 
in human DNA. Nature 314, 67-73. 
131 
References 
Jelinek, T., Ronn, A. M., Lemnge, M. M., Curtis, J., Mhina, J., Duraisingh, M. T., 
Bygbjerg, I. C., and Warhurst, D. C. 1998. Polymorphisms in the 
dihydrofolate reductase (DHFR) and dihydropteroate synthetase (DHPS) 
genes of Plasmodium falciparum and in vivo resistance to 
suiphadoxine/pyrimethamine in isolates from Tanzania. Tropical Medicine 
and International Health 3, 605-609. 
Kai, M., Matsuoka, M., Nakata, N., Maeda, S., Gidoh, M., Maeda, Y., Hashimoto, 
K., Kobayashi, K., and Kashiwabara, Y. 1999. Diaminodophenylsulfone 
resistance of Mycobacterium leprae due to mutations in the dihydropteroate 
synthase gene. FEMS Microbiology Letters 177, 231-235. 
Kemp, D. J., Thompson, J. K., Walliker, D., and Corcoran, L. M. 1987. Molecular 
karyotype of Plasmodium falciparum: conserved linkage groups and 
expendable histidine-rich protein genes. Proceedings of the National 
Academy of Sciences of the USA 84, 7672-7676. 
Kilbey, B., Fraser, I., McAleese, S., Goman, M., and Ridley, R. G. 1993. Molecular 
characterisation and stage-specific expression of proliferating cell nuclear 
antigen (PCNA) from the malaria parasite, Plasmodiumfalciparum. Nucleic 
Acids Research 21, 239-243. 
Killick-Kendrick, R. and Peters, W. 1978. Rodent malaria. Academic Press, London, 
New York, San Francisco. 
Kohler, S., Delwiche, C. F., Denny, P. W., Tilney, L. G., Webster, P., Wilson, R. J. 
M., Palmer, J. D., and Roos, D. S. 1997. A plastid of probable green algal 
origin in apicomplexan parasites. Science 275, 1485-1489. 
Kreier, J. P. 1977. The isolation and fractionation of malaria-infected cells. Bulletin 
of the World Health Organisation. 55, 317-331. 
Krogstad, D. J., Gluzman, I. Y., Kyle, D. E., Oduola, A. M. J., Martin, S. K., 
Milhous, W. K., and Schlesinger, P. H. 1987. Efflux of chloroquine from 
Plasmodium falciparum: mechanism of chioroquine resistance. Science 238, 
1283-1285. 
Krungkrai, J., Webster, H. K., and Yuthavong, Y. 1989. De novo and salvage 
biosynthesis of pteroylpentaglutamates in the human malaria parasite, 
Plasmodiumfalciparum. Molecular and Biochemical Parasitology 32, 25-37. 
Lander, E. S. and Botstein, D. 1989. Mapping Mendelian factors underlying 
quantitative traits using RFLP linkage maps. Genetics 121, 185-199. 
132 
References 
Lane, B. R., Ast, J. C., Hossler, P. A., Mindell, D. P., Bartlett, M. S., Smith, J. W., 
and Meshnick, S. R. 1997. Dihydropteroate synthase polymorphisms in 
Pneumocystis carinii. Journal of Infectious Diseases 175, 482-485. 
Lim, A. S. and Cowman, A. F. 1996. Plasmodiumfalciparum: chioroquine selection 
of a cloned line and DNA rearrangements. Experimental Parasitology 83, 
283-294. 
Lopez, P., Espinosa, M., Greenberg, B., and Lacks, S. A. 1987. Sulfonamide 
resistance in Streptococcus pneumoniae: DNA sequence of the gene encoding 
dihydropteroate synthase and characterization of the enzyme. Journal of 
Bacteriology 169, 4320-4326. 
Mackinnon, M. J. 1997. Survival probability of drug resistant mutants in malaria 
parasites. Proceedings of the Royal Society, London B 264, 53-59. 
MacLeod, R. A. F. and Brown, A. 1976. Development of Plasmodium chabaudi 
gametocytes in splenectomised rats. Transactions of the Royal Society of 
Tropical Medicine and Hygiene 70, 286. 
MacLeod, R. A. F. 1977. The genetics of drug resistance in malaria parasites. PhD 
Thesis, University of Edinburgh. 
Maegraith, B. G., Deegan, T., and Jones, E. S. 1952. Suppression of malaria 
(Plasmodium berghei) by milk. British Medical Journal 2, 1382-1384. 
Marshall, V. M., Peterson, M. G., Lew, A. M., and Kemp, D. J. 1989. Structure of 
the apical membrane antigen 1 (AMA-1) of Plasmodium chabaudi. 
Molecular and Biochemical Parasitology 37, 281-284. 
Martin, S. K., Oduola, A. M., and Milhous, W. K. 1987. Reversal of chloroquine 
resistance in Plasmodiumfalciparum by verapamil. Science 235, 899-901. 
McConkey, G., Ittarat, I., Meshnick, S. R., and McCutchan, T. F. 1994. Auxotrophs 
of Plasmodium falciparum dependent on p-aminobenzoic acid for growth. 
Proceedings of the National Academy of Sciences of the USA 91, 4244-4248. 
Meier, B., Döbeli, H., and Certa, U. 1992. Stage-specific expression of aldolase 
isoenzymes in the rodent malaria parasite Plasmodium berghei. Molecular 
and Biochemical Parasitology 52, 15-28. 
Merkli, B. and Richie, R. W. 1980. Studies on the resistance to single and combined 
antimalarials in the Plasmodium berghei mouse model. Acta Tropica 37, 228-
231. 
Merkli, B. and Richie, R. 1983. Plasmodium berghei: Diet and drug dosage regimes 
influencing selection of drug-resistant parasites in mice. Experimental 
Parasitology 55, 372-376. 
133 
References 
Meshnick, S. R. 1997. Why does quinine still work after 350 years of use? 
Parasitology Today 13, 89-90. 
Meshnick, S. R. 1998. From quinine to qinghaosu: historical perspectives in 
Sherman, I. W. Malaria parasite biology, pathogenesis and protection pages 
341-353. ASM Press, Washington DC. 
Milhous, W. K., Weatherly, N. F., Bowdre, J. H., and Desjardins, R. E. 1985. In vitro 
activities of and mechanisms of resistance to antifol antimalarial drugs. 
Antimicrobial Agents in Chemotherapy 27, 525-530. 
Moore, D. V. and Lanier, J. E. 1961. Observations on two Plasmodium falciparum 
infections with abnormal response to chloroquine. American Journal of 
Tropical Medicine and Hygiene 10, 5-9. 
Morgan, S. 1974. The genetics of malaria parasites: studies on pyrimethamine 
resistance. PhD Thesis University of Edinburgh. 
Murakami, K., Tanabe, K., and Takada, S. 1990. Structure of the Plasmodium yoelii 
gene-encoded protein homologues to the Ca 2 -ATPase of rabbit skeletal 
muscle sarcoplasmic reticulum. Journal of Cell Science 97, 487-495. 
Nguyen-Dinh, P. and Payne, D. 1980. Pyrimethamine sensitivity in Plasmodium 
falciparum: determination in vitro by a modified 48-hour test. Bulletin of the 
World Health Organisation. 58, 909-912. 
Ntoumi, F., Contamin, H., Rogier, C., Bonnefoy, S., Trape, J.-F., and Mercereau-
Puijalon, 0. 1995. Age-dependent carriage of multiple Plasmodium 
falciparum merozoite surface antigen-2 alleles in asymptomatic malaria 
infections. American Journal of Tropical Medicine and Hygiene 52, 81-88. 
Nzila, A. M., Nduati, E., Mberu, E. K., Sibley, C. H., Monks, S. A., Winstanley, P. 
A., and Watkins, W. M. 2000a. Molecular evidence of greater selective 
pressure for drug resistance exerted by the long-acting antifolate 
pyrimethamine-sulfadoxine compared with the shorter-acting 
chlorproguanil/dapsone on Kenyan Plasmodium falciparum. Journal of 
Infectious Diseases 181, 2023-2028. 
Nzila, A. M., Mberu, E. K., Sub, J., Dayo, H., Winstanley, P. A., Sibley, C. H., and 
Watkins, W. M. 2000b. Towards an understanding of the mechanism of 
pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: genotyping 
of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites. 
Antimicrobial Agents in Chemotherapy 44, 991-996. 
134 
References 
O'Brien, E., Kurdi-Haidar, B., Wanachiwannaawin, W., Carvajal, J. L., Vulliamy, T. 
J., Cappadorro, M., Mason, P. J., and Luzzatto, L. 1994. Cloning of the 
glucose 6-phosphate dehydrogenase gene from Plasmodium falciparum. 
Molecular and Biochemical Parasitology 64, 313-326. 
Oduola, A. M. J. 1988. Plasmodium falciparum: Induction of resistance to 
mefloquine in cloned strains by continuous drug exposure in vitro. 
Experimental Parasitology 67, 354-360. 
Padua, R. A. and Walliker, D. 1978. Mefloquine-resistance in Plasmodium chabaudi. 
Transactions of the Royal Society of Tropical Medicine and Hygiene 72, 643. 
Padua, R. A. 1980. Genetics of drug resistance in rodent malaria. PhD Thesis 
University of Edinburgh. 
Padua, R. A. 1981. Plasmodium chabaudi: Genetics of resistance to chloroquine. 
Experimental Parasitology 52, 419-426. 
Pashley, T., Volpe, F., Pudney, M., Hyde, J. E., Sims, P. F. H., and Delves, C. J. 
1997. Isolation and molecular characterization of the bifunctional 
hydroxymethyldihydropterin pyrophosphokinase-dihydropteroate synthase 
gene from Toxoplasma gondii. Molecular and Biochemical Parasitology 86, 
37-47. 
Paterson, A. H., Lander, E. S., Hewitt, J. D., Peterson, S., Lincoln, S. E., and 
Tanksley, S. D. 1988. Resolution of quantitative traits into Mendelian factors 
by using a complete RFLP linkage map. Nature 335, 721-726. 
Paul, R. E. L., Packer, M. J., Walmsley, M., Lagog, M., Ranford-Cartwright, L. C., 
Paru, R., and Day, K. P. 1995. Mating patterns in malaria parasite populations 
of Papua New Guinea. Science 269, 1709-1711. 
Payne, D. 1987. Spread of chioroquine resistance in Plasmodium falciparum. 
Parasitology Today 3, 241-246. 
Peel, S. A., Bright, P., Yount, B., Handy, J., and Baric, R. S. 1994. A strong 
association between mefloquine and halofantrine resistance and 
amplification, overexpression, and mutation in the p-glycoprotein gene 
homologue (pfmdr) of Plasmodium falciparum in vitro. American Journal of 
Tropical Medicine and Hygiene 51, 648-658. 
Peters, W. 1974. Prevention of drug resistance in rodent malaria by the use of drug 
mixtures. Bulletin of the World Health Organisation. 51, 379-383. 
135 
References 
Peters, W. and Robinson, B. L. 1984. The chemotherapy of rodent malaria XXXV. 
Further studies on the retardation of drug resistance by the use of a triple 
combination of mefloquine, pyrimethamine and sulfadoxine in mice infected 
with Plasmodium berghei and 'Plasmodium berghei NS'. Annals of Tropical 
Medicine and Parasitology 78, 459-466. 
Peters, W. 1987. Chemotherapy and drug resistance in malaria. Second edition. 
Academic Press, London. 
Peterson, D. S., Walliker, D., and Wellems, T. E. 1988. Evidence that a point 
mutation in dihydrofolate reductase-thymidyl ate synthase confers resistance 
to pyrimethamine in falciparum malaria. Proceedings of the National 
Academy of Sciences of the USA 85, 9114-9118. 
Phillips, R. S. 1997. A multi-pronged attack on malaria. Parasitology Today 13, 324-
328. 
Plowe, C. V., Cortese, J. F., Djimde, A., Nwanyanwu, 0. C., Watkins, W. M., 
Winstanley, P. A. et al. 1997. Mutations in Plasmodium falciparum 
dihydrofolate reductase and dihydropteroate synthase and epidemiological 
patterns of pyrimethamine-sulfadoxine use and resistance. Journal of 
Infectious Diseases 176, 1590-1596. 
Plowe, C. V., Kublin, J. G., and Doumbo, 0. K. 1998. Plasmodium falciparum 
dihydrofolate reductase and dihydropteroate synthase mutations: 
epidemiology and role in clinical resistance to antifolates. Drug Resistance 
Updates 1, 389-396. 
Powers, K. G., Jacobs, R. L., Good, W. C., and Koontz, L. C. 1969. Plasmodium 
vinckei: production of a chioroquine-resistant strain. Experimental 
Parasitology 26, 193-202. 
Pringle, G. 1965. A count of sporozoites in an oocyst of Plasmodium falciparum. 
Transactions of the Royal Society of Tropical Medicine and Hygiene 59, 289-
290. 
Ramakrishnan, S. P., Prakash, S., and Sen Gupta, G. P. 1956. Studies on Plasmodium 
berghei, Vincke and Lips, 1948 XXIII. Isolation of and observations on a 
"milk resistant" strain. Indian Journal of Malariology 10, 175-182. 
Ranford-Cartwright, L. C., Balfe, P., Carter, R., and Walliker, D. 1993. Frequency of 
cross-fertilisation in the human malaria parasite Plasmodium falciparum. 
Parasitology 107, 11-18. 
136 
References 
Reacher, M., Campbell, C. C., Freeman, J., Doberstyn, E. B., and Brandling-Bennett, 
A. D. 1980. Drug therapy for Plasmodium falciparum malaria resistant to 
pyrimethamine-sulphadoxine (Fansidar). A study of alternate regimes in 
Eastern Thailand. Lancet 2, 1066-1069. 
Reed, M. B., Saliba, K. J., Caruana, S. R., Kirk, K., and Cowman, A. F. 2000. Pghl 
modulates sensitivity and resistance to multiple antimalarials in Plasmodium 
falciparum. Nature 403, 906-909. 
Reeder, J. C., Rieckmann, K. H., Genton, B., Lorry, K., Wines, B., and Cowman, A. 
F. 1996. Point mutations in the dihydrofolate reductase and dihydropteroate 
synthase genes and in vitro susceptibility to pyrimethamine and cycloguanil 
of Plasmodium falciparum isolates from Papau New Guinea. American 
Journal of Tropical Medicine and Hygiene 55, 209-213. 
Richards, W. H. G. 1966. Antimalarial activity of sulphonamides and a sulphone, 
singly and in combination with pyrimethamine, against drug resistant and 
normal strains of laboratory Plasmodia. Nature 212, 1494-1495. 
Ridley, R. G., White, J. H., McAleese, S., Goman, M., Alano, P., and Vries, Ed. 
1991. DNA polymerase ö: gene sequences from Plasmodium falciparum 
indicate that this enzyme is more highly conserved that DNA polymerase a. 
Nucleic Acids Research 19, 6731-6736. 
Riordan, J. R., Deuchars, K., Kartner, N., Alon, N., Trent, J., and Ling, V. 1985. 
Amplification of P-glycoprotein in multidrug-resistant mammalian cell lines. 
Nature 316, 817-819. 
Roberts, F., Roberts, C. W., Johnson, J. J., Kyle, D. E., Krell, T., Coggins, J. R., 
Coombs, G. H., Milhous, W. K., Tzipori, S., Ferguson, D. J. P., Chakrabarti, 
D., and McLeod, R. 1998. Evidence for the shikimate pathway in 
apicomplexan parasites. Nature 393, 801-805. 
Roland, S., Ferone, R., Harvey, R. J., Styles, V. L., and Morrison, R. W. 1979. The 
characteristics and significance of sulfonamides as substrates for Escherichia 
coli dihydropteroate synthase. Journal of Biological Chemistry 254, 10337-
10345. 
Rollo, I. M. 1952. Daraprim resistance in experimental malarial infections. Nature 
168,332-333. 
Rosario, V. B. 1976a. Genetic studies of malaria parasites, especially in relation to 
drug resistance. PhD Thesis, University of Edinburgh. 
137 
References 
Rosario, V. E. 1976b. Genetics of chioroquine resistance in malaria parasites. Nature 
261, 585-586. 
Rosenberg, R. and Rungsiwongse, J. 1991. The number of sporozoites produced by 
individual malaria oocysts. American Journal of Tropical Medicine and 
Hygiene 45, 574-577. 
Rowe, A. W., Eyster, E., and Kellner, A. 1968. Liquid nitrogen preservation of red 
blood cells for transfusion; a low glycerol-rapid freeze procedure. 
Cryobiology 5, 119-128. 
Saiki, R. K., Gelfand, D. H., Stoffel, S., Scharf, S. J., Higuchi, R., Horn, G. T., 
Mullis, K. B., and Ehrlich, H. A. 1988. Primer-directed enzyme amplification 
of DNA with a thermostable DNA polymerase. Science 239, 487-491. 
Sambrook, J., Fritsch, E. F., and Maniatis, T. 1989. Molecular cloning: A Laboratory 
Manual. Cold Spring Harbour Laboratory, New York. 
Sanchez, C. P., Wunsch, S., and Lanzer, M. 1997. Identification of a chioroquine 
importer in Plasmodium falciparum: differences in import kinetics are 
genetically linked with the chloroquine-resistant phenotype. Journal of 
Biological Chemistry 272, 2652-2658. 
Sanderson, A., Walliker, D., and Molez, J.-F. 1981. Enzyme typing of Plasmodium 
falciparum from some African and other old World countries. Transactions of 
the Royal Society of Tropical Medicine and Hygiene 75, 263-267. 
Schapira, A., Bygbjerg, I. C., Jepsen, S., Flachs, H., and Bentzon, M. W. 1986. The 
susceptibility of Plasmodiumfalciparum to sulfadoxine and pyrimethamine - 
correlation of in vivo and in vitro results. American Journal of Tropical 
Medicine and Hygiene 35, 239-245. 
Sharkey, A., Langsley, G., Patarapotikul, J., Mercereau-Puijalon, 0., McLean, A. P., 
and Walliker, D. 1988. Chromosome size variation in the malaria parasite of 
rodents, Plasmodium chabaudi. Molecular and Biochemical Parasitology 28, 
47-54. 
Shinondo, C. J., Lanners, H. N., Lowrie, R. C., and Wiser, M. F. 1994. Effect of 
pyrimethamine resistance on sporogony in a Plasmodium berghei/Anopheles 
stephensi model. Experimental Parasitology 78, 194-202. 
Shortt, H. E., Fairley, N. H., Covell, G., Shute, P. G., and Garnham, P. C. C. 1951. 
The pre-erythrocytic stage of Plasmodium falciparum. Transactions of the 
Royal Society of Tropical Medicine and Hygiene 44, 405-4 19. 
138 
References 
Silveira, J. F., Sibilli, L., Brunet, E., and Mercereau-Puijalon, 0. 1984. Cloning of 
cDNAs that code for Plasmodium chabaudi antigens of the erythrocytic 
forms and cross-hybridise with P. falciparum. Molecular and Biochemical 
Parasitology 11, 133-143. 
Sinden, R. E. and Strong, K. 1978. An ultrastmctural study of the sporogonic 
development of Plasmodium falciparum in Anopheles gambiae. Transactions 
of the Royal Society of Tropical Medicine and Hygiene 72, 477-491. 
Sinden, R. E. 1982. Gametocytogenesis of Plasmodium falciparum in vitro: an 
electron microscopic study. Parasitology 84, 1-11. 
Sinden, R. E. 1984. The biology of Plasmodium in the mosquito. Experientia 40, 
1330-1343. 
Sinden, R. E. and Hartley, R. H. 1985. Identification of the meiotic division of 
malarial parasites. Journal of Protozoology 32, 742-744. 
Siriwaraporn, W. and Yuthavong, Y. 1984. Kinetic and molecular properties of 
dihydrofolate reductase from pyrimethamine-sensitive and pyrimethamine-
resistant Plasmodium chabaudi. Molecular and Biochemical Parasitology 10, 
355-367. 
Siriwaraporn, W. 1998. Dihydrofolate reductase and antifolate resistance in malaria. 
Drug Resistance Updates 1, 397-406. 
Slock, J., Stahly, D. P., Han, C.-H., Six, E. W., and Crawford.I.P. 1990. An apparent 
Bacillus subtilis folic acid biosynthetic operon containing pab, an amphibolic 
trpG gene, a third gene required for synthesis of para-aminobenzoic acid, and 
the dihydropteroate synthase gene. Journal of Bacteriology 172, 7211-7226. 
Southern, E. M. 1975. Detection of specific sequences among DNA fragments 
separated by gel electrophoresis. Journal of Molecular Biology 98, 503-517. 
Spencer, H. C., Watkins, W. M., Sixsmith, D. G., Koech, D. K., and Chulay, J. D. 
1984. A new in vitro test for pyrimethamine-sulfadoxine susceptibility of 
Plasmodium falciparum and its correlation with in vivo resistance in Kenya. 
Bulletin of the World Health Organisation. 62, 615-621. 
Stevenson, M. M., Lyanga, J. L., and Skamene, E. 1982. Murine malaria: genetic 
control of resistance to Plasmodium chabaudi. Infection and Immunity 38, 
80-88. 
Su, X.-Z. and Wellems, T. E. 1994. Sequence, transcript characterisation and 
polymorphisms of a Plasmodiumfalciparum gene belonging to the heat-
shock protein (HSP) 90 family. Gene 151, 225-230. 
139 
References 
Su, X.-Z. and Wellems, T. E. 1997. Complex polymorphisms in an —330 kDa protein 
are linked to chioroquine-resistant Plasmodium falciparum in Southeast Asia 
and Africa. Cell 91, 593-603. 
Su, X.-Z., Ferdig, M., Huang, Y., Huynh, C. Q., Liu, A., You, J., Wootton, J. C., and 
Wellems, T. E. 1999. A genetic map and recombination parameters of the 
human malaria parasite Plasmodiumfalciparum. Science 286, 1351-1353. 
Su, X.-Z. and Canton, J. M. R. 2000. Genome display and typing of Plasmodium 
parasites using anchored polyA and polyT oligonucleotides. Experimental 
Parasitology 94, 273-278. 
Swedberg, G., Ringertz, S., and Sköld, 0. 1998. Sulfonamide resistance in 
Streptococcus pyo genes is associated with differences in the amino acid 
sequence of its chromosomal dihydropteroate synthase. Antimicrobial Agents 
in Chemotherapy 42, 1062-1067. 
Tan-Ariya, P. and Brockelman, C. R. 1983. Plasmodiumfalciparum: Variations in p-
aminobenzoic acid requirements as related to sulfadoxine sensitivity. 
Experimental Parasitology 55, 364-371. 
Taylor, L.H. 1997. Epidemiological and evolution consequences of mixed-genotype 
infections of malaria parasites. PhD Thesis University of Edinburgh. 
Triglia, T., Wellems, T. E., and Kemp, D. J. 1992. Towards a high resolution map of 
the Plasmodium falciparum genome. Parasitology Today 8, 225-229. 
Triglia, T. and Cowman, A. F. 1994. Primary structure and expression of the 
dihydropteroate synthase gene of Plasmodiumfalciparum. Proceedings of the 
National Academy of Sciences of the USA 91, 7149-7153. 
Triglia, T., Wang, P., Sims, P. F. G., Hyde, J. E., and Cowman, A. F. 1998. Allelic 
exchange at the endogenous genomic locus in Plasmodiumfalciparum proves 
the role of dihydropteroate synthase in sulfadoxine-resistant malaria. EMBO 
Journal 17, 3807-38 15. 
Ursos, L. M. B., Dzekunov, S. M., and Roepe, P. D. 2000. The effects of chloroquine 
and verapamil on digestive vacuolar pH of Plasmodium falciparum either 
sensitive or resistant to chioroquine. Molecular and Biochemical 
Parasitology 101, 125-134. 
Vaidya, A. B., Muratova, 0., Guinet, F., Keister, D., Wellems, T. E., and Kaslow, D. 
C. 1995. A genetic locus on Plasmodiumfalciparum chromosome 12 linked 
to a defect in mosquito infectivity and male gametogenesis. Molecular and 
Biochemical Parasitology 69, 65-71. 
140 
References 
van Belkum, A., Ramesar, J., Trommelen, G., and Uitterlinden, A. G. 1992. Mini-
and micro-satellites in the genome of rodent malaria parasites. Gene 118, 81-
86. 
van Dijk, M. R., McConkey, G. A., Vinkenoog, R., Waters, A. P., and Janse, C. J. 
1994. Mechanisms of pyrimethamine resistance in two different strains of 
Plasmodium berghei. Molecular and Biochemical Parasitology 68, 167-17 1. 
van Dijk, M. R., Waters, A. P., and Janse, C. J. 1995. Stable transfection of malaria 
parasite blood stages. Science 268, 1358-1362. 
van Lin, L. H. M., Janse, C. J., and Waters, A. P. 2000. The conserved genome 
organisation of non-falciparum malaria species: the need to know more. 
International Journal for Parasitology 30, 357-370. 
Vanderberg, J. P., Yoeli, M., and Rhodin, J. 1967. Electron microscopical and 
histochemical studies of sporozoite formation in Plasmodium berghei. 
Journal of Protozoology 14, 82-103. 
Volpe, F., Dyer, M., Scaife, J. G., Darby, G., Stammers, D. K., and Delves, C. J. 
1992. The multifunctional folic acid synthesis fas gene of Pneumocystis 
carinii appears to encode dihydropteroate synthase and 
hydroxymethyldihydropterin pyrophosphokinase. Gene 112, 213-218. 
Vos, P., Hogers, R., Bleeker, M., Reijans, M., van de Lee, T., Homes, M., Frijters, 
A., Pot, J., Peleman, J., Kuiper, M., and Zabeau, M. 1995. AFLP: a new 
technique for DNA fingerprinting. Nucleic Acids Research 23, 4407-4414. 
Walker-Jonah, A., Dolan, S. A., Gwadz, R. W., Panton, L. J., and Wellems, T. E. 
1992. An RFLP map of the Plasmodiumfalciparum genome: Recombination 
and favored linkage groups in a genetic cross. Molecular and Biochemical 
Parasitology 51, 313-320. 
Walliker, D., Carter, R., and Morgan, S. 1971. Genetic recombination in malaria 
parasites. Nature 232, 561-562. 
Walliker, D., Carter, R., and Morgan, S. 1973. Genetic recombination in Plasmodium 
berghei. Parasitology 66, 309-320. 
Walliker, D., Carter, R., and Sanderson, A. 1975. Genetic studies on Plasmodium 
chabaudi: recombination between enzyme markers. Parasitology 70, 19-24. 
Walliker, D. 1983. The contribution of genetics to the study of parasitic protozoa. 
Research Studies Press, Herts, UK. 
141 
References 
Walliker, D., Quakyi, I. A., Wellems, T. E., McCutchan, T. F., Szarfman, A., 
London, W. T., Corcoran, L. M., Burkot, T. R., and Carter, R. 1987. Genetic 
analysis of the human malaria parasite Plasmodium falciparum. Science 236, 
1661-1666. 
Walter, R. D. and Konigk, E. 1980. 7,8-Dihydropteroate-synthesizing enzyme from 
Plasmodium chabaudi. Methods in Enzymology 66, 564-570. 
Wang, P., Brooks, D. R., Sims, P. F. G., and Hyde, J. E. 1995. A mutation-specific 
PCR system to detect sequence variation in the dihydropteroate synthetase 
gene of Plasmodium falciparum. Molecular and Biochemical Parasitology 
71, 115-125. 
Wang, P., Read, M., Sims, P. F. G., and Hyde, J. E. 1997a. Sulfadoxine resistance in 
the human malaria parasite Plasmodiumfalciparum is determined by 
mutations in the dihydropteroate synthase and an additional factor associated 
with folate utilization. Molecular Microbiology 23, 979-986. 
Wang, P., Lee, C.-S., Bayoumi, R., Djimde, A., Doumbo, 0., Swedberg, G., Duc 
Dao, L., Mshinda, H., Tanner, M., Watkins, W. M., Sims, P. F. G., and Hyde, 
J. E. 1997b. Resistance to antifolates in Plasmodiumfalciparum monitored by 
sequence analysis of dihydropteroate synthase and dihydrofolate reductase 
alleles in a large number of field samples of diverse origins. Molecular and 
Biochemical Parasitology 89, 161-177. 
Wang, P., Sims, P. F. G., and Hyde, J. E. 1997c. A modified in vitro sulfadoxine 
susceptibility assay for Plasmodiumfalciparum suitable for investigating 
Fansidar resistance. Parasitology 115, 223-230. 
Wang, P., Brobey, R. K. B., Horii, T., Sims, P. F. G., and Hyde, J. E. 1999. 
Utilization of exogenous folate in the human malaria parasite Plasmodium 
falciparum and its critical role in antifolate drug synergy. Molecular 
Microbiology 32, 1254-1262. 
Warhurst, D. C. 1986. Pteridine synthesis in malaria parasites. Parasitology Today 2, 
57-58. 
Watkins, W. M., Sixsmith, D. G., Chulay, J. D., and Spencer, H. C. 1985. 
Antagonism of sulfadoxine and pyrimethamine antimalarial activity in vitro 
by p-aminobenzoic acid, p-aminobenzoylglutamic acid and folic acid. 
Molecular and Biochemical Parasitology 14, 55-61. 
142 
References 
Watkins, W. M. and Mosobo, M. 1993. Treatment of Plasmodium falciparum 
malaria with pyrimethamine-sulfadoxine - selective pressure for resistance is 
a function of long elimination half-life. Transactions of the Royal Society of 
Tropical Medicine and Hygiene 87, 75-78. 
Watkins, W. M., Mberu, E. K., Winstanley, P. A., and Plowe, C. V. 1997. The 
efficacy of antifolate antimalarial combinations in Africa: a predictive model 
based on pharmacodynamic and pharmacokinetic analyses. Parasitology 
Today 13, 459-464. 
Weidekamm, E., Plozza-Nottebrock, H., Forgo, I., and Dubach, U. C. 1982. Plasma 
concentrations of pyrimethamine and sulfadoxine and evaluation of 
pharmacokinetic data by computerised curve fitting. Bulletin of the World 
Health Organisation. 60, 115-122. 
Wellems, T. E., Panton, L. J., Gluzman, I. Y., Rosario, V. E. d., Gwadz, R. W., 
Walker-Jonah, A., and Krogstad, D. J. 1990. Chloroquine resistance not 
linked to mdr-like genes in a Plasmodium falciparum cross. Nature (London) 
345, 253-255. 
Wellems, T. E., Walker-Jonah, A., and Panton, L. J. 1991. Genetic mapping of the 
chloroquine-resistance locus on Plasmodium falciparum chromosome 7. 
Proceedings of the National Academy of Sciences of the USA 88, 3382-3386. 
Wernsdorfer, W. H. 1991. The development and spread of drug-resistant malaria. 
Parasitology Today 7, 297-303. 
White, N. J. 1998. Preventing antimalarial drug resistance through combinations. 
Drug Resistance Updates 1, 3-9. 
White, N. J., Nosten, F., Looareesuwan, S., Watkins, W. M., Marsh, K., Snow, R. 
W., Kokwaro, G., Ouma, J., Hien, T. T., Molyneux, M. E., Taylor, T. E., 
Newbold, C. I., Ruebush II, T. K., Danis, M., Greenwood, B. M., Anderson, 
R. M., and 011iaro, P. L. 1999. Averting a malaria disaster. Lancet 353, 1965-
1967. 
WHO. 1999. http://www.who.int/aboutwho/en/preventing/malaria.htm  
Wilson, C. M., Serrano, A. E., Wasley, A., Bogenschutz, M. P., Shankar, A. H., and 
Wirth, D. F. 1989. Amplification of a gene related to mammalian mdr genes 
in drug-resistant Plasmodiumfalciparum. Science 244, 1184-1186. 
Wilson, C. M., Volkman, S. K., Thaithong, S., Martin, R. K., Kyle, D. E., Milhous, 
W. K., and Wirth, D. F. 1993. Amplification of pf,ndr-1 associated with 
mefloquine and halofantrine resistance in Plasmodium falciparum from 
Thailand. Molecular and Biochemical Parasitology 57, 151-160. 
143 
References 
Wilson, R. J. M., Denny, P. W., Preisner, P. R., Rangachari, K., Roberts, K., Roy, A., 
Whyte, A., Strath, M., Moore, D. J., Moore, P. W., et al. 1996. Complete 
gene map of the plastid-like DNA of the malaria parasite Plasmodium 
falciparum. Journal of Molecular Biology 261, 155-172. 
Wu, Y. M., Kirkman, L. A., and Wellems, T. E. 1996. Transformation of 
Plasmodium falciparum malaria parasites by homologous integration of 
plasmids that confer resistance to pyrimethamine. Proceedings of the 
National Academy of Sciences of the USA 93, 1130-1134. 
Yates, J. R. 2000. Mass spectrometry from genomics to proteomics. Trends in 
Genetics 16, 5-8. 
Yoeli, M., Upmanis, R. S., and Most, H. 1969. Drug-resistance transfer among 
rodent plasmodia. 1. Acquisition of resistance to pyrimethamine by a drug-
sensitive strain of Plasmodium berghei in the course of its concomitant 
development with a pyrimethamine-resistant Plasmodium vinckei strain. 
Parasitology 69, 173-178. 
Young, M. D. and Moore, D. V. 1961. Chloroquine resistance in Plasmodium 
falciparum. American Journal of Tropical Medicine and Hygiene 10, 317-
320. 
Zhao, L. P., Aragaki, C., Hsu, L., and Quiaoit, F. 1998. Mapping of complex traits by 
single-nucleotide polymorphisms. American Journal of Human Genetics 63, 
225-240. 
144 
